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Abstract 
Background 
HIV infection has remained a major global health burden since its discovery in 1983 and 
Sub-Saharan Africa remains the region hardest hit by the HIV/AIDS pandemic.  The HIV 
pandemic continues to ravage most parts of Southern African countries, current prevalence 
between 10-20%. Individuals worldwide differ in their degree of susceptibility to HIV 
infection and genetic polymorphisms play a major role.  Mannose Binding Lectin (MBL) is 
one such immunological factor found in serum/plasma, it is a normal liver-derived protein 
and is a key component of the innate immune defence system.  MBL deficiency, due to 
mutations in the MBL2 gene and promoter region, leading to decreased plasma/serum MBL 
concentration, characterised by defective opsonisation activities of the innate immune system 
and increased susceptibility to infections including HIV-1 and schistosomiasis.   
 
Rationale 
While there is a lot of advancement in HIV prevention and treatment in Southern African 
countries, there is still need to investigate host genetic molecules in adults and mother-baby 
pairs that could be playing a role in HIV-1 transmission/acquisition, disease progression and 
survival.   It was imperative to carry out this study because of the need to quantify the burden 
of MBL deficiency in this Zimbabwean adult and PMTCT study populations.  Alsoto 
contribute to the knowledge gap on the role of MBL deficiency in HIV-1 transmission, 
disease progression and survival in African populations in adults and children.  The available 
literature shows that the majority of studies on the association of MBL deficiency and HIV-1 
infection in adults and children have been done on populations outside the African continent.  
There is dearth of information on the role of MBL in this era when access to ART has greatly 
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improved even in developing countries like Zimbabwe. This will be the second study that 
will assess MBL2 genes and promoter typing in mother-infant pairs in HIV vertical 
transmission/acquisition.  This study aimed to identify and explore potential biomarkers for 
susceptibility to HIV infection and disease progression. 
 
We assessed role of MBL deficiency in HIV-1 and schistosoma infections in Zimbabwean 
adults enrolled in the Mupfure Schistosomiasis and HIV Cohort (MUSH Cohort) (Paper 
1).We also assessed the role of MBL deficiency on HIV progression and survival in this 
African adult population.  We hypothesized that MBL deficiency has a role to play in HIV 
infection by increasing HIV disease progression and decreasing survival (Paper 2). We also 
determined prevalence of MBL deficiency, as estimated by MBL2 haplotypes among 
Zimbabwean mothers and their children aged 9-18 months old as well as its association with 
risk of HIV-1 infection and vertical transmission from their HIV positive mothers (Paper 3). 
 
Main Aim 
The broad objective of this study was to determine the relationship between MBL deficiency 
and HIV infection in an adult population of males and females and among mother-infant pairs 
in Zimbabwe.  
Study Specific Objectives 
1. To determine the prevalence of MBL deficiency among the Zimbabwean adult  
population.   2. To determine the relationship of MBL deficiency with HIV infection among  
the Zimbabwean adult population.   3. To determine the effect of MBL deficiency on disease  
progression and survival among the Zimbabwean adult population.  4. To determine  
prevalence of MBL deficiency among mothers and their infants in a Zimbabwean population.   
5. To determine the relationship between MBL deficiency and HIV transmission from mother  
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to child in a Zimbabwean population. 
 
Methods 
DNA and plasma samples for MBL and HIV analysis were collected from the 379 adult 
males and females from the MUSH cohort and stored dried blood samples from 622 mother 
infant pairs from a national PMTCT survey.   
 
HIV-1, S. haematobium and S. mansoni infections were determined at baseline using HIV 
commercial kits and parasitologically respectively.  Plasma MBL concentration was 
measured by ELISA and MBL2 genotypes determined by PCR.  We calculated and compared 
the proportions of plasma MBL deficiency, MBL2 structural variant alleles B (codon 
54A>G), C (codon 57A>G), and D (codon 52T>C) as well as MBL2 promoter variants -
550(H/L), -221(X/Y) and +4(P/Q) between HIV-1 and schistosoma co-infection and control 
groups using Chi Square test (Paper 1). 
 
We also assessed the role of MBL deficiency on HIV disease progression and survival inthe 
adult (MUSH) cohort.We analysed blood samples for MBL levels, MBL2 genotypes, HIV-1 
status, viral load and CD4+ T cell counts (Paper 1).  Participants were followed up for 3 years 
wherein the endpoints were measured at baseline, 6 weeks, 3, 6, 12, 24 and 36 months.  
Disease progression was measured as the rate of decline in CD4+ T cell counts and the rate of 
increase in HIV viral load (Paper 2).  Generalised Estimating Equations (GEE) models were 
used to compare rates of change of the CD4+ T cell count and viral load measurements over 
the three-year follow-up period.  The role of plasma MBL deficiency and MBL2 genetic 
variants on survival over the 3-year period were estimated using the Cox proportional hazard 
models. Regression analysis was used to test for interaction and confounding between MBL 
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deficiency, MBL2 genetic variance, age and sex.  We used the Wald Chi-square statistic to 
choose between full and nested models. 
 
We also assessed MBL2 polymorphisms in Zimbabwean HIV positive mothers and their 
children enrolled in a national PMTCT survey carried out in 2012.   MBL deficiency was 
defined as presence of A/O and O/O genotypes in the mothers and their children.  We 
extracted DNA from two dried blood spots for 622 mothers and infant pairs using the Gene 
Extract and Amp kit reagents.  MBL2 Exon 1 genotypes and promoter region alleles -
221(X/Y) and -550(H/L) SNP were detected by pyrosequencing.  Differences in distribution 
frequency between HIV infected and uninfected children, of the MBL2 genotypes, promoter 
region variants and MBL2 haplotypes, were determined by the Chi square test or Fisher’s 
exact tests (Paper 3). 
 
Key  findings 
For specific objective number 1, we assessed 379 adults, 80% females, median age (IQR) 30 
(17-41) years.  HIV-1, S. haematobium and S. mansoni prevalence were 26%, 43% and 18% 
respectively in the MUSH baseline survey.   Median (IQR) plasma MBL concentration was 
800µg/L (192-1936µg/L).  Prevalence of plasma MBL deficiency was 18% with high 
frequency of the C (codon 57G>A) mutant allele (20%).   For specific objective number 2,  
we found no significant difference in median plasma MBL levels between HIV negative 
(912µg/L) and HIV positive (688µg/L), p=0.066.  However plasma MBL levels at the assay 
detection limit of 20µg/L were more frequent among the HIV-1 infected (p=0.007).  S. 
haematobium  andS. mansoni infected participants had significantly higher MBL levels than 
uninfected.  All MBL2 variants were not associated with HIV-1 infection but promoter 
variants LY and LL were significantly associated with S. haematobium infection (Paper 1). 
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For specific objective number 3, we assessed 197 HIV positive adults where 83% (164) were 
women with a median age of 31 years old.  Prevalence of plasma MBL deficiency (less than 
100µg/L) and MBL2 deficient genetic variants (A/O and O/O genotypes) was 21% (42 out of 
197) and 39% (74 out of 190), respectively.  We did not observe a significant role to explain 
individual variation in mortality, change of CD4+ T cell count and viral load by MBL plasma 
deficiency or MBL2 genetic variants from baseline to 3 years follow up period in this adult 
population (Paper 2). 
 
For specific objective number 4, from the PMTCT study, the median age (IQR) of the 
mothers was 30(26 - 34) years and the children mean age (IQR) was 12 (11-15) months old at 
the time of enrolment.   All 622 mothers were HIV-1 infected, 574 babies were HIV negative 
and 48 were HIV-1 positive babies.  MBL2 normal structural allele A and variants B (codon 
5A>G), C (codon 57 A>G) and promoter region SNPs -550(H/L) and -221(X/Y) were 
detected.  Prevalence of MBL deficiency was 34% among the mothers and 32% among the 
children.  For specific objective number 5, we found no association between maternal MBL2 
deficiency and HIV-1 transmission to their children.  We found no difference in the 
distribution of HIV-1 infected and uninfected children between the MBL2 genotypes of the 
mothers and those of the children (Paper 3).   
 
Conclusions 
The results from our study indicate high prevalence of MBL deficiency but we found no 
evidence of association between MBL deficiency and HIV-1 infection.  However, lower 
plasma MBL levels were associated with reduced prevalence of both S. haematobium and S. 
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mansoni infections and MBL2 promoter and variants LY and LL were associated with 
increased susceptibility to S. haematobium infection (Paper 1).   
 
Our findings attest to the large between-population variability in a host of factors that can 
predispose individuals susceptible to HIV progression and mortality. We therefore cannot 
recommend at this time the use of plasma MBL levels or MBL2 genetic variants as a 
prognostic marker in HIV infection, disease progression and survival in this adult population 
in Africa (Paper 2). MBL deficiency was not associated with HIV-1 infection among the 
children nor was it associated with HIV-1 vertical transmission in this study population 
(Paper 3).   
 
Key words 
Mannose Binding Lectin (MBL), plasma MBL levels, MBL2 genetic polymorphism, single-
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polymorphism, MBL2 exon 1 region, MBL2 promoter region, single-nucleotide 
polymorphisms (SNPs), MBL deficiency, viral load, CD4+ T cell counts, disease progression, 
survival, longitudinal study, Zimbabwean adults, pyrosequencing, mothers, children, HIV-1 
vertical transmission, prevention of mother to child transmission (PMTCT). 
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Thesis overview and structure 
This PhD was undertaken using the route of thesis with publications.  This thesis therefore 
consists of two parts: an integrating narrative which provides the introduction, rationale, the 
research methodology and findings of the research, which are summarised, the research 
papers produced as part of this PhD (Appendix A. B and C) and a methodology paper on 
pyrosequencing still under review (Appendix D).  This research comprised two related 
studies: the adult MBL study which explored MBL polymorphism and its possible 
association with susceptibility to HIV infection and the PMTCT study which also explored 
MBL polymorphism among mothers and their babies and possible association with HIV 
infection and vertical transmission.  The adult MBL study was a sub-study of the MUSH 
cohort implemented in Zimbabwe to investigate immunological mechanisms in HIV and 
schistosomiasis co-infections.  The PMTCT study used stored dried blood samples for 
mothers and their infants collected during a national PMTCT survey carried out in 2012 in 
Zimbabwe.   
 
Integrating Narrative 
The integrating narrative comprises eight chapters.  Chapter one includes the introduction 
and background to the study and has the following sections: introduction, origination of the 
research idea, role of the candidate in this research thesis, brief background on role of MBL 
in HIV disease, study rationale, broad objective, study specific objectives, study hypothesis 
and the conceptual framework.  Chapter two provides a detailed profile of Zimbabwe, the 
country where the research was undertaken, putting this research into context. 
Chapter three is literature review, divided into the following sections: collectins, MBL 
discovery, MBL gene structure, MBL pseudogene, MBL genetic variants, role of MBL in 
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diseases, then final sections reviewing available literature on studies done exploring role of 
MBL in HIV infection in adults and children worldwide, in Africa and in Zimbabwe.  
Chapter four is a synthesis of all the methods that were used in the two studies reported in 
this thesis and includes the following sections: study design, setting, adult study sample size 
and its calculation, PMTCT study sample size and its calculation, research participants, 
inclusion criteria, exclusion criteria, laboratory methods, data collection and statistical 
analysis methods).  Detailed methods for each individual study are described in the appended 
Papers 1-3.  Chapter five provides a synthesis and summary of the main findings of the adult 
MBL and PMTCT studies (detailed results are presented in the individual papers attached). 
The key cross-cutting themes that emerge from this work are discussed in Chapter six, while 
highlighting the significance of the findings in light of available literature, and the 
implications of our results to public health focusing on role of MBL genetic polymorphism in 
HIV infection and susceptibility.   This chapter also discusses the contributions of this thesis 
to available literature and knowledge and also gives the conclusions made based on the 
results from our two studies, highlights the limitations of our research, the public health 
implications of our results and recommendations for future studies that can be explored.   The 
three published papers, the manuscript under review and approval/permission letters are 
attached as (Appendices A-R) and other papers on the MUSH study co-authored by the 
candidate, related to my PhD work, but not included in this thesis (Appendix R). 
 
  
xxvii 
 
List of papers included in this PhD thesis 
This thesis is submitted in the integrating narrative format, approved by the Faculty of Health 
Sciences, of published work.  This thesis consists of three academic papers and one 
manuscript under review, listed below: 
 
1. Rutendo B.L Zinyama-Gutsire, Charles Chasela, Hans O. Madsen,  Simbarashe 
Rusakaniko, Per Kallestrup, MichaelChristiansen, ExneviaGomo, Henrik Ullum,  Christian 
Erikstrup,  Shungu Munyati, Edith N. Kurewa, Babill Stray-Pedersen,Peter Garred, Takafira 
Mduluza. 
Role of Mannose-Binding Lectin Deficiency in HIV-1 and schistosoma Infections in a Rural 
Adult Population in Zimbabwe 
PLoS One. 2015 Apr 1;10(4):e0122659. doi: 10.1371/journal.pone.0122659. eCollection 
2015. 
Student’s contribution to the paper 
Design of the study, seeking funding for the project grant, project management 
(including training fieldworkers and supervision of data collection), data management 
including data entry, cleaning and coding, data analysis and writing of the manuscript. 
 
 
2. Rutendo B.L Zinyama-Gutsire, Charles Chasela, Per Kallestrup,Simbarashe 
Rusakaniko, MichaelChristiansen, Bernard Ngara, ExneviaGomo, Henrik Ullum,  Christian 
Erikstrup,  Hans O. Madsen,Babill Stray-Pedersen,Peter Garred, Takafira Mduluza. 
HIV-1 Disease Progression and Survival in an Adult Population in Zimbabwe: Is There an 
Effect of the Mannose Binding Lectin Deficiency? 
xxviii 
 
 
 OMICS. 2015 Sep;19(9):542-52. doi: 10.1089/omi.2015.0047. 
 
Student’s contribution to the paper 
Design of the study, seeking funding for the project grant, project management 
(including training fieldworkers and supervision of data collection), data management 
including data entry, cleaning and coding, data analysis and writing of the manuscript. 
 
3. Rutendo B.L. Zinyama-Gutsire, Michael Christiansen, Christian Hagen, Simbarashe 
Rusakaniko, Paula L. Hedley, Babill Stray-Pedersen, Raluca Buzdugan R,Frances Cowan F, 
Charles Chasela. 
HIV-1 Vertical Transmission in Zimbabwe in 622 Mother and Infant Pairs: Rethinking the 
Contribution of Mannose Binding Lectin Deficiency in Africa. 
 
(OMICS: Journal of Integrative Biology, 2016 July;20(7):542-52. DOI: 
10.1089/omi.2016.0056. 
 
Student’s contribution to the paper 
Design of the sub-study, sought permission to access and use stored dried blood samples, 
seeking funding for the project grant, project management, data management including data 
entry, cleaning and coding, data analysis and writing of the manuscript. 
 
4. Rutendo B.L. Zinyama-Gutsire, MichaelChristiansen, Christian Hagen, Simbarashe 
Rusakaniko, Paula L. Hedley, Babill Stray-Pedersen, Raluca Buzdugan R,Frances Cowan F, 
Charles Chasela. 
xxix 
 
 
Optimization of MBL2 genotyping assay using dried blood spots: Experiences from the  
PMTCT Survey in Zimbabwe.   
(manuscript under review) 
 
Student’s contribution to the paper 
Design of the study, seeking funding for the project grant, project management 
data management including cleaning and coding, data analysis and writing of the manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxx 
 
Policy Brief 
 
Role of Mannose Binding Lectin Genetic Polymorphism in HIV-1 Infection among Adults 
and Children in Zimbabwe 
 
This policy brief can be found at: 
 
http://www.chp.ac.az/PolicyBriefs/Documents 
  
xxxi 
 
List of Abbreviations 
AIDS   - Acquired Immunodeficiency Syndrome 
CD4+ T cell count - Cluster of Differentiation 4 T cell count 
CD8+ T cell count -  Cluster of Differentiation 8 T cell count 
CDC   - Centres for Disease Control 
CI   - Confidence interval 
DHS     Demographic and Health Survey 
DNA   - Deoxyribonucleic Acid 
EIA   - Enzyme Immuno Assay 
e.g.   -  for example 
et al   - and others 
ENHR   - Essential National Health Research 
°C   -   Degrees Celcius 
Fig   - Figure 
HIV-1   - Human Immunodeficiency Virus 
hr   -  hour    
MASP-1  - MBL-associated serine protease-1 
MASP-2  - MBL-associated serine protease-2 
MBL   -  Mannose Binding Lectin 
MDGs -    Millenium Development Goals 
MoHCC    Ministry of Health and Child Care 
MRCZ    Medical Research Council of Zimbabwe 
MUSH Cohort -  Mupfure Schistosomiasis and HIV cohort 
PCR   -  Polymerase Chain Reaction  
xxxii 
 
PMTCT  - Prevention of Mother to Child Transmission 
RNA   - Ribonucleic Acid  
µl   - microlitres 
ml   - millilitres 
%   - percentage 
UNAIDS  - Joint United Nations Programme on HIV/AIDS 
WHO   - World Health Organization 
ZDHS    - Zimbabwe Demographic and Health Survey 
ZIMSTAT                 -          Zimbabwe National Statistics Agency 
 
 
 
 
  
xxxiii 
 
Table of Contents 
Candidate Declaration ................................................................................................................ ii 
Dedication ................................................................................................................................ iii 
Foreword ................................................................................................................................... vi 
Acknowledgements ................................................................................................................... ix 
Research Grant and Scholarship Support ............................................................................... xiv 
Abstract ................................................................................................................................... xvi 
Presentations arising from this thesis ..................................................................................... xxii 
Thesis overview and structure ............................................................................................... xxv 
List of papers included in this PhD thesis ............................................................................ xxvii 
Policy Brief ............................................................................................................................ xxx 
List of Abbreviations ............................................................................................................ xxxi 
Table of Contents ............................................................................................................... xxxiii 
List of Figures ........................................................................................................................... xl 
List of Tables ......................................................................................................................... xlii 
CHAPTER 1   BACKGROUND TO THE STUDY............................................................ 1 
1.0 Introduction ................................................................................................................. 1 
1.1 The Idea ....................................................................................................................... 1 
1.2 Originality of the thesis and role of the candidate ...................................................... 2 
1.3 Role of the PhD candidate in the MUSH study .......................................................... 2 
1.4 Role of the PhD candidate in the national PMTCT national survey ........................... 3 
1.5  The Candidate’s Role in Relation to the Thesis .......................................................... 3 
1.6 Expected Contributions ............................................................................................... 5 
1.7  Public Health Research ............................................................................................... 5 
xxxiv 
 
1.8 Policy Makers (Implementation) ................................................................................. 5 
1.9 Mannose Binding Lectin (MBL) ................................................................................. 6 
1.10 Polymorphism in the Mannose Binding Lectin Gene and Promoter Region .......... 7 
1.11 Mannose Binding Lectin and disease ...................................................................... 8 
1.12 Mannose Binding Lectin and HIV infection ........................................................... 9 
1.13 Mannose Binding Lectin and HIV infection in adults and children ........................ 9 
1.14 Role of MBL deficiency in HIV disease progression and survival ....................... 10 
1.21  Conceptual Framework ......................................................................................... 12 
CHAPTER  2  CONTEXT: PROFILE OF ZIMBABWE ................................................. 16 
2.0 Introduction ............................................................................................................... 16 
2.1 Geographic and Demographic Features .................................................................... 16 
2.2 Economic Status ........................................................................................................ 18 
2.3 Health Sector Overview ............................................................................................ 19 
2.4 HIV AIDS Trends in Zimbabwe ............................................................................... 19 
2.5 Organisational Structure of Health in Zimbabwe ..................................................... 20 
2.6 Health Indicators of Zimbabwe ................................................................................. 20 
CHAPTER 3  LITERATURE REVIEW .............................................................................. 22 
3.0 Introduction ............................................................................................................... 22 
3.1 Collectins ................................................................................................................... 22 
3.2  Mannose Binding Lectin  (MBL) ............................................................................. 23 
3.3  MBL discovery ......................................................................................................... 24 
3.4 MBL2 gene structure ................................................................................................. 24 
3.5 MBL1 pseudogene .................................................................................................... 25 
3.6  MBL2 gene and its variants ..................................................................................... 25 
3.7 MBL2 promoter region and its variants .................................................................... 27 
xxxv 
 
3.8 MBL2 genetic selection pressure .............................................................................. 30 
3.9  Biological Role of MBL : MBL and the complement system ................................. 30 
3.10 Biological role of MBL in HIV infection .............................................................. 32 
3.11 The biological mechanism of MBL binding to HIV ............................................. 32 
3.12 Role of ART on MBL deficiency and HIV infection ............................................ 33 
3.13 Definition of MBL deficiency ............................................................................... 36 
3.14 Prevalence of MBL deficiency worldwide ............................................................ 36 
3.15 MBL studies on African and Southern Africa populations ................................... 37 
3.16 Clinical trials on using recombinant MBL as therapy ........................................... 37 
3.18 MBL deficiency and susceptibility to infections in children ................................. 37 
3.19  MBL deficiency and susceptibility to infections in adults .................................... 37 
3.20 Mannose Binding Lectin and HIV infection: Biological mechanisms .................. 38 
3.21 Mannose Binding Lectin and HIV infection in adults ........................................... 39 
3.22 Role of MBL deficiency in HIV and schistosomiasis co-infections ..................... 40 
3.23 Mannose Binding Lectin and HIV infection in children ....................................... 42 
3.24 Diversity of the HLA gene .................................................................................... 42 
3.25 Diversity of the HLA gene in the Zimbabwean population and role in HIV 
infection 43 
3.26 Problem Statement ................................................................................................. 44 
3.27 Rationale ................................................................................................................ 44 
3.28 Research Questions................................................................................................ 45 
3.29 Broad Objective ..................................................................................................... 46 
3.30 Study Specific Objectives ...................................................................................... 46 
3.31 Hypothesis ............................................................................................................. 46 
3.32 Scope of this thesis ................................................................................................ 47 
xxxvi 
 
3.33 Thesis themes ........................................................................................................ 48 
4.0 Introduction ............................................................................................................... 49 
4.1  Study description ....................................................................................................... 49 
4.2 Study design .............................................................................................................. 49 
4.3 Study site and Population .............................................................................................. 51 
4.4 PMTCT cross sectional study ................................................................................... 52 
4.5 Exposures measured .................................................................................................. 52 
4.6 Outcomes measured .................................................................................................. 52 
4.7 Potential Confounders ............................................................................................... 53 
4.8 Sample size calculations............................................................................................ 54 
4.8.1 Sample size calculation for the main MUSH study ........................................... 54 
4.8.2 Sample size calculation for the original PMTCT national survey ..................... 55 
4.8.3 Sample size calculation for the MBL PMTCT sub-study .................................. 56 
4.8.4 Sampling plan of the PMTCT cross sectional study .......................................... 57 
4.9  Selection of study sample ......................................................................................... 58 
4.9.1  Inclusion criteria Adult study............................................................................ 58 
4.9.2 Exclusion criteria, Adult study .......................................................................... 58 
4.9.3  Inclusion criteria PMTCT cross sectional study ............................................... 58 
4.9.4 Exclusion criteria, PMTCT cross sectional study .............................................. 58 
4.10  Study procedures .................................................................................................. 59 
4.10.1  Procedures at enrolment .................................................................................... 59 
4.10.2  Source of samples for PMTCT study................................................................ 59 
4.11 Laboratory methods ............................................................................................... 59 
4.11.1 Adult study ......................................................................................................... 59 
4.12.0 PMTCT STUDY ....................................................................................................... 76 
xxxvii 
 
4.12.1 Study design and study population .................................................................... 76 
4.12.2 Laboratory procedures ........................................................................................... 76 
4.12.2.1 Collection of dried blood spots ...................................................................... 76 
4.13.0  Pyrosequencing Method.................................................................................... 80 
4.13.1  Amplification of MBL2 genes by Initial general PCR ...................................... 80 
4.13.2  Visualisation of PCR products by agarose gel electrophoresis ........................ 81 
4.13.3 Pyrosequencing reaction .................................................................................... 81 
4.13.4 MBL2 genotypes and haplotype functional groups ............................................ 84 
4.14 Data Management and Analysis ............................................................................ 84 
4.15 Additional statistical analysis carried out post publication of the three papers ..... 90 
4.15.1 Fractional polynomials to analyse disease progression ..................................... 90 
4.15.2 Power analysis for MUSH MBL study .............................................................. 91 
4.15.3  Power analysis for PMTCT study .................................................................. 91 
4.16. Ethics Considerations ............................................................................................ 92 
4.16.1 Ethics clearance for the PhD research project ................................................... 92 
4.16.2 Ethics clearance and considerations for the main MUSH study ........................ 92 
4.16.3 Blood sampling .................................................................................................. 93 
4.16.4 Testing the participants for HIV ........................................................................ 93 
4.16.5 The prevention of HIV and other STIs .............................................................. 93 
4.16.6 Treatment for schistosomiasis............................................................................ 93 
4.16.7Ethics considerations for the PMTCT survey and access to dried blood samples. 93 
4.16.8 Data protection and absolute confidentiality ..................................................... 94 
CHAPTER 5  RESULTS: SUMMARY OF KEY FINDINGS ............................................ 95 
5.0 Introduction ............................................................................................................... 95 
5.1   Socio-demographic characteristics of the two study populations ................................ 95 
xxxviii 
 
5.2.     Synthesising the two sub-studies .............................................................................. 96 
5.3.   Study themes ............................................................................................................... 96 
5.4 Additional statistical analysis not included in paper 1 .............................................. 99 
5.4.1 Power analysis for the Adult MBL study .......................................................... 99 
5.4.2 Power analysis of the adult MBL study corresponding to different hazard ratios
 100 
5.5 Additional statistical analysis not included in paper 2 ............................................ 100 
5.5.1 Role of MBL deficiency in disease progression after controlling for 
schistosomiasis ............................................................................................................... 100 
5.5.2 Multiple GEE regression analysis .................................................................... 100 
5.5.3 Analysis of disease progression, treating MBL as a continuous variable using 
fractional polynomials ................................................................................................... 101 
5.6 Additional statistical analysis not included in paper 3 ............................................ 109 
CHAPTER 6:  DISCUSSION, CONCLUSIONS, PUBLIC HEALTH IMPLICATIONS OF 
THE STUDY AND RECOMMENDATIONS FOR FURTHER RESEARCH. ................... 110 
6.1 Introduction ............................................................................................................. 110 
6.2 Study Limitations .................................................................................................... 112 
6.3 Public Health Implications ...................................................................................... 112 
6.4 Recommendations for Future Studies ..................................................................... 113 
REFERENCES ...................................................................................................................... 114 
Appendices ............................................................................................................................. 127 
Appendix A: Published paper 1 and published supplementary materials .......................... 128 
Appendix B: Published paper 2 and Supplementary materials .......................................... 162 
Appendix C: Published paper 3 and published supplementary materials .......................... 177 
Appendix D: Manuscript under review.............................................................................. 189 
xxxix 
 
Appendices   E TO R ......................................................................................................... 207 
Other Papers on the MUSH study co-authored by the candidate related to my PhD work, 
but not included in this thesis: ........................................................................................... 221 
 
  
xl 
 
List of Figures 
CHAPTER 1 
Figure 1.1:The conceptual framework for association between MBL deficiency and HIV  
infection in adults and children. ...........................................................................................18 
 
CHAPTER 2 
Figure 2.1:Map of Zimbabwe and Surrounding Countries. .................................................19 
Figure 2.2:Map of Zimbabwe showing location of Capital City Harare and other cities....20 
 
CHAPTER 3 
Figure 3.1:Structure of MBL2 gene, MBL polypeptide and MBL structural subunits..........31 
Figure 3.2:  Organization of Exon 1 of the MBL2 gene and MBL2 promoter region.  The  
variant alleles are B,C and D.  The promoter region alleles are H/L, X/Y and 
PQ........................................................................................................................32 
Figure 3.3:  Worldwide distribution of MBL genotypes ........................................................33 
Figure 3.4:Role of MBL protein in the complement system.  Complement activation can  
occur through the classical, the alternative or the lectin     
pathway............................38 
Figure 3.5:  Role of MBL protein in the Complement system. ..............................................39 
 
CHAPTER 4 
Figure 4.1:Map of Zimbabwe.  Showing study area for the adult cohort, Mupfure in the  
North of the capital City Harare.  Samples for the PMTCT study were collected  
from all the 10 provinces of Zimbabwe..............................................................52 
xli 
 
Figure 4.2:  Community Sensitization in Mupfure, Mt Darwin..............................................53 
Figure 4.3:Schistosoma parasitology.  Processing urine and stool samples in Mupfure........61 
Figure 4.4: Processing PBMCs at the site laboratory in Mupfure...........................................64 
Figure 4.5:  DNA extraction at Rigshospitalet in Denmark, Dr Peter Garred laboratory.......66 
Figure 4.6: Photographs of the MBL gels taken in the UV Transilluminator........................71 
Figure 4.6b Photograph of MBL gel.......................................................................................72 
Figure 4.7:  Dried blood spots from mother and baby pairs....................................................76 
Figure 4.8:  Preparation of dried blood spots, punching 3mm spots for DNA extraction.......77 
Figure 4.9:  Principle of the pyrosequencing reaction.............................................................79 
Figure 4.10:Preparation of pyrosequencing primers...............................................................79 
Figure 4.11:Checking quality of the pyrosequencing programs.............................................80 
  
xlii 
 
List of Tables 
CHAPTER 2 
Table 2.1: Health Indicators for Zimbabwe. ...........................................................................24 
 
CHAPTER 3 
Table 3.1: Classification ofMBL2 haplotypes and plasma MBL concentration  
 
CHAPTER 4 
Table 4.1: Showing different sample size calculations for the PMTCT study carried out using  
      Epi Info Version 7 programme..............................................................................58 
Table 4.2:The 12 oligonucleotide primer sequences and the Exon 1 internal control primer,  
that were used in this study for detection of MBL2 coding and promoter normal  
and variant alleles. .................................................................................................70 
Table 4.3: Showing the determination of MBL2 genotypes and promoter types using the  
electrophoresis gel bands on the photograph taken by the UV trans-illuminator..73 
 
CHAPTER 5 
Table 5.1:The factors associated with change in CD4+ T cell counts from baseline to 3 years  
 follow up period, after controlling for schistosomiasis infection…………………93 
Table 5.2:Thefactors associated with change in viral load from baseline to 3 years follow up  
 period, after controlling for schistosomiasis ………….…………………………96 
Table 5.3:GEE Multiple Regression analysis of factors associated with change in CD4+ T  
 cell counts from baseline to 3 years follow up period, after controlling for  
schistosomiasis …………………………………………………………………98 
Table 5.4: GEE Multiple regression analysis of factors associated with change in viral load  
xliii 
 
from baseline to 3 years follow up period, after controlling for  
Schistosomiasis………………………………………………………………...100 
1 
 
CHAPTER 1   BACKGROUND TO THE STUDY 
1.0 Introduction 
This chapter describes what inspired me to undertake this study on the role of MBL 
deficiency in HIV infection among Zimbabwean adults and children.  Zimbabwe is 
one of the countries in the world worst affected by the HIV pandemic and the 
prevalence declined from a high of 33% in the 1990s and has now declined to 13% 
among the 15-49 age group [4].  However, HIV related diseases still remain the main 
causes of morbidity and mortality among both adults and children in Zimbabwe.  
With my background as a laboratory scientist, I was very keen to know about and 
followed developments with keen interest on the immunological and genetic factors 
that were being reported from other countries that increased susceptibility to HIV 
infection among sexually active age groups and vertical transmission from mothers to 
their children.  For this research I decided to focus on Mannose Binding Lectin as 
there was conflicting evidence available in literature about its role in HIV infection.  
We therefore determined the role of MBL deficiency in HIV infection in a rural adult 
study population from the MUSH cohort and from a PMTCT national survey which 
enrolled mothers and their infants.  Some of the adults in the MUSH cohort were also 
co-infected with schistosomiasis, a common infection in rural Zimbabwe.   
 
1.1 The Idea 
The role of MBL deficiency in diseases has been a topic of interest over the last two 
decades.  We decided to investigate the role of MBL deficiency in the Zimbabwean 
adults and children because of the high HIV prevalence in our population.  An 
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understanding and appreciation of the immunological factors fuelling the HIV-1 
epidemic and increasing susceptibility to the infection in African populations is very 
important in an effort to curb the HIV-1 scourge. 
 
Over the last decades there has been increased interest in investigating the host 
genetic factors that could lead to increased susceptibility to infections including HIV.  
Mannose Binding Lectin (MBL) is one such molecule that has been reported on.  
Mannose-Binding Lectin is a key component of the innate immune system and 
polymorphism in the MBL2 gene and promoter region lead to MBL deficiency [5-7]. 
My hope and expectation is that the results from this research will result in 
improvement in the health of the population of my country as we understand the role 
of host genetic factors in infections focussing on HIV and schistosomiasis. 
 
1.2 Originality of the thesis and role of the candidate 
The candidate conceived the MBL adult sub-study in 2001.  Then in 2013 to give a 
more complete picture of the role of MBL in HIV infection the candidate developed 
the PMTCT MBL sub-study.  The candidate carried out MBL analysis on the samples 
from the adult and from the PMTCT samples.  The results of MBL analysis in the 
adult MUSH cohort and the PMTCT samples form the basis of this thesis.     
 
1.3 Role of the PhD candidate in the MUSH study 
The adult cohort addressing the role of MBL in disease progression was a sub-study 
that was nested into the MUSH cohort in Zimbabwe, conceived and led by the PhD 
candidate.  The sub-study assessed the relationship between MBL plasma 
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concentration, MBL2 genotypes, HIV infection, HIV disease progression and survival 
in these adults.  The PhD candidate carried out HIV testing, MBL ELISA and MBL2 
genotyping by PCR in an established laboratory using established primers in Dr 
Garred’s MBL laboratory in Denmark in 2006.   
 
1.4 Role of the PhD candidate in the national PMTCT national survey 
The candidate did not take part in the national PMTCT survey and did not participate 
in sample collection.  Stored dried blood samples from mothers and baby pairs were 
obtained from the CESHAAR Research Centre in Zimbabwe that had stored whole 
blood samples for mother –infant pairs from a national PMTCT survey carried out in 
2012.   Permission to access and use stored dried blood spots for this research project 
was sought and granted by the CESHAAR study team and University of California.  
Ethical and scientific clearance was granted by University of the Witwatersrand and 
the Medical research Council of Zimbabwe 
 
1.5  The Candidate’s Role in Relation to the Thesis 
In relation to this thesis the candidate’s role can be outlined as follows: 
1 Conception of the adult and PMTCT MBL sub-studies and design of the 
protocol. 
2 Supervision of the collection of all MUSH related data which included 
variables used for this analysis. 
4 
 
3 Participation in follow up of MUSH research participants for sample 
collection over the three year follow up period and for schistosomiasis 
treatment. 
4 Preparation of research ethics submissions to University of the 
Witwatersrand and the Medical research Council of Zimbabwe. 
5 Preparation and submission of application to ship dried blood samples to 
Denmark in 2014. 
6 Securing a Letten PhD fellowship for registration at University of the 
Witwatersrand. 
7 Conduct of detailed literature review for the study protocol and the thesis. 
8 Negotiation with Professor Michael Christiansen for permission to do 
MBL assays on the PMTCT samples at serum State Institute in Denmark. 
9 Optimisation of the DNA extraction, PCR and pyrosequencing assays for 
the PMTCT samples. 
10 Data cleaning, recoding of variables, exploration analysis, tracking of 
missing data, not only for data related to this analysis but from data 
collected for the main MUSH cohort.  The tracking of missing data was 
done on site from the study results laboratory sheets. 
11 Conduct of statistical analysis using STATA. 
12 Interpretation of results and generation of all tables and figures included in 
this thesis.  
13 Scientific presentations of results from this thesis at:  
(a) 6th South Africa AIDS, conference, Durban as a poster, 18–21 June 
2013 
(b) IAS Conference 2015 in Vancouver, Canada, July 2015 
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(c) Letten Research Symposium held at the Letten House, Harare, 
Zimbabwe on 14-15 August 2016. 
(d) AIDS 2016, 21st International AIDS Conference,18–22 July 2016, 
Durban, South Africa 
 
1.6 Expected Contributions 
The potential contributions of this study to public health research and to public health 
policy in Zimbabwe are identified as follows: 
1.7  Public Health Research 
1. Establish the prevalence of MBL deficiency among adults in the Zimbabwe 
MUSH cohort. 
2. Establish the prevalence of MBL deficiency among adults in the Zimbabwe 
MUSH cohort and its role in HIV infection. 
3. Determine the role of MBL deficiency in HV disease progression and survival 
among the MUSH cohort adults 
4. Establish the prevalence of MBL deficiency among mothers and their infants  
a subset of samples collected during a PMTCT national survey. 
5. Establish the prevalence of MBL deficiency among Zimbabwean mothers and 
their infants and its role in HIV vertical transmission.  
1.8 Policy Makers (Implementation) 
1. Provide evidence on the role of MBL deficiency in HIV infection and vertical 
transmission 
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2. Explore the use of dried blood spots for MBL genotyping using the PMTCT 
samples 
3. This study aimed to identify and explore potential biomarkers for 
susceptibility to HIV infection and disease progression since Zimbabwe has a 
high burden of HIV infection it is important to undertstand the immunological 
correlates. 
 
1.9 Mannose Binding Lectin (MBL) 
Human MBL is a normal serum protein discovered in the 1980s, produced in the liver 
and derived from a single gene on chromosome 10 [8].  It is a multichain calcium 
dependent lectin that belongs to the collectin family, a group of carbohydrate binding 
proteins [8, 9].  It is a key first line defence molecule, acts as an opsonin in innate 
immunity and activates the complement system by binding to the sugar groups found 
on the surfaces of various infectious agents like bacteria, viruses and parasites [8, 10].  
MBL deficiency which is an inherited condition, is due to point mutations in the 
MBL2 gene and promoter region and this is common in both black and white 
populations[7].   The MBL2 gene has well documented promoter region positions, -
550, -221 and +4 [7].  Point mutations in the MBL2 gene and MBL2 promoter region 
lead to genetic polymorphism, defined as the appearance of different forms of the 
MBL2 gene and promoter region genetic variants [6, 7].   MBL2 genetic 
polymorphism negatively affects gene expression and results in impaired protein 
function [8].  The normal MBL concentration in plasma/serum is 1000µg/L and above 
and MBL deficiency is below 100µg/L [5-7, 10-13].  The presence of MBL2 genetic 
and promoter region variants are strongly associated with low plasma/serum MBL 
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levels defined as MBL deficiency [6, 7].  MBL deficiency has been reported to be 
associated with increased susceptibility to several infections like TB [14], malaria 
[15], cystic fibrosis [16], cytomegalovirus infection [17], cryptosporidiosis [18], 
schistosomiasis [19], early childhood infections like recurrent respiratory infections 
[20]  and HIV [10, 21, 22]. 
 
1.10 Polymorphism in the Mannose Binding Lectin Gene and Promoter 
Region 
Polymorphism in the MBL2 gene due to  genetic point mutations result in presence of 
variant MBL2 alleles.  The normal MBL2 allele is known as A [8].  The variant MBL2 
alleles encode three different structural  variants B, C, and D, due to mutations at 
codons 54, 57 and 52 respectively of the MBL polypeptide, which affect the structural 
integrity of MBL protein, resulting in 2-fold to 100-fold decrease in circulating MBL 
serum/plasma levels [6].  Mutations and variations in the MBL2 gene are the basis 
why there is such a wide range of circulating MBL levels in different populations [6].  
These mutations lead to a reduction of functional MBL to 10% in individuals that are 
heterozygous for defective alleles compared with the functional MBL found in 
individuals with two functional alleles [6, 8].  Mutations in the MBL2 gene cannot 
explain all the large interracial and inter-individual variations in MBL concentrations 
reported so far.  In addition to the mutations in the MBL2gene, there are also point 
mutations in the MBL2 promoter region at positions -550 (H/L), -221 (X/Y) and in the 
5’ untranslated region of exon 1 at position+4 (P/Q), which also affect plasma/serum 
MBL levels which have been well documented [6].   
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1.11 Mannose Binding Lectin and disease 
The ability to respond effectively to infectious agents is a prerequisite for the survival 
of multi-cellular organisms.  MBL is a key constituent of the innate immune defence 
system where it acts as an opsonin and it belongs to a group of host-defence 
associated protein domains involved in recognition of infectious agents [23].  MBL 
recognises a broad range of sugar molecular patterns on a broad range of infectious 
agents and is able to distinguish these from normal host cells.  MBL activates the 
complement system by binding to sugar groups, which include high mannose and N-
acetylglucosamine oligosaccharides which are found on the surface of various gram 
positive and gram negative bacteria, viruses, yeasts, mycobacteria and parasites [8, 9].  
 
Upon binding to the micro-organism, MBL activates the complement system through 
co-opting the action of MBL-associated serine proteases (MASPs) called MASP1 and 
MASP2 [24, 25].  MBL, recognises sugar molecules on the surface of an infecting 
pathogen, binds to both pathogen and MASPs, MASP2 binds and cleaves C3 
component of the complement system and this indirectly activate the complement 
system cascade in an antibody independent manner, leads to deposition of opsonins 
on the surface on infecting pathogens  and clearance of the infection [24, 26].  MBL 
deficiency therefore results in an impaired first line host defence system therefore 
leading to increased susceptibility to various infections.  
  
9 
 
1.12 Mannose Binding Lectin and HIV infection 
MBL has been shown to play a defensive role in HIV infection as MBL and HIV both 
compete for binding to the CCR5 receptor, the major receptor for HIV-1 [27].  MBL 
activates the complement system by binding to carbohydrate molecules which are also 
present on the HIV-1 virion surface thus contributing to HIV-1 clearance [28].  MBL  
binds and opsonizes the HIV-1 virus hence affecting HIV-1 virus trafficking and 
antigen presentation during HIV infection [29].  In vitro studies suggest a link 
between MBL levels and HIV pathogenesis , purified MBL has been shown to bind to 
HIV infected cell lines and can inhibit infection of lymphoblast by HIV, MBL can 
bind to and activate gp120 complement and MBL binds to both CCR5 and CXCR4-
tropic HIV primary strains[29].  Individuals with MBL deficiency have dysfunctional 
MBL protein and are more at risk of acquiring HIV infection and HIV disease 
progression, amongst infected populations [10, 21].       
1.13 Mannose Binding Lectin and HIV infection in adults and children 
Zimbabwe is one of the countries that are worst affected by the HIV pandemic with a 
prevalence of 13.6% among adults [4].  HIV MTCT is the second major route of HIV 
transmission and the national MTCT rate in Zimbabwe has declined from a high level 
of 26-29%  in 2009 [30] to 6.6% in 2015 [31, 32].Several studies have been done 
worldwide on MBL because of its role in innate immunity and the possible 
association of MBL deficiency with HIV infection  and disease progression in  adults 
and children, reviewed in  [33, 34].  Results from studies in adults on the role of MBL 
in HIV infection are still conflicting, there are reports of a detrimental effect of the 
promoter region variants XA [22]  and increased susceptibility to HIV transmission 
[21]. There is conflicting information on role of MBL deficiency on HIV infection 
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and disease progression among infected adults[35].  While other studies have reported 
association of MBL deficiency with increased risk of HIV infection [21], others have 
reported no association between MBL gene polymorphism  and also promoter region 
polymorphism and HIV infection [36].   Similarly, while some studies have reported 
increased rate of HIV disease progression to AIDS, others have shown either no effect 
or delayed rate of disease progression [37].  Most of these studies have been done in 
European populations, only two studies have been done on African adults, in 
Tanzania [10] and Gabon [38], which showed increased risk of HIV infection among 
those with MBL deficiency, but no such study has been reported for any adult 
population from Southern African countries.  Only 3 studies have reported 
investigations on MBL deficiency and HIV in children in Southern Africa [39-41] and 
only one such study reported on Zimbabwean children [39].  The results from these 
three studies are conflicting, Mhandire et al [39] and Zupin et al [41] both reported no 
association between presence of MBL2 exon 1 variants and HIV infection in the 
Zimbabwean children investigated, in contrast to results showing statististically 
significant association between MBL deficiency, MBL variants among HIV infected 
children [40].   Our research study aimed to address the research gap that while there 
have been many studies on MBL and HIV among adults and children, the available 
results are conflicting.   
 
1.14 Role of MBL deficiency in HIV disease progression and survival 
Several studies have investigated the role of MBL deficiency in HIV disease 
progression [21, 42-50]and survival [21, 44].  HIV disease progression is 
characterized by decline in CD4+ T cell count and increase in HIV viral load [51-
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57]eventually leading to death in the absence of treatment [51-57].  Available 
literature on the association between MBL deficiency and disease progression is 
conflicting, some report faster HIV disease progression due to MBL deficiency [21, 
46, 49, 50] but others found no association [42, 47, 58, 59].  Others report association 
between MBL deficiency and decreased survival in HIV infected people [21]but 
conflictingly others reported increased survival in those with variant MBL2 genotypes 
and MBL deficient individuals [44].  We hypothesized that MBL deficiency had a 
role to play in HIV infection by increasing HIV disease progression and decreasing 
survival.  We therefore assessed the role of plasma MBL deficiency and MBL2 
genetic variants, on HIV-1 disease progression and survival in a Zimbabwean adult 
population enrolled in the Mupfure Schistosomiasis and HIV cohort (MUSH) cohort.   
 
 There is therefore need to carry out more such investigations in Sub-Saharan Africa 
where there are high HIV prevalence rates and where the predominant HIV is subtype 
C, unlike in European populations with mostly HIV subtypes A and B, reviewed in 
[33].   Several studies have been done investigating MBL and its association with 
HIV infection in children [60], looking at different aspects and most of these have 
been done in populations outside Africa, except three studies carried out on Southern 
African children [39-41].  Some studies investigated association between MBL 
deficiency and HIV transmission from mother to child, some studied MBL deficiency 
and HIV disease progression  and some have looked at both [33].   Unlike studies that 
are linking MBL deficiency and HIV infection and disease progression in adults, there 
is concordance in all the studies among children [33].   Studies on MBL deficiency 
and HIV transmission showed that MBL deficient genotypes were significantly 
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increased in HIV infected children compared to either HIV exposed but uninfected 
children or HIV unexposed controls [33].   
 
For this research project, immunological analysis of plasma samples and genetic 
analysis of DNA samples for MBL2genetic variants among the adult population used 
the Mupfure Schistosomiasis and HIV (MUSH) cohort [61, 62], while questions 
regarding the role of MBL deficiency in HIV acquisition and transmission from 
mother to child used stored blood from and PMTCT program. The blood samples 
from the PMTCT cross survey provided us with an opportunity to investigate if MBL 
deficiency is a factor in vertical transmission or acquisition of HIV among infants in 
Zimbabwe.   
1.21  Conceptual Framework  
The conceptual framework [63] for our study was based on the graphical disease 
causality model recommended for use in health sciences research [64, 65], adapted 
and modified to suite the requirements of this study (Fig.1.1).  Diagrams of causal 
pathways are used to visually summarize hypothetical relations among variables of 
interest [64].  Nolan et al 2004 provided a broad conceptual framework for 
considering the impact of host genetic diversity on HIV/AIDS, arguing that host 
genetic variation is an important factor in the response to HIV for every infected 
individual [66].  The causal graph provides a visual representation of key concepts of 
the research to be undertaken and the expected outcomes [64, 67,68].  Our study 
consists of six main concepts namely HIV exposure, MBL2 genetic polymorphism, 
adult HIV infection/acquisition, mother to child HIV vertical transmission, HIV/AIDS 
disease progression and survival.  The relationship of these concepts is presented in 
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the conceptual framework below (Fig. 1).  Our research fitted well into this 
conceptual framework as we aimed to determine role of MBL deficiency on HIV 
infection as only three such studies have been done in African adults in Tanzania [10] 
and Gabon [38]and three carried out on African children [39-41].  Our study is the 
second reported after the Zambian study [41], to investigate the MBL2 genotypes of  
HIV positive mothers and their infants in association with HIV vertical transmission. 
 
1.19.1 HIV exposure 
Adults are exposed to HIV infection through unprotected sexual contacts, sharing 
sharp instruments for example drug users and blood transfusion [69, 70].  Unborn 
babies are exposed to HIV infection in the uterus and/or during delivery and one third 
of the children born to HIV positive mothers but who test negative for HIV infection 
can become infected through breastfeeding in the absence of ART [69, 70].  
 
1.19.2    MBL2 genetic polymorphism 
MBL deficiency is an inherited immunological condition that results in appearance of 
variant forms of the MBL molecule[5-7].  Mutation in the MBL2 gene and promoter 
region results in variant MBL2 alleles and low MBL concentration in plasma[5-7]. 
MBL deficiency leads to impaired phagocytic ability of the innate immune system 
therefore increase susceptibility to several infections including HIV[35]. 
1.19.3    HIV infection/acquisition in adults 
Three main routes of HIV infection are known namely sexual contact, through 
infected body fluids and mother to child transmission [70, 71].  The national HIV 
prevalence in Zimbabwe is currently 13.6% among adults and the main mode of 
transmission is heterosexual contacts[71, 72].  
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1.19.4    Mother to child HIV transmission 
An HIV infected mother can transmit infection to her unborn child during pregnancy, 
during delivery or through breastfeeding [73].  MTCT is the second major route of 
HIV transmission and the national MTCT rate in Zimbabwe has declined from a high 
level of 26-29%  in 2009 [30] to 6.6% in 2015 [31, 32].   
 
1.19.5    HIV/AIDS disease progression 
After infection, in the absence of ART, HIV infection progresses to AIDS disease 
through four main stages, primary infection, clinically asymptomatic stage, 
symptomatic HIV infection and progression from HIV to AIDS [69, 70].  As done in 
several other studies viral load and CD4+ T cell counts were used as indicators of 
disease progression in our adult study population [45, 74].  Our study compared 
disease progression in the HIV positive adults between those with the wild type MBL2 
alleles and promoter types and those with variant MBL2 alleles and promoter types. 
 
1.19.6    Survival 
Survival after HIV infection greatly varies between individuals, but an infected 
individual can succumb to AIDS after about 5 years without treatment  but with ART  
survival rate increases [69, 70].  Mortality due to HIV/AIDS was used to compare  
survival rates among the adults with normal MBL2gene and promoter region types  
and those with variant MBL2 alleles and promoter types.  Survival rates were  
compared among the HIV positive adults between those with the wild type MBL2 
alleles and promoter region types and those with variant MBL2 alleles and promoter  
type 
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Figure 1.1: The conceptual framework for association between MBL deficiency and 
HIV infection in adults and children.  
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CHAPTER  2  CONTEXT: PROFILE OF ZIMBABWE 
2.0 Introduction 
This chapter provides background information on Zimbabwe and gives a broader 
picture of the study setting, describing geographical, economic and health context of 
the country.  
 
2.1 Geographic and Demographic Features 
Zimbabwe is located in Sub-Saharan Africa, south of the equator[75].  Zimbabwe is a 
landlocked country, sharing borders with South Africa to the south, the Republic of 
Mozambique to the east and the Republic of Zambia to the north (Fig. 2.1). 
 
 
Figure 2.1.Map of Zimbabwe and Surrounding Countries 
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Figure 2.2:Map of Zimbabwe showing location of Capital City Harare and other 
cities 
 
Zimbabwe covers an area of 390 759 square kilometres[75-77].  The country has 10 
provinces divided into 58 administrative districts[76].  The districts are divided into  
wards and the wards are further sub-divided into traditional villages and each village 
is headed by chiefs[76].  Zimbabwe has 10 major cities and several smaller towns, 
Harare is the political and commercial capital (Fig.2.2).  Other major cities include 
Bulawayo to the South, Mutare in the East, Marondera, Masvingo, Gweru and 
Kwekwe (Fig. 2.2).   
The population of the country is estimated currently to be 13,7 million, with 52% 
females[75, 77].  The annual growth of the population is 2.1% as determined in the 
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2012 national census[77].  The population density is 33 persons per square 
kilometre[77].  The average number of children per household is 4 with most families 
in rural areas having 5 children[75, 78].  Zimbabwe has 42% of the population under 
18 years of age and the average life expectancy is 54 years for men and 53 years for 
women years[76].  The high population density puts the country under considerable 
economic stress, especially when most of the population is rural and the economy is 
agro-based.  Zimbabwe‘s main languages include Shona, Ndebele, Chichewa, Tonga.  
English is used as the official language[75].  
 
2.2 Economic Status 
Zimbabwe is classified as a developing country[75].  Zimbabwe, a former British 
colony, obtained its independence from Britain in April 1980 after a long armed 
guerilla warfare[75]. All sectors of the economy performed well then, until the early 
1990s.Zimbabwe is the only country in the Southern Africa Development Community 
(SADC) region currently experiencing a negative economic growth rate, 
hyperinflation leading to a huge political and economic crisis since year 2000[75].  
Over the last 15 years the Zimbabwean economy has deteriorated from being one of 
Africa's strongest to being the world's worst with the official inflation rate estimated 
at more than 1 000% in 2006[75, 79]. 
 
More than half of the population (70%) is currently living a life below the poverty 
datum line (less than one USA dollar/day) in 2016 with about half (50%) living in 
ultra poverty[75, 79].  The economy is predominantly agriculture but this sector of the 
economy has been affected by the economic crisis characterised by high costs of 
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inputs and cash shortages[75, 79].  Much of Zimbabwe’s poverty is caused by poor 
economic governance, unemployment and the HIV/AIDS pandemic[75, 79].  
 
2.3 Health Sector Overview 
Zimbabwe is currently experiencing poor health indicators among the general 
population [76].  The major causes of morbidity and mortality are preventable and 
curable diseases such as malaria, pneumonia, diarrhoea, tuberculosis, and other 
infectious diseases which are endemic.   
 
2.4 HIV AIDS Trends in Zimbabwe 
HIV and AIDS remain the leading causes of morbidity and mortality among the 15 to 
49 years old [31].  The first AIDS case was reported in 1985 in Zimbabwe, from 1985 
to the mid-90s the HIV prevalence rose sharply to reach a peak of 27.7% in 1997 and 
started declining thereafter[4, 31].  The decline in prevalence is attributed to the 
impact of prevention programs aimed at behavior change (high condom use and 
reduction in multiple sexual partners), elimination of Mother to Child Transmission 
services, and successful treatment care and support services[4, 31].The HIV epidemic 
together with tuberculosis (TB) has become the major cause of morbidity and 
mortality affecting both adults and children over the last three decades [31].  The 
main underlying causes of poor health indicators include widespread poverty, 
unemployment, chronic malnutrition, low educational status mostly in rural areas, 
poor sanitation, poor access to safe water, and inadequate capacity of the healthcare 
system to deliver quality and accessible health services[75, 79].  
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2.5 Organisational Structure of Health in Zimbabwe 
The delivery of health services in Zimbabwe relies on locally trained doctors and 
nurses but we have experienced huge brain drain over the last 20 years as the trained 
medical professionals have left the country for greener pastures in surrounding 
countries and overseas[75, 79]..  Thus critically paralyzing the health care system 
with only one physician per 100,000 and 40 nurses per 100,000 populations [31, 75, 
79] (Table 2.1).  Health service delivery has four main levels of care:  rural health 
centres / rural health posts, rural hospitals servicing three or four health centres, 
district hospitals and a central hospital in each of the 10 provinces.  Coverage of 
antenatal care is 71% with 60% of babies delivered by skilled attendants (nurses, or 
doctors)[75, 76], (Table 2.1).  Funding for the health services has been through 
partnerships between the Ministry of Health and Child care and donor agencies 
including WHO, UNICEF, CDC, UNAIDS, JICA and others[31, 76]. 
 
2.6 Health Indicators of Zimbabwe 
Health care in Zimbabwe is provided predominantly through the public sector.  The 
major central referral hospitals are Parirenyatwa and Harare hospitals situated in 
Harare and Mpilo situated in Bulawayo.  This study was conducted among adult 
males and females in Mashonaland Central Province and among mothers and their 
children enrolled for a national PMTCT evaluation programme which involved all 10 
provinces in Zimbabwe. 
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Table 2.1: Health Indicators for Zimbabwe 
Health Indicators for Zimbabwe  
Crude Birth Rate per 1,000 population[31, 75-77] 33 
Infant  Mortality Rate per 1,000 live births [76, 77] 90 
Mortality Rate in <5 year olds per 1,000 live births [76, 77] 72 
Life expectancy at Birth (both sexes) [76, 77] 53 years 
Maternal Mortality Rate per 100,000 live births [76, 77] 960 
Physicians per 100,000 population [75-77] 1 
Nurses per 100,000 population [76, 77] 40 
GDP per capita[75-77, 79] 953.38US$ 
HIV prevalence in 15-49 years in 2014 [4, 75-77] 13.6% 
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CHAPTER 3  LITERATURE REVIEW 
3.0 Introduction 
This chapter provides details on literature on collectins, their role in innate immunity, 
introduces the MBL molecule, its discovery and role in innate immunity.   
3.1 Collectins 
Mannose Binding lectin (MBL), which is the molecule of interest in this research 
project, belongs to a group of chimeric molecules comprising globular heads, which 
contain the carbohydrate recognition domain, and collagen tails and are defined as 
collectins [80-82].  Collectins are the humoral lectins found in mammals and birds, 
they are oligomers whose subunits comprise three polypeptide chains each containing 
a collagenous section and a C-terminal lectin domain[80-82].  Collectins are reported 
to be related structurally and functionally to the first component of the classical 
complement pathway, C1q, and serve important roles in innate immunity through 
opsonization and complement activation[80-82].  Collectins are carbohydrate binding 
proteins containing a carbohydrate recognition domain at one end and a collagen-like 
stalk domain at the other end.  The lectin domains is capable of binding carbohydrates 
on microorganisms, while the collagenous regions are ligands for the collectin 
receptor on phagocytes and also to mediate C1q-independent activation of the 
classical complement pathway.  The mannose-binding lectin (MBL), pulmonary 
surfactant apoproteins A and D and conglutinin are members of the collectin family, 
whose function is mainly as pattern recognition molecules involved in the first line of 
defence in the innate immunesystem [80, 82, 83]. 
23 
 
3.2  Mannose Binding Lectin  (MBL) 
Human MBL is a normal serum protein, synthesized in the liver and released into the 
bloodstream and belongs to the above mentioned calcium-dependent collectin family 
[80, 84-86].   The MBL protein is encoded by the MBL2 gene located on 
chromosome 10 at 10q.11.2q21 [83, 84, 87,88] and MBL1 is a pseudogene [88].  An 
analysis of the genomic nucleotide sequence and the cDNA sequence of MBL showed 
that the MBL protein coding region was made up of four exons separated by three 
introns of 600, 1350 and 800 base pairs [84].  Exon 1 and 2 encode the signal peptide, 
a cystein and glycine rich domain of repeated amino acids motif, typical for the triple 
helix formation of collagen structures and exon 3 encodes the neck region and exon 4 
encodes the carbohydrate binding domain [84].  The MBL protein is synthesised in 
the liver as structures consisting of three to six triple helix oligomers[84].  The final 
MBL protein is made up of oligomers, each with three identical polypeptide 32 kDa 
chains as evaluated on SDS-PAGE [89].  Many oligomeric forms of MBL with 
different functional capabilities have been found in human serum/plasma[90-93].  The 
functions of MBL  are strongly influenced by its concentration and its oligomerization 
both of which are affected by factors like race, age, host  immune-competent state, 
infection status, and also determined by presence of mutations in the gene or promoter 
region[5-7, 83, 94].   
A small proportion of MBL protein is produced from transcripts which originate from 
exon 0 but the vast majority of liver synthesised MBL protein is from exon 1 initiated 
transcripts[6]. 
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Low MBL levels in serum/plasma have been associated with various diseases 
including increased risk of infection with HIV [21], tuberculosis [38], lung diseases 
[95] and unusual infections in adults [96]. 
3.3  MBL discovery 
In 1968 a patient with a serum-dependent opsonic defect in phagocytosis of yeast 
particles was described for the first time [97].  The opsonic defect was subsequently 
linked to the complement system as the C3 complement molecule was deposited in 
lower amounts on yeast surfaces incubated in sera of individuals with the opsonic 
defect [98, 99].  Independent of the efforts in humans, a protein was discovered and 
extracted from rabbit liver using mannan particles from Saccharomyces cerevisiae as 
a probe [100]. This protein was initially given the name mannan binding protein 
(MBP) that was later renamed to Mannose Binding Lectin [80, 101].  It was later 
shown that MBL was also present in human serum and that it could activate the 
complement system when it binds to a mannan surface [85, 102].  Subsequently it was 
shown that the originally described opsonic/phagocytic defect was due to MBL 
deficiency and was first described in 1989 [103].  MBL was first documented in 1988 
when a cDNA clone that encoded MBL was isolated [89].  In 1989, the following 
year, independent reports on cloning and sequencing of the human MBL2gene were 
released[84].   
 
3.4 MBL2 gene structure 
The MBL2 gene is made up of 4 exons and 3 introns [80, 101, 104,105], Fig 3.1.  The 
MBL protein is a multi-chain molecule of two to six subunits, each subunit consisting 
of three identical 32 KDa polypeptide chains that contain a cystein-rich region, a neck 
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region, a collagenous region and a carbohydrate-binding domain (CBD)[80, 84], (Fig 
3.1)   The MBL protein can be a monomer, trimer, tetramer, pentamer or hexamer 
depending on the number of assembled polypeptide chains, the most common 
assembly is the tetramer with 4 chains and [80, 84].  Disulphide bonds which are 
found between cysteine residues, situated in the terminal part of the protein, stabilize 
the collagenous triple helix structure[80, 106].  MBL is able to recognise carbohydrate 
patterns in the form of terminal mannose groups, found in abundance on the surfaces 
of a broad range of microorganisms including bacteria, viruses, fungi, parasites[80, 
84].  
3.5 MBL1 pseudogene 
Pseudogens are defined as functionless versions of genes that have lost their gene 
expression capacity or ability to code protein in the cells[107].  In man the MBL 
genetic system consists of one functional gene (MBL2) and one pseudogene  
(MBL1P1)which is also expressed, presence of an MBL pseudogene has been 
reported [88, 108, 109].  The MBL genes, MBL1P1 andMBL2 are reported to be most 
likely products of a gene duplication process [109].  The pseudogene was silenced and 
selectively turned off through the evolution process by mutations in the glycine 
residues of the MBL collagen region [108].  MBL1P1has been characterised as an 
expressed pseudogene, consisting of two nonsense mutations in exon 3 and exon 4 
and also a splicing defect that leads to the preservation of intron 1 and results in pre-
termination of the protein [88] thus explains its non-functional status.   
3.6  MBL2 gene and its variants 
The normal MBL2allele is known as A and point mutations in the MBL2gene result in 
presence of variant alleles [7], (Fig 3.2).   Three single independent nucleotide 
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substitutions in exon 1 of the MBL2 gene cause a dominant decrease of functional 
MBL protein in the circulation namely: at codon 54 due to substitution of glycine with 
aspartic acid (GGC to GAC, allele B) [110], at codon 57 due to substitution of  
glycine with glutamic acid (GGA to GAA, allele C) [111] and at codon 52 due to 
substitution of  arginine with cysteine (CGT to TGT allele D) [5].  The variant MBL2 
alleles encode three different structural variants, B, C, and D,(Fig 3.1, Fig 3,2)which 
result in lower MBL serum/plasma concentrations and the variant alleles have been 
found to be quite frequent in normal, healthy populations of African, Caucasian, 
Asian and Eskimo origin and they are present in 20 to 50% of such individuals [7].   
 
It has been suggested, in previous studies, that all three structural variant alleles may 
disrupt the normal assembly of MBL2 polypeptide chains into the basic trimer 
structure or make variant MBL2 more vulnerable to degradation of the protein during 
circulation, or both, resulting in a decrease of the serum/plasma MBL 
concentrations[5-7].  Individuals with MBL2 structural gene mutations express an 
unstable protein due to the interruption of the Gly-X-Y repeat motif of the 
collagenous domain, reducing molecular stability through abnormal disulphide 
linkages[110, 112, 113]. The MBL2 variants interfere with the correct assembly of the 
MBL subunits, disrupts formation of higher MBL2 oligomers and also disrupts 
interaction of MBL with MASPs[114].  This instability of the MBL molecule 
contributes to both low concentration and poor function of MBL observed in 
individuals with MBL2 variants.  MBL2 heterozygosity results in 5 to 10 times 
reduction of functional MBL protein [5-7].  These mutations lead to a reduction of 
functional MBL to 10% in individuals that are heterozygous for defective alleles 
compared with the functional MBL found in individuals with two normal functional 
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alleles [5-7].  Reduced serum MBL is not itself pathogenic, but it predisposes 
individuals to infections and faster disease progression and there are reports of 
accelerated disease progression in HIV infected individuals with low MBL [21].  
Extensive scientific and clinical evidence suggests that administration of MBL to 
MBL-deficient individuals will restore the MBL function in vivo and thereby cure the 
immuno-deficiency [115, 116]. 
3.7 MBL2 promoter region and its variants 
Madsen et al., 1994, 1995  were the first to describe the existence of additional 
polymorphisms in the MBL2 promoter and 5Un Translated Region (UTR), upstream 
of the MBL2 gene, at positions –550 (H/L variants) and –221 (X/Y variants (both are G 
to C nucleotide substitutions)[5, 6], Fig 3.2.   The promoter haplotypes HY, LY and LX 
were the first promoter haplotypes to be documented and they were reported to show 
associations with high, medium and low levels of MBL in serum or plasma, 
respectively [7].   Later presence of the PQ haplotype, located in the 5’untranslated 
portion of the gene at position +4, was reported [6], Fig 3.2.  These three promoter 
region polymorphisms are in strong linkage disequilibrium with exon 1 SNPSs, and 
so fare seven haplotypes have been described namely HYA, LYQA, LYPA, LXPA, 
LYBP, LYQC and HYPD [7], (Fig 3.3) [101, 117]. 
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Table 3.1: Classification ofMBL2 haplotypes and plasma MBL concentration  
_____________________________________________________________________ 
MBL2 haplotype MBL levels classification MBL levels categories 
YA/YA, YAXA normal plasma MBL levels above 500µg/L 
XA/XA, YA/YO intermediate or reduced levels 100µg/L- 500µg/L 
XA/YO, YO/YO deficient levels below 100µg/L 
_____________________________________________________________________________ 
 The functional categories of MBL2 haplotypes  
 
 
 
 
 
 
Figure 3.1: Structure of MBL2 gene, MBL polypeptide and MBL structural subunits  
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Figure 3.2:  Organization of Exon 1 of the MBL2 gene and MBL2 promoter region.  
The variant alleles are B,C and D.  The promoter region alleles are H/L, X/Y and PQ.   
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Figure 3.3.  Worldwide distribution of MBL2 genotypes   
3.8 MBL2 genetic selection pressure 
There are reports in available literature on the possible advantage of evolution of the 
MBL2 variants and the high prevalence of MBL2 variants on the African continent 
[38, 118].  MBL2 variants have been reported to offer protection to infection by 
intracellular parasites like TB and Leishmania such that individuals with variant 
MBL2 genotype are less susceptible to these infections as activation of the 
complement system promotes microbial uptake through opsonophagocytosis, 
accelerates spread and establishment of the infection [38, 118].   
 
3.9  Biological Role of MBL : MBL and the complement system 
The MBL protein plays a key biological role through activating the complement 
immune system [119], (Fig 5).  Complement is part of the innate immune system and 
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the complement’s main functions are defence against infection, bridging innate and 
adaptive immunity and disposing of immune complexes and the products of 
inflammatory injury [119].  Complement activation can occur through the classical, 
the alternative or the lectin pathway and the three pathways are involved in pathogen 
opsonisation, chemotaxis, activation of phagocytes and direct pathogen lysis through 
the formation of membrane attack complexes [119], (Fig 3.4, Fig 3.5).  MBL is a key 
factor and an important constituent of the innate immune defence system where it acts 
as an opsonin [81, 82, 105, 120]and activates the complement system through the 
lectin pathway, by binding to sugar groups or oligosaccharides on the surface of 
various bacteria, viruses, fungi and parasites [35, 80, 89, 92, 94, 119-122] including 
HIV [89]. The ligands for MBL which include high mannose, N-acetylglucosamine 
oligosaccharides, N-acetylmannoseamine, N-acetylgalactoseamine.maltose, glucose 
and galactoseare present on a variety of micro-organisms [80, 92, 123,124].  Upon 
binding to the micro-organism, MBL activates the complement system through the 
action of MBL-associated serine proteases (MASPs) called MASP1, MASP2 [125], 
MASP3 [126] and MAP-19 [127] and also interacts with novel receptors on 
phagocytes [24, 25, 120, 123, 128, 129], reviewed in [105], (Fig 6).   
About 5-10% of serum MASP1, MASP2 and MASP3 appear complexed with MBL 
[130] but MASP-2 is the main initiator of the MBL pathway [131].   Upon MBL 
ligand binding, the activation of the lectin pathway occurs by the capacity of MASP-2 
to cleave C2 and C4 complement components, which causes the transformation of C3 
into C3a and C3b, (Fig 6).  Very important to note that MASP-2 can only interact 
with C4 if it is in a complex with MBL and after MBL has been bound to a 
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carbohydrate ligand, emphasizing the significance of proper MBL structure for 
effective MBL function [112, 113, 127, 131], (Fig 6).   
3.10 Biological role of MBL in HIV infection 
MBL is an acute phase protein and a pattern recognition molecule that has been 
shown to recognize the high mannose glycans present on gp120 molecules of the HIV 
viruses [89].  MBL has been reported to bind directly to recombinant gp120 
molecules, the binding is saturable, mannan inhibitable and can be removed by N-
glycanase treatment [89].  In vitro studies have shown that infection by HIV is 
inhibited by MBL which binds to the gp120 molecules on the surface of target cells 
thus blocking HIV viral entry to susceptible cells [89].  HV has also been reported to 
resist complement-mediated attack [32]. 
 
3.11 The biological mechanism of MBL binding to HIV 
MBL is a pattern recognition biological molecule, it recognises sugar molecules found 
naturally on the surfaces of bacteria, viruses and fungi [80, 132]. The ligands for 
MBL which include high mannose, N-acetylglucosamine oligosaccharides, N-
acetylmannoseamine, N-acetylgalactoseamine.maltose, glucose and galactose are 
present on a variety of micro-organisms including HIV [80, 89, 92, 117, 123, 124].  
MBL has been shown to recognize and bind the high mannose glycans present on 
gp120 molecules of the HIV viruses [89], thus activating the complement system as 
illustrated in (Fig 5, Fig 6), resulting in neutralization and killing of the viruses [34, 
130, 133].   
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3.12 Role of ART on MBL deficiency and HIV infection 
Few studies have reported role of MBL deficiency on HIV infection in populations 
that were on ART [37, 41, 48, 134, 135].Availability and access to ART in 
developing countries including in Zimbabwe has greatly improved over the last 
decade and this has resulted in reduction of HIV prevalence among adults and also 
considerably reduced HIV mother to child transmission [32, 136].  Heggelund et al 
reported MBL serum levels significantly increased during HAART therapy and this 
increase was significantly associated with good response virologically [37].  
 
HIV can be considered as a moving goal post as lots of progress has been made in 
HIV prevention and treatment, with improved access to ART and declining HIV 
prevalence[32, 136].   Even though HIV prevalence and MTCT have greatly reduced 
due to ART it still remains important to carry out immunological investigation of role 
of host factors because favourable treatment response is no achieved in all patients, 
drug resistant strains and serious side effects to ART are still being reported [37].  
There still remains great need to understand the immune-pathogenesis of HIV 
infection and role of host genetic factors like MBL deficiency, to help understand the 
varying responses of patients on ART [37]. 
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Figure 3.4.Role of MBL protein in the complement system.  Complement activation 
can occur through the classical, the alternative or the lectin pathway.   
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Figure 3.5.Role of MBL protein in the complement system.  The three complement 
pathways are involved in pathogen opsonisation, chemotaxis, activation of phagocytes 
and direct pathogen lysis through the formation of membrane attack complexes. 
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3.13 Definition of MBL deficiency 
There is currently no standard definition of MBL deficiency as several studies have 
used different cut-offs to define plasma/serum MBL deficiency[105].   Some define 
MBL deficiency as plasma/serum MBL severe deficiency below 50µg/L[137-140] 
some below 100µg/L [11] , some below 500µg/L [12, 141, 142] and some below 
1000µg/L [115, 143, 144].   For our study we used and defined plasma MBL 
deficiency to be below100µg/L  [50, 116, 140, 143-145] and this cut off has been 
used in an MBL Phase 1 clinical trial[116]. 
3.14 Prevalence of MBL deficiency worldwide 
MBL levels in plasma or serum show considerable variation between individuals.  
Deficiency in MBL exist in about a third of the population in Caucasians and MBL 
deficiency is particularly common in African populations in which it can exceed 50% 
[7].  This makes MBL the most common immunodeficiency described to date [34], 
(Fig 4). 
 
The impact of MBL deficiency appears to be most marked in immune-compromised 
individuals with co-existing immunodeficiency [144, 146,147].  A high incidence of 
infectious disease is seen in immune-compromised persons and immunologically 
immature neonates and infants who are also MBL-deficient. Patients may be immune-
compromised due to: immunologic immaturity, acute critical illness, chronic disease, 
chemotherapy, transplantation, major surgery, and other immune-deficiencies. 
 
37 
 
3.15 MBL studies on African and Southern Africa populations 
According to available literature several studies on role of MBL deficiency in 
infections have been carried out on African populations, some of these have 
investigated role in HIV infections.  Of these studies, only a few were carried out in 
Southern Africa [39-41] and only one study has so far been reported from a 
Zimbabwean population [39].  
 
3.16 Clinical trials on using recombinant MBL as therapy 
Two clinical trials have been carried so far to determine the safety of recombinant 
MBL in human beings, before its recommendation for general use to treat MBL 
deficiency[116].  A clinical trial reported the effectiveness of MBL replacement 
therapy and it is recommended for children and adults suffering from recurrent 
infections and poorly responding to available medications [116].   
3.18 MBL deficiency and susceptibility to infections in children 
Association of MBL deficiency and infections has been reported in several studies in 
children[147-151], diarrhoea and failure to thrive [20, 97, 152-154]children with 
malignancy receiving chemotherapy due to prolonged episodes of febrile neutropenia 
and bacteremia [144, 155].   
 
3.19  MBL deficiency and susceptibility to infections in adults 
Association of MBL deficiency has been investigated in several studies in adults.  
Low MBL levels and variant MBL2 genotype associated with increases sepsis, septic 
shock and fatal outcome in patients with systemic inflammatory response syndrome 
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(SIRS) [156, 157], fatal outcome patients in intensive care units [158], severe 
infections after chemotherapy [142], urinary tract infections after pancreas and kidney 
transplantation [159], increased infections after liver transplant [160, 161], respiratory 
tract infections [139], pneumonia [162], hepatitis B virus infections [101, 163, 164] 
 
3.20 Mannose Binding Lectin and HIV infection: Biological mechanisms 
MBL has been reported to play a role in prevention of infection of target immune 
cells by the HIV virus [35].  The entry of HIV into target cells is mediated by the 
glycoproteins gp120 and gp41 which are naturally present on the HIV viral envelope 
of all HIV strains and are heavily glycosylated consisting of N-linked carbohydrates 
[35, 130, 133, 165-167].  A number of studies have clearly indicated that MBL binds 
to the HIV virions [35].  MBL activates the complement system by binding to 
carbohydrate molecules present on the HIV-1 virion surface thus contributing to HIV-
1 clearance [28, 165, 166, 168,169].  MBL binds and opsonizes the HIV-1 virus hence 
affecting HIV-1 virus trafficking and antigen presentation during HIV infection [29] 
leading to destruction or clearance of HIV by complement activation and 
opsonophagocytosis [29, 35, 89, 130, 167, 170].  Although MBL has been shown not 
to be able to neutralize the HIV virus however the binding and opsonisation of HIV 
by MBL may help to alter virus trafficking and viral antigen presentation during HIV 
infection[29].  MBL has been reported to influence uptake of HIV virions by dendritic 
cells, which express a cell surface lectin called DC-Specific intracellular adhesion 
molecule (DC-SIGN)[29].  MBL binds to HIV inhibiting the binding of DC-SIGN 
and HIV and hence prevents uptake of HIV virions by dendritic cells, thus preventing 
DC-SIGN mediated transinfection of T cells [29]. 
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MBL has been shown to play a defensive role in HIV infection as MBL and HIV both 
compete for binding to the CCR5 receptor, the major receptor for HIV-1, thus 
blocking MBL attachment and entry into target cells [27].   The HIV virions bind to 
cellular receptor protein CD4 and also to co-receptor CXCR4 and or /CCR5 [133].   
 
In vitro studies suggest a link between MBL levels and HIV pathogenesis , purified 
MBL has been shown to bind to HIV infected cell lines and can inhibit infection of 
lymphoblast by HIV, MBL can bind to and activate gp120 complement and MBL 
binds to both CCR5 and CXCR4-tropic HIV primary strains.   
 
Individuals with MBL deficiency have dysfunctional MBL protein and are more at 
risk of acquiring HIV infection and HIV disease progression, amongst infected 
populations [10, 21].       
3.21 Mannose Binding Lectin and HIV infection in adults 
Several studies have been done on MBL because of its role in innate immunity and 
the possible association of MBL deficiency with HIV infection in  adults [10, 21, 37, 
38, 42-44, 46, 47, 49, 50, 59, 134, 171-179], HIV disease progression and has been 
reviewed inseveral papers [34, 35, 105, 179].  There is conflicting information on role 
of MBL deficiency on HIV infection and disease progression among infected adults.  
Some studies have evaluated association between MBL concentration and HIV 
infection and found low MBL levels increasing susceptibility to HIV infection [21], 
some no association [49, 58,174].  Other studies have determined effect of MBL2 
genetic polymorphism and found an association between MBL genetic mutants and 
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HIV infection [21, 50, 59, 176], some reported no association[173, 180].  Other 
studies have looked at both MBL levels and MBL2 genotypes and reported as 
association between MBL deficiency and HIV infection [21, 50, 59,176].  Other 
studies have looked at MBL2 promoter region variants and found an association [21, 
50, 59, 176], others reported no association [173, 180].  Results from studies in adults 
on the role of MBL in HIV infection are still conflicting, there are reports of a 
detrimental effect of the promoter region variants XA [22]  and increased 
susceptibility to HIV transmission [21]. While other studies have reported association 
of MBL deficiency with increased risk of HIV infection [21], others have reported no 
association between MBL2 gene polymorphism  and also promoter region 
polymorphism and HIV infection [36].   Similarly, while some studies have reported 
increased rate of HIV disease progression to AIDS, others have shown either no effect 
or delayed rate of disease progression [37].  Most of these studies have been done in 
European populations, only two studies have been done on African adults, in 
Tanzania [10] and Gabon [38], which showed increased risk of HIV infection among 
those with MBL deficiency, but no such study has been reported for any Southern 
African countries.  For this study we evaluated the effect of MBL plasma deficiency, 
MBL2 genetic variants and promoter region variants on HIV infection in these adults. 
 
3.22 Role of MBL deficiency in HIV and schistosomiasis co-infections 
The adults enrolled in the MUSH cohort comprised of some individuals co-infected 
with HIV and schistosomiasis, some with schistosomiasis only and controls.  We also 
investigated role of MBL during S. haematobium and S. mansoni infections.  Both 
HIV-1 and schistosomiasis co-infections are very common in Africa and have been 
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reported in several studies [181-186].Schistosoma infection is one of the neglected 
tropical diseases, which the World Health Organization is targeting for elimination 
[187-189].  An estimated 85% of the world’s estimated 200 million people with 
schistosomiasis live in Sub-Saharan Africa [190].  S. haematobium is associated with 
urogenital schistosomiasis characterised by severe pathological conditions including 
hematuria and bladder cancer and S. mansoni causes intestinal schistosomiasis 
characterised by chronic or intermittent abdominal pain bleeding from gastro-
oesophageal varices and bloody stool [191].  Schistosomes are complex multi-cellular 
helminths with several developmental stages well documented in the human host 
[191].   
Schistosomes are reported to carry sugar molecules or glycoconjugates on the surface 
of all their developmental stages [192, 193]and these glycoconjugates interact with 
innate immune recognition molecules including MBL [194-196].  In vitro studies 
have demonstrated complement mediated killing of all stages of the schistosome 
parasite [195].  Only one study has reported the role of MBL deficiency in 
schistosomiasis [190] where high MBL levels were associated with protection, but no 
study could be found in literature that investigated role of MBL deficiency in HIV and 
schistosomiaisi infections.  We therefore investigated the role of plasma MBL 
deficiency and MBL2 polymorphism in HIV-1, S. mansoni and S. haematobium 
infections in Zimbabwean adults who were enrolled in the MUSH cohort.   
 
Schistosomiasis immunological pathway and its effect on HIV 
Several studies have reported on investigations on schistosoma and HIV co-
infections[181, 182, 197-208].   Schistosoma haematobiumhas been reported to cause 
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urogenital schistosomiaisis causing lesions due to granuloma formations which is a 
risk factor for HIV acquisition [199-206, 209-211].  
3.23 Mannose Binding Lectin and HIV infection in children 
So many studies have been done investigating MBL and its association with HIV 
infection in children [22, 33, 39, 40, 45, 212-218], reviewed in  [33-35],  looking at 
different aspects and most of these except one [33, 40] has been done in other 
populations outside Africa.  Some studies investigated association between MBL 
deficiency and HIV transmission from mother to child [40, 213,215].   Unlike studies 
that are linking MBL deficiency and HIV infection and disease progression in adults, 
there is concordance in all the studies among children [33].   Studies on MBL 
deficiency and HIV transmission showed that MBL deficient genotypes were 
significantly increased in HIV infected children compared to either HIV exposed but 
uninfected children or HIV unexposed controls [33].  MBL studies have been done on 
African children [39, 41] and only two reported on Zimbabwean children [3, 39].  For 
this study we evaluated the effect of MBL plasma deficiency, MBL genetic variants 
and promoter region variants on HIV infection in a PMTCT survey of mothers and 
their babies. 
 
3.24 Diversity of the HLA gene 
The human leukocyte antigen (HLA) also known as the major histocompatibility 
complex is found on chromosome 6 [219, 220] .  HLA consists of highly polymorphic 
genes and the protein products play a role in the immune response by presenting 
foreign antigens to T cells [219, 220].  HLA diversity has been reported to play a 
significant role in human disease associations [219, 220].  There is an advantage of 
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HLA diversity related to the presentation of peptides derived from pathogens to 
effector T cells [219, 220].  Individuals who are heterozygous for HLA alleles can 
present more antigens than homozygous individuals, referred to as the HLA 
heterozygosity advantage [219-222] .   Populations that are exposed to a high 
pathogen burden have been reported to show high HLA diversity, pathogen driven 
selection [223].  Mechanisms that have resulted in HLA diversity and polymorphism 
include positive selection, splicing of HLA genes giving rise to diverse isoforms[224].  
Other mechanisms of generating HLA diversity include point mutations (substitution, 
deletion, insertion), gene conversion and gene crossover [225].   
 
3.25 Diversity of the HLA gene in the Zimbabwean population and role in HIV 
infection 
The Diversity of the HLA gene in the Zimbabwean population has been reported in a 
few studies [226-229]and the HLA gene was reported to be highly polymorphic which 
is an immunological advantage to the population exposed to high burden of pathogens 
[226-228].  The HLA loci polymorphic profiles reported in the Zimbabwean 
populations includes HLA-A, HLA-B, HLA-C[228, 230], DQA1, DQB1, DRB1 and 
DPB1 [228], HLA-DQA1, LDLR, GYPA, HBGG, D7S8, Gc and D1S80 [227], HLA-
E and H:A-G [231],  reviewed in [226, 232].HLA proteins are reported to be 
important determinants of susceptibility and resistance to HIV infection and disease 
progression.  The highly polymorphic HLA gene has been reported to be strongly 
predictive of HIV infection outcome in adults [233], with some HLA alleles leading 
to increased susceptibility and some being protective [234, 235], some HIV infected 
adults with protective HLA alleles showed capacity to control viral load [234, 235].  
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The high genetic polymorphism in the HLA loci is the basis of the host’s ability to 
mount an immune response to the different epitopes of HIV.  
The study populations for our research comprised of Zimbabwean adult males and 
females and children who most likely also have high HLA polymorphism which could 
also play a role in HIV susceptibility. 
 
3.26 Problem Statement 
While there have been many studies on MBL and HIV among adults, the results are 
conflicting.  Some studies report increased susceptibility to HIV infection among 
those with variant MBL2 genes, others report no association.  Unlike MBL studies in 
the general adult population, results of MBL deficiency and HIV infection among 
children are concordant and have found increased susceptibility to HIV transmission 
amongst children with variant MBL2genes born to HIV positive mothers, but none of 
these studies have determined the MBL2 genotype of the HIV positive mothers.   
3.27 Rationale 
While there is a lot of advancement in HIV prevention and treatment, there is still 
need to investigate host genetic molecules in adults and mother-baby pairs that could 
be playing a role in HIV-1 transmission/acquisition, disease progression and survival.  
It was imperative to carry out this study because: 
 We needed to quantify the burden of MBL deficiency in this African 
population comprised of adults and children. 
 To contribute to the knowledge gap on the role of MBL deficiency in HIV-1 
transmission, disease progression and survival in African populations in adults 
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and children.  The available literature shows that the majority of  studies on 
the association of MBL deficiency and HIV-1 infection in children have been 
done on populations outside the African continent, in Argentina, USA, Brazil, 
UK, Italy [33].  Only three studies on children have been done in Sub-Saharan 
Africa [39-41], this region is still experiencing high prevalence of HIV-1 
among adults and vertical transmission from mothers to their babies. 
This is the second study after the Zambian study [41], to assess MBL2 genes and 
promoter typing in mother-infant pairs in HIV vertical transmission/acquisition. 
There is dearth of information on the role of MBL in this era when access to ART has 
greatly improved even in developing countries like Zimbabwe.  
 
3.28 Research Questions 
Based on the above, below are the questions that we wanted to answer in this 
study: 
1. What is the prevalence of MBL deficiency among the adult Zimbabwean 
population? 
2. Is MBL deficiency a risk factor for HIV infection among Zimbabwean adults? 
3. Does MBL deficiency affect HIV disease progression and survival among the 
HIV positive adults? 
4. What is the prevalence of MBL deficiency among mothers and their infants?  
5. Is MBL deficiency a risk factor for HIV transmission from mother to child? 
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3.29 Broad Objective 
The broad objective of this study was to determine the relationship between MBL 
deficiency and HIV infection in an adult cohort of males and females and among 
mother-infant pairs in Zimbabwe.  
3.30 Study Specific Objectives 
1. To determine the prevalence of MBL deficiency among the Zimbabwean adult 
population. 
2. To determine the relationship of MBL deficiency with HIV infection among the 
Zimbabwean adult population.  
3. To determine the effect of MBL deficiency on disease progression and survival 
among the Zimbabwean adult population over a period of 3 years in the study. 
4.  To determine prevalence of MBL deficiency among mothers and their infants in a 
Zimbabwean population. 
5.  To determine the relationship between MBL deficiency and HIV transmission  
from mother to child in a Zimbabwean population. 
3.31 Hypothesis 
Hypothesis 1 :MBL plasma deficiency is a risk of  HIV infection, increases disease 
progression and lowers survival rate in adults.  
Hypothesis 11: MBL plasma deficiency is a risk of HIV vertical transmission 
/acquisition in the children born to HIV positive mothers. 
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3.32 Scope of this thesis 
Genetic analysis of MBL among the adult population will use the available results 
from the Mupfure  Schistosomiasis and HIV (MUSH) study carried out in Zimbabwe 
between 2001-2007, while questions regarding the role of MBL deficiency in HIV 
acquisition and transmission from mother to child will use stored dried blood from a 
PMTCT national survey also carried out in Zimbabwe in 2012.  The blood samples 
from the PMTCT cross sectional survey provides us with an opportunity to investigate 
if MBL deficiency is a factor in transmission or acquisition of HIV among infants in 
Zimbabwe.   
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3.33 Thesis themes 
This research and thesis is based on the following broad themes which were 
based on the five research questions and five research objectives outlined earlier: 
 
1. Determination of plasma MBL levels, prevalence of MBL deficiency, 
prevalence of normal and variant MBL2 genotypes and promoter region 
types in Zimbabwean adult males and females. 
 
2. Determination of the role of Mannose Binding Lectin Deficiency in HIV-1 
Infection in a Rural Adult Population in Zimbabwe. 
 
3. Determination of the role of Mannose Binding Lectin Deficiency in HIV-1 
disease progression and survival in a rural adult population in Zimbabwe. 
 
4. Determination of prevalence of normal and variant MBL2 genotypes and 
promoter region in Zimbabwean mothers and their babies. 
 
5. Determination of the role of Mannose Binding Lectin Deficiency inHIV-1 
infection and vertical transmission in a PMTCT national survey in 
Zimbabwe. 
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CHAPTER 4  MATERIALS AND METHODS 
4.0 Introduction 
This chapter describes the methods and materials used for this research project.  The 
methods used in sample collection, laboratory analysis for the adult MUSH study and 
gives details about the source of samples for the PMTCT MBL study. 
4.1  Study description 
This research protocol was composed of data from two studies, Mupfure 
Schistosomiasis and HIV cohort (MUSH) which enrolled adult males and females and 
a PMTCT cross sectional study comprised of mothers and their infants, both 
conducted in Zimbabwe (Fig 7).  The MUSH cohort was established and blood 
samples collected and analyzed between 2001 to 2006.  Using this cohort we assessed 
MBL plasma levels, MBL2 genotypes, MBL2 promoter types and HIV-1 infection and 
all MBL assays were carried out at Righospitalet, Copenhagen Denmark.  The 
PMTCT cross sectional study consisted of data on mother-baby pairs from a national 
PMTCT evaluation survey carried out in Zimbabwe by the CESHAAR Research 
Centre in 2012 during which whole blood was collected and dried on filter papers for 
HIV-1 testing of mother-infant  pairs.  The dried blood spots from the PMTCT study 
were used forMBL2 genotyping at Serum State Institute in Copenhagen, Denmark. 
 
4.2 Study design 
This research consisted of two study designs, a longitudinal cohort and a cross 
sectional design.  The cohort design (MUSH sub-study) aimed at assessing the 
relationship between MBL plasma concentration, MBL2 genotypes, HIV infection, 
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HIV disease progression and survival in adults.  The cross sectional PMTCT study 
was laboratory based and used archived whole blood filter samples for MBL2 
genotyping in mothers and their infants from the PMTCT national survey.  Samples 
for the PMTCT study were collected during a one month long evaluation of the 
PMTCT programme in Zimbabwe carried out in 2012 (Fig. 4.1).   
 
 
Figure 4.1:  Map of Zimbabwe.  Showing study area for the adult cohort, Mupfure, 
Mt Darwin 150km to the North of the capital City Harare.  Samples for the PMTCT 
study were collected from all the 10 provinces of Zimbabwe. 
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Figure 4.2:Community Sensitization in Mupfure, Mt Darwin 
4.3  Study site and Population 
Adult cohort : The field work and sample collection was conducted starting from 
October 2001 to June 2006 in Mupfure and its adjacent areas in Shamva district, 
Mashonaland Central Province, Shamva District in the north-eastern parts of 
Zimbabwe[62, 181, 182, 198], (Fig 4.1).  The study-population comprised of adults 
18 years old and above, residing in the area, who gave their informed consent to be 
bled and tested for HIV.  Blood samples were collected after community sensitization 
(Fig.4.2), written informed consent and explaining the aims and objectives of the 
research project.  Blood samples were collected at 7 time points over a 3 year period 
and study participants were not on ART during this period as ART was not yet 
available in the public health care centres across Zimbabwe. 
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4.4 PMTCT cross sectional study 
Stored samples from mothers and baby pairs were obtained from the CESHAAR 
Research Centre in Zimbabwe that had stored whole blood samples for mother –infant 
pairs from a national PMTCT survey carried out in 2012.  All the mothers were HIV 
positive, 72.3% (450 out of 622 mothers) were on ART, Nevirapine, AZT, Nevirapine 
and AZT.  Of the 622 perinatally exposed children 71.5% (445 out of 622) were on 
ART during the time of the survey using such drugs as Nevirapine only, Nevirapine 
and AZT syrup and AZT only. 
4.5 Exposures measured 
MBL plasma concentration in the adult cohort.The normal MBL concentration in 
plasma/serum is 1000µg/L and above and MBL deficiency is defined as below 
100µg/L [6, 7].MBL2 genotype and promoter type in the adult cohort and the PMTCT 
samples.  We were not  able to measure MBL plasma concentration for the PMTCT 
samples as plasma or serum samples were not available, but we usedMBL2 genotype 
as a proxy for MBL deficiency as the relationship between MBL2 genotypes and 
MBL plasma concentration is well documented [6, 7]. 
4.6 Outcomes measured 
The following outcomes were used to define HIV-1infection in the adult MUSH  
cohort and HIV transmission/acquisition in the PMTCT study.  Schistosomiasis was 
assessed by determination of presence or absence of eggs  in stools and urine and  
recorded as infected or uninfected.  HIV status by standard HIV testing kits.  Those  
defined as HIV positive were the ones with a reactive blood test on standard HIV  
testing kits.  Viral load, measured as HIV RNA, change defined as the change  
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(increase or decrease) in viral load from the baseline value, measurements were taken  
at baseline, 6 weeks, 3, 6, 12, 24 and 36 months.CD4 T cell count change defined as  
the change (increase or decrease) in CD4+ T cell count from the baseline value,  
measurements were taken at baseline, 6 weeks, 3, 6, 12, 24 and 36 months.  Survival:  
dead or alive at end of study.  The information on death of each participant was  
collected from hospital records or first-hand information from family members. 
4.7 Potential Confounders 
Age, gender, marital status in the MUSH cohort. 
Use of ART by the mothers and children in the PMTCT study. 
 
  
54 
 
4.8 Sample size calculations 
4.8.1 Sample size calculation for the main MUSH study 
The sample size for the main MUSH study was based on HIV status as the primary 
outcome. The Zimbabwe national prevalence of HIV was 25% in 2001 when the 
MUSH study was proposed and implemented.  This prevalence was used to calculate 
the minimum sample size of adult males and females for inclusion.  To calculate the 
sample size within 5% significance level, the following prevalence formula was used 
[31]:  
                                                                 N=Z2p(1-p) 
                                                                ____________ 
                                                                           d2 
Where:  
Z = Z statistic for a level of confidence (95% level of confidence used, therefore Z 
value is 1.96) 
P = expected prevalence of proportion 
d = precision 
 
N=1.96  x 0.25 (1-0.25) 
_______________________ 
0.052 
 
N= 288 
20% more participants were enrolled to compensate for loss to follow up 
288+20% of 288=288+58=346 
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The required minimum sample size for the MUSH study was 346 adult males and 
females.  For the MUSH study, 2281 adult males and females were screened for HIV 
and schistosomiasis and 379 were recruited into the follow-up cohort.  At the end of 
the enrolment period 379 participants had been enrolled.  These had plasma and 
PBMCs collected and stored for use in the MBL study. 
 
4.8.2 Sample size calculation for the original PMTCT national survey 
The target study population for the national survey was biological mothers and their 
infants 9 to 18 months old.  The sample size was based on the need to compare the 
proportion of living 9 to 18 months old infants born to HIV infected mothers who 
were HIV infected before versus after implementation of the national PMTCT 
programme.  The focus of the PMTCT survey was primarily on detecting an impact of 
the national PMTCT programme on HIV prevalence among the 9 to 18 months old 
infants.  Catchment areas for PMTCT clinics were determined in all the provinces in 
Zimbabwe before randomly selecting catchment areas for inclusion.  The study team 
expected a reduction in HIV prevalence from 25% to 18.75 %, assuming 95% 
significance level and 80% power, the calculated required minimum sample size was 
7800 mothers and their children.  For the national PMTCT survey, 8800 dried blood 
spots were collected from biological mother baby pairs for HIV testing, 880 mothers 
(10%) were HIV positive (Fig 1), paper III  [236, 237].  These are the dried blood 
spots that were available and in storage at the CESHAAR Research offices [3].   
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4.8.3 Sample size calculation for the MBL PMTCT sub-study 
 The sample size calculation for the MBL sub-study was based on the exposure of 
interest (MBL deficiency using MBL2 gene as a proxy) among HIV infected mothers, 
and the primary outcome was infant HIV status. Based on literature, assuming mother 
– infant pair are on ART, transmission rates range from 20 to 5% [238].  This study 
used repository specimens collected as part of the National PMTCT evaluation survey 
carried out by the CESHAAR Research Centre in Zimbabwe and the preliminary 
results showed 10% infant HIV status at 9-12 months of age (personal communication 
with Dr Cowan). Sample sizes under a range of different scenarios are as summarized 
(Table 4.1).  Assuming an alpha of 0.05 and beta of .90 and 5% significance level and 
a risk ratio of  2.0 with10% infant HIV status among the infants born from mothers 
with normal MBL2 genotype, we had a sample size, among the exposed population, of 
572 mother infant pairs, giving  a total 1144 blood filters out of a total of 8800 
available filters in storage at CESHAAR study site in Harare.  In order to allow for 
dried blood spots that would not give adequate DNA for PCR reaction, ten (10%) 
more samples were selected, to give a final sample size of 632 mother baby pairs 
calculated using Epi Info 7 programme [31].  DNA was extracted from all 632 
mother-baby pairs selected for inclusion into the PMTCT MBL study (Fig. 1).  A 
complete dataset on the HIV status and MBL2 genotype was available for 622 mother-
baby pairs which were used in the final analysis [3]. 
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Table 4.1: Showing different sample size calculations for the PMTCT study carried 
out using Epi Info Version 7 programme 
% Transmission 
(unexposed)  
Risk  ratio 
 
Sample Size 
  80% 
Power 
90% power 
5 1.5 3100 4096 
 2 948 1242 
 2.5 496 646 
 3 320 414 
10 1.5 1452 1914 
 2 438  572  
 2.5 226  292  
 3 144  184  
20 1.5 626 824 
 2 182 238 
 2.5 90 116 
 3 56 70 
 
4.8.4 Sampling plan of the PMTCT cross sectional study 
MBL2 genotyping on the PMTCT cross sectional study used archived dried blood 
samples.  Simple random probability sampling stratified according to HIV status of 
the children, was used to select the children whose mothers were HIV positive when 
these children were born.  The list of mothers and their babies was available at the 
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CESHAAR Research Centre in Harare.  Random number tables were used to select 
the required number of mother-baby pairs from the stratified list.  Only those meeting 
the inclusion criteria will be selected. 
4.9  Selection of study sample 
4.9.1  Inclusion criteria Adult study 
Adult males and females, 18 to 60 years old, were the target population for this study.  
Only those who had given informed written consent, were willing to submit the 
necessary blood samples and willing to be bled and tested for HIV, were enrolled into 
the cohort.    The uninfected were included as controls.   
 
4.9.2 Exclusion criteria, Adult study 
Those over 60 years old, symptomatic TB and HIV, severe anaemia, bedridden and 
too sick to come to the clinic were excluded.  All women were tested for pregnancy 
before inclusion, pregnant women were excluded.  Other bacterial co-infections were 
not checked for in this study. 
 
4.9.3  Inclusion criteria PMTCT cross sectional study 
Blood samples from HIV positive mothers and their children (HIV positive or 
negative) below the age of two years were used in this study.   
 
4.9.4 Exclusion criteria, PMTCT cross sectional study 
Blood samples from HIV negative mothers and their children. 
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4.10  Study procedures 
4.10.1  Procedures at enrolment 
For the adult cohort, adult males and females were enrolled for MBL analysis during 
a programme evaluating effect of treating schistosomiasis infection on HIV disease 
progression.  
 
4.10.2  Source of samples for PMTCT study 
Stored whole blood samples on filter paper for mother baby pairs were obtained from 
the CESHAAR Research Centre in Harare.  These samples were collected in 2012 as 
part of a national PMTCT evaluation programme.  For quality control the selected 
samples used were be checked that they were kept at room temperature, desiccant was 
in place in the zip lock storage bag and that the blood spots did not have moulds 
growing on them the due to humid conditions.  Plasma samples nor serum samples 
were not collected on the PMTCT survey, so we did not have samples for 
determination of MBL concentration in the mothers and their children.  Nevertheless, 
this would not compromise the findings of our research because the association 
between MBL2 genotype and MBL deficiency is well documented [6, 7].    
4.11 Laboratory methods 
4.11.1 Adult study 
4.11.1.1 Schistosoma parasitology 
 
Microscopic examination of fixed-volume urine samples filtered on Nytrel filters 
(VesterGaard Frandsen) was used to identify and quantify eggs of S. haematobium by 
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the syringe urine filtration technique [239], Fig. 4.3.    To accommodate the diurnal 
and day-today variation in egg output, the urine samples were collected on 3 
consecutive days [240, 241].  We used the modified formol-ether concentration 
technique was used on 1 stool sample from each participant to detect eggs of S. 
mansoni and other helminth or parasites [242].  Levels of the Circulating Anodic 
Antigen (CAA) were measured in serum samples using an ELISA assay, to 
complement the parasitological detection methods mentioned above.  The CAA 
originates from the parasite gut and is used as a bio marker of active schistosome 
infection [243].    
 
 
Figure 4.3:  Schistosoma parasitology.  Processing urine and stool samples at 
Mupfure Clinic, Mt Darwin, Zimbabwe. 
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4.11.1.2 HIV-1 serology 
 
HIV testing was performed in respect of the confidentiality principle and pre- and 
post-test counselling was provided by qualified medical personnel in the participants’ 
native language, Shona.  Initially a rapid HIV-1/2 test kit was used on a dry blood 
spot collected from the participants in the field (Determine, Abbott Laboratories, 
Tokyo, Japan).  This test was then followed by two different rapid HIV tests (namely 
Oraquick by Orasure and Serodia by Fujirebio) for all who tested initially positive.  
All those included in the MUSH study had their HIV positive test confirmed by two 
ELISA tests ( Recombigen by Cambridge Biotech and Ortho (Ortho Clinical 
Diagnostics) on serum.  We found no discrepancies in results were found between the 
initial Determine HIV test and the two subsequent ELISAs.  Strict confidentiality was 
assured to the research participants and was maintained throughout the study.  All 
research participants who requested their HIV results were given after receiving post 
test counselling from the study nursing staff [1].   
 
4.11.1.3 Quantification of CD4+ T cells and viral load  
 
CD4+ T cell counts were measured at the Department of Haematology of 
Parirenyatwa Hospital Harare, Zimbabwe (FacsCalibur, Becton Dickinson) [182, 
244,245].  HIV RNA was measured using the Roche Amplicor (F. Hoffmann la-
Roche).  None of the enrolled participants were receiving antiretrovials at the time of 
sample collection as these were not yet available in the public health sector [1, 2]. 
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4.12.1.4 Determination of MBL plasma concentrations 
 
Plasma was stored at -20°C until analysis.  MBL concentrations were measured in 
baseline plasma samples using the double enzyme immuno-assay (EIA) [16].  The 
lower detection limit in the assay was 20µg/L [16, 246,247].  The micro titre plates 
(Maxisorp, NUNC, Denmark) were coated with a specific mouse anti-human MBL 
monoclonal antibody, clone 131-1, IgG1, Kappa (Antibody Shop, Denmark).  Plasma 
samples were diluted in Tris/HCL buffer (Bie and Bernsten) containing EDTA (Bie 
and Bernsten) and 0,05% Tween 20 (Sigma).   A pool of EDTA plasma with a known 
concentration of MBL was used as the standard.  Biotinylated clone 131-1 anti-MBL 
(Antibody Shop, Denmark) was used as the detection antibody.  Horseradish 
peroxidase labelled streptavidin (Amersham, UK) was added.  The substrate uses O-
phenylene diamine (OPD) (DakoCytomation) hydrochloride in citrate-phosphate (Bie 
and Bernsten) buffer pH 5.0. The colour reaction was stopped by the addition of 
sulphuric acid (Sigma).  The optical density (OD) was read on an ELISA reader 
(MR5000/7000,Dynatech Laboratories, Denmark) at 490 nm with reference filter 
630nm and the final output printed (Proprinter 11, IBM Netherlands).  The final MBL 
values are given as µg MBL per µl.  In addition, parallel control plates were coated 
with equivalent amounts of mouse IgG1 and processed as above.   The parallel plates 
are done in order to reveal binding of rheumatoid factors, anti mouse 
immunoglobulins and non-specific binding of the MBL interfering in the system.  
ODs were read at 490 nm and reference filter 630 nm [1, 2].   
4.11.1.6  Processing and freezing of PBMCs 
 
Twenty millilitres of blood were collected from each participant in sodium heparized 
tubes to prevent coagulation (Fig.4.4).  The white blood cells were separated from the 
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red cells in 50ml centrifuge tubes with lymphoprep liquid (Greiner Bio-one)with a 
separation disk.  The buffy coat layer was collected into 15ml tubes and the red cells 
discarded.  The cells were further centrifuged in 40ml wash media RPMI (Sigma), 5% 
AB serum(Blood Transfusion Service, Zimbabwe), 3ml re-suspension media (RPMI + 
10% AB serum + 1% penicillin/ streptomycin) the cell suspension was aliquoted into 
4 sterile cryotubes, about 750µl into each tube and 1ml freeze media (RPMI +25% 
AB serum + 20% DMSO + 1penicillin/streptomycin) added.  Ten micro litres from 
each cell suspension was used to determine the cell count, viable and nonviable ratios 
using a haemocytometer.  Cells were frozen immediately by gradient freezing method 
in liquid nitrogen[1, 2].   
 
 
Figure 4.4.Processing PBMCs at the site laboratory in Mupfure, Mt Darwin. 
 
4.11.1.7 DNA extraction 
 
The salting out procedure [248] was used to isolate DNA from frozen cells of each 
cohort participant (Fig. 4.5).  Frozen cells, in RPMI freezing media, kept in liquid 
nitrogen until analysis, were first thawed at room temperature.  Cells were transferred 
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to 2ml centrifuge tubes which were filled up with buffer A (1M sucrose, 1M Tris-
HCL, 1M MgCl, Triton-X-100 and distilled water) and spun in a centrifuge (Stuers, 
Sigma) at 3000rpm for 2 minutes.  The supernatant was poured off, tubes were filled 
up with buffer A again, mixed by vortexing to dislodge the pellet, tubes spun in a 
micro centrifuge at 3000rpm for 2 minutes and the supernatant discarded.  Buffer B 
(3M NaCl, 0,5M EDTA) and 25µl SDS (Bie and Bernstern, Denmark), 10-20µl 
proteinase K enzyme (Macherey Nagel, Denmark) (depending on the size of the 
pellet) were added, mixed by vortexing and the tubes incubated at 42°C for I hour in a 
rotation incubator (Hereus Instruments, Holm and Halby, Germany).  An additional 
10µl proteinase K (Roche, Germany)was added to tubes with visible pellets, vortexed 
and incubated again.  To clean the DNA, 6M NaCl (Fluka chemicals, Denmark) was 
added.  Tubes were topped up with 2-iso-propanol (J.T Baker) and the DNA strands 
viewed under a work- bench light source.  All samples in which DNA was 
successfully extracted had strands appear when iso-propanol was added[1, 2].  
 
Then 70% ethanol (De Danske Spirifabriker, Denmark) was added to the pellet and 
the tubes spun down for a further 5 minutes.  The DNA pellets were air dried in the 
tubes for about 15 minutes, 50µl sterile water (H/S Apoteket, Rigshospital, 
Copenhagen) added to each tube to dissolve the DNA, tubes incubated at 42°C for 
half an hour.  Pellets were checked for complete dissolution in the sterile water[1, 2].  
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Figure 4.5:  DNA extraction at Rigshospitalet in Denmark, Dr Peter Garred 
laboratory 
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4.11.1.8 Determination of DNA concentration 
 
The DNA concentration for each sample was determined using a DNA 
spectrophotometric analyser (Spectrachrom, Shimadzu, Japan).  The ideal DNA 
concentration for MBL genotyping by PCR is 0.3µg/µl, if DNA concentration was 
more than 0.3µg/µl it was adjusted by adding sterile water.  The ideal DNA protein 
ratio, A260/A280, was between 1,5 and 2.  Any measurement below 1,0 indicated that 
the DNA was contaminated and it was not clean, additional proteinase K was added to 
further purify the DNA.   Purified DNA was stored at -20°C until analysis by PCR[1, 
2]. 
 
4.11.1.9 Preparation of MBL PCR Master mix 
 
The PCR master-mix was made by mixing the following in 2ml centrifuge tubes: 
400µl sterile water (H/S Apoteket, Rigshospital, Copenhagen), 150µl of 1.5mM 
MgCl2 (Invitrogen, Denmark), 150µl at 0.07mM final concentration of each 
deoxynucleotide triphosphate (dNTPs) (Amersham Biosciences, UK Limited), 500 µl 
PCR Buffer containing 50mM KCL, 10 mM Tris-HCl (pH 8.3), 0.001% (w/v) gelatin 
p.H.8.3 (Invitrogen, Denmark), 250µl glycerol at 5% final concentration , 50µl cresol 
red at final concentration 100µg/µl.  Cresol red (Invitrogen, Denmark) was added as a 
colour marker.  The PCR Master mix could be kept at 4°C for 2 weeks[1, 2]. 
 
4.11.1.10 Preparation of PCR primers 
 
A total of 12 primer solutions (DNA Technology) were prepared for each sample 
(Table 2.3).  The set of 12 primers for MBL variants and promoter region mutations 
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were prepared by mixing 5 sense and 3 sense primers with water according to 
manufacturers instructions.  Final concentration of each primer was 0.25uM for each 
specific primer.  PCR primers were pre-aliquoted in 5µl volumes into the PCR plates 
and the plates could be kept at 4°C for 1 week[1, 2].   
 
4.11.1.11 Preparation of MBL PCR sample reaction mixture 
 
The PCRs were performed in 10µl volumes containing 30ng genomic DNA and 
0.25µmM of the specific primers PCR reaction mixtures for each sample were 
prepared in PCR microtubes, marked clearly with sample identification numbers.   
Fifty four µl of PCR mastermix, 3,5µl sample DNA (if the DNA concentration was 
0,3µg/µl), 31µl sterile water, and0.25 Units of Platinum Taq DNA polymerase 
(Invitrogen, Denmark) in each 90µl initial reaction mixture volume.  Mixture was 
mixed with a multi-channel pippette three times and 5 µl of the reaction mixture 
added  to the 12 wells, clearly marked for each sample, which contained 5µl of 
different sets of primers for the genotyping and promoter typing.  Only eight samples 
could be run on each PCR plate.  Plates were put in a plate micro centrifuge at 
3000rpm for 1 minute to spin down the well contents.  Plates were tightly sealed with 
foil paper and put in a PCR thermocycler for I hour 15 minutes[1, 2]. 
 
4.11.1.12  Determination of MBL2 genotype and promoter typing 
 
The genomic DNA was extracted from the collected and frozen Peripheral Blood 
Mononuclear Cells (PBMCs) using the standard salting out procedure [248].    DNA 
was amplified by allele-specific oligonucleotide PCR (ASO-PCR) where specific 
sequences were used for each allele[7, 138].  The MBL2 genotypes and promoter 
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region alleles were detected by sequence –specific primer polymerase chain reaction 
assay where specific sequences were used for each polymorphism according to 
manufacturer’s instructions.   The following detailed steps were carried out: 
 
4.11.1.13 Amplification of MBL2 genes by allele-specific oligonucleotide 
PCR (ASO-PCR) 
 
TheMBL2 single nucleotide polymorphisms (SNPs) in the form of structural variants 
named B (codon 54), C (codon 57) and D (codon 52), as well as the regulatory 
promoter region variants H/L (-550), X/Y (-221) and PQ (+4),  were genotyped by 
Polymerase Chain Reaction (PCR) using sequence-specific priming, which includes 
the 12 reactions listed in Table 3.1.   The genetic primers for 5 and 3 sense exon 4 of 
the MBL2 gene (DNA Technology, Denmark) were included in each PCR reaction as 
an internal positive control.   
The DNA was amplified by allele-specific oligonucleotide PCR (ASO-PCR)in a 
programmed thermocycler (Gene Amp PCR Systems 9600, Perkin Elmer).  All PCRs 
were initiated by a 2-min denaturation step at 94°Cand completed by a 5-min 
extension step at 72°C.  The temperature cycles for the PCR were as follows: 10 
cycles of 10 s at 94°C  (denaturation) and 60 s at 65°C (annealing and extension), and 
a further 20 cycles of 10s at 94°C (denaturation), 50s at 61°C (annealing), 30s at 72°C 
(extension) and 2 minutes at 25°C. Gel electrophoresis was done on the PCR products 
on the same day or kept at 4°C for a maximum 1 week[1, 2]. 
 
4.11.1.14 Visualisation of PCR products by agarose gel electrophoresis 
 
PCR products were separated by a 2% agarose gel (Invitrogen) electrophoresis run 
and this was carried out in an electrophoresis chamber (Sub-cell Biorad) at 150V, 
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400mA for 32 minutes.  The agarose gel was made by dissolving 6g of agarose 
powder (Invitrogen) in 300ml TEA buffer (Trizma base, EDTA).  The gels were 
stained with Ethidium bromide  (Invitrogen).  Molecular weight marker V (Roche 
Diagnostics, Manhein Germany) at 0.25µg/µl, was included in each electrophoresis 
run.  The gels were then carefully transferred to the UV Transilluminator (Syngene 
Synoptics Ltd, Denmark) where a photograph of the gel was taken (Figure 4.6).  The 
MBL gene and promoter region typer (Table 3.2) was used to determine the MBL 
genotype of each sample.  All the different MBL gene and promoter region 
combinations available to date are as listed (Appendix 6)[1, 2]. 
 
 
4.11.1.15 Detection of variant MBL2 alleles 
 
The genomic DNA was extracted from frozen Peripheral Blood Mononuclear Cells 
(PBMCs) using the standard salting out procedure [248].  DNA was amplified by 
allele-specific oligonucleotide PCR (ASO-PCR) and the amplified alleles were 
detected using allele-specific oligonucleotide PCR (ASO-PCR) procedures [247].  
The MBL2single nucleotide polymorphisms (SNPs) in the form of structural variants 
named B (codon 54), C (codon 57) and D (codon 52), as well as the regulatory 
promoter region variants H/L (-550), X/Y (-221) and PQ (+4), were genotyped by 
PCR using sequence-specific priming.  The MBL2 genotypes and promoter region 
alleles were detected by sequence –specific primer polymerase chain reaction assay 
where specific sequences were used for each allele.  Twelve oligonucleotide primer 
sequence solutions (DNA Technology) were prepared for each sample (Table 4.1).  
The 12 primers for MBL2 variants and promoter region mutations were prepared by 
mixing 5 sense and 3 sense primers with water according to manufacturer’s 
70 
 
instructions.  The final concentration of each primer was 0.25uM for each specific 
primer.  Primers for 5 and 3 sense exon 4 of the MBL2 gene (DNA Technology, 
Denmark) were included in each PCR reaction as an internal positive control.  PCR 
primers were pre-aliquoted in 5µl volumes into PCR plates and plates could be kept at 
4°C for 1 week [1, 2].   
 
4.11.1.16 Amplification of MBL2 genes by allele-specific oligonucleotide 
PCR (ASO-PCR) 
 
DNA was amplified by allele-specific oligonucleotide PCR (ASO-PCR) in a 
programmed thermocycler (Gene Amp PCR Systems 9600, Perkin Elmer).  All PCRs 
were initiated by a 2-min denaturation step at 94°Cand completed by a 5-min 
extension step at 72°C.  The temperaturecycles for the PCR were as follows: 10 
cycles of 10 s at 94°C and 60 s at 65°C, and a further 20 cycles of 10s at 94°C, 50s at 
61°C, 30s at 72°C and 2 minutes at 25°C. Gel electrophoresis was done on the PCR 
products on the same day or kept at 4°C for a maximum 1 week [1, 2]. 
 
4.11.1.17 Visualisation of PCR products by agarose gel electrophoresis 
 
PCR products were separated using a 2% agarose gel (Invitrogen) electrophoresis run 
in an electrophoresis chamber (Sub-cell Biorad) at 150V, 400mA run for 32 minutes.  
The gels were then carefully transferred to the UV Transilluminator (Syngene 
Synoptics Ltd, Denmark) where a photograph of the gel was taken.  The MBL2 gene 
and promoter region typer was then used to determine the MBL2 genotype of each 
individual sample (Table 4.2) [1, 2]. 
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Figure 4.6a.Photographs of the MBL gels taken in the UV Transilluminator. 
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Figure 4.6b:  Picture of gel showing the different MBL genotypes obtained in the  
        MUSH cohort
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Table 4.2:  The 12 oligonucleotide primer sequences and the Exon 1 internal control primer used in this study 
for the detection of MBL2 coding, promoter normal and variant alleles. 
primer 
 
Specific sequence 
         5´-3´ 
Primer 
localization 
Product 
Size 
A54   
none B     
5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-CCTTTTCTCCCTTGGTGC-5´ 
617-640 278 
B 5´-GGGCTGGCAAGACAACTATTA-3´ 
3´-GCAAAGATGGGCGTGATGA-5´ 
617-240 278 
A57 
None C 
5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-CCTGGTTCCCCCTTTTCTC-5´ 
617-240 290 
C 5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-ACCTGGTTCCCCCTTTTCTT-5´ 
617-240 290 
A52 
none D 
5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-TCCCTTGGTGCCATCACG-5´ 
617-240 268 
D 5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-CTCCCTTGGTGCCATCACA-5´ 
617-240 268 
Promoter X 5´-CTCAGGGAAGGTTAATCTCAG-3´ 
3´-CATTTGTTCTCACTGCCACC-5´ 
6-25 440 
Promoter Y 5´-CTCAGGGAAGGTTAATCTCAG-3´ 
3´-CATTTGTTCTCACTGCCACG-5´ 
6-25 443 
Promoter H 5´-GGCTTAGACCTATGGGGCTA-3´ 
3´-GCTTCCCCTTGGTGTTTTAC-5´ 
76-96 316 
Promoter L 5´-GGCTTAGACCTATGGGGCTA-3´ 76-96 316 
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3´-GCTTCCCCTTGGTGTTTTAG-5´ 
P 5´-AGGATCCAGGCAGTTTCCTCTGGAAGG-3´ 
3´-TAGGACAGAGGGCATGCTC-5´ 
624-649 335 
Q 5´-AGGATCCAGGCAGTTTCCTCTGGAAGG-3´ 
3´-TAGGACAGAGGGCATGCTT-5´ 
628-649 331 
Exon 1 
internal 
Control 
5´-GAGTTTCACCCACTTTTTCACA-3´ 
3´-GCCTGAGTGATATGACCCTCC-5´ 
892-913 431 
These specific sequences were used for the identification of the MBL2 and promoter region types, according to 
the manufacturer’s instructions. 
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Table 4.3: Showing the determination of MBL2 genotypes and promoter types using the electrophoresis gel 
bands on the photograph taken by the UV trans-illuminator 
MBL 
genotype 
1 
A54 
2 
B 
3 
A57 
4 
C 
5 
A52 
6 
D 
7 
X 
8 
Y 
9 
H 
10 
L 
11 
P 
12 
Q 
AAYHP X  X  X   X X  X  
AAYHLPQ X  X  X   X X X X X 
AAYLP X  X  X   X  X X  
AAYLPQ X  X  X   X  X X X 
AAYLP X  X  X   X  X X  
AAXYLP X  X  X  X X  X X  
AAXYHLP X  X  X  X X X X X  
AAXYLPQ X  X  X  X X  X X X 
AAYHLP X  X  X   X X X X  
AAXLP X  X  X  X   X X  
ABYHLP X X X  X   X X X X  
ABYLPQ X X X  X   X  X X X 
ABYLP X X X  X   X  X X  
ABXYLP X X X  X  X X  X X  
ABYHP X X X  X   X X  X  
ACYHLP X  X X X X  X X X X  
ACYLQ X  X X X X  X  X  X 
ACYLPQ X  X X X X  X  X X X 
ACXYLPQ X  X X X X X X  X X X 
ADYHP X  X  X X  X X  X  
ADYHLPQ X  X  X X  X X X X X 
ADYHLP X  X  X X  X X X X  
ADXYHLP X  X  X X X X X X X  
BBYLP  X X  X   X  X X  
BCYLPQ  X X X X   X  X X X 
BDYHLP X X X   X  X X X X  
CCYLP    X X   X  X X  
CDYHLPQ X  X X X X  X X X X X 
DDYHP X  X   X  X X  X  
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This geno-typer was used to determine the combined MBL genotype and promoter type for each DNA sample.   
4.12.0 PMTCT STUDY 
4.12.1 Study design and study population 
This was a laboratory based sub-study where we used dried blood spot (Fig. 4.7), samples that were collected as 
part of a national cross-sectional survey [236, 237]on prevention of mother to child transmission (PMTCT) 
carried out by the CESHAAR Research Centre, Harare Zimbabwe.  The main study was entitled Evaluation of 
Zimbabwe’s Accelerated PMTCT of HIV Program [236, 237,249].   We carried out MBL2 genotyping on a 
subset of the dried blood samples collected during this national PMTCT survey (Fig. 4.7).  Details of the 
PMTCT national survey, including blood sample collection, screening procedures and the study population 
have been described in detail elsewhere [249]. Briefly, the national PMTCT survey was undertaken in 
September 2012 and targeted women aged 16 years and above who had children between 9 and 15 months old 
[236, 237].  The survey examined the uptake of services and behaviours in the national PMTCT programme in 
Zimbabwe and determined the factors associated with MTCT and maternal antiretroviral therapy (ART) or 
antiretroviral (ARV) prophylaxis.  Dried blood spots were collected from 8800 babies and their biological 
mothers [236, 237] and of these we used 632 mother-baby pair blood samples [3].   
 
4.12.2 Laboratory procedures 
4.12.2.1 Collection of dried blood spots 
Venous blood from the heel of the child and a finger of the mother was collected on filter  
papers (Perkin Elmer 226, Health Sciences, USA), (Fig. 4.7).  Blood was collected on five  
designated spots on the filter papers. The filter papers were air dried overnight and then  
packed the next day in zip lock bags with desiccant granules to prevent humid formation and  
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keep the spots dry. The zip lock bags were kept at room temperature until analysis of the  
spots[3]. 
 
4.12.2.3. HIV testing  
 
All the mothers were initially tested for HIV antibodies  using EIA HIV test kits 
(AniLabsystems  Ltd, OyToilette 3, FIN-01720, Vantaa, Finland).   All the mothers that  
tested HIV positive on the initial screening tests were confirmed using Enzygnost Anti-HIV  
½ Plus ELISA (Dade Behring, Marburg, Germany) and discrepant results were resolved by  
Western Blot   All the children as they were below two years of age were tested using HIV  
polymerase chain reaction test kits (Roche Amplicor HIV-1 DNA Test, version1.5)[3, 236].   
 
4.12.2.4 DNA extraction  
 
1.Sigma Generation kit 
Initially DNA was extracted using the Sigma Generation kit.  Two 3mm punches [5] were made for each dried 
blood sample and put in a 200µl 96 well PCR plate (DNA/NDase/RNase/PCR inhibitor free, SARSTEDT, UK).  
One hundred and forty (140 µl) of assay buffer were added and the plates vortexed for 45 minutes to clean the 
dried blood spots.  Supernatant was discarded and another 140µl assay buffer added, vortexed for 45 minutes 
and supernatant discarded.   Ninety (90µl) Generation DNA Solution 1 added and allowed to stand for 1 minute 
and supernatant discarded , this step repeated once more.  Ninety (90µl) Generation DNA Solution 2 added and 
allowed to stand for 1 minute and supernatant discarded.  Sixty (60µl) of filtered milli-Q water was added and 
extract vortexed at -20°C and transferred to a PCR machine set for 1 cycle at  99°C for 25 minutes to stabilize 
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the DNA.  The extracted DNA dissolved in the water was stored in a freezer at -20°C until ready for use in 
PCR.    
 
Initially DNA extraction was done using the above mentioned Sigma Generation kit.  We could not amplify by 
PCR the DNA from this method.  Then extraction was done using the second kit SIGMA Extract and Amp kit 
and DNA extracts from this method could be amplified by PCR.  The initial protocol for the lysis step during 
DNA extraction was 55°C for 15 minutes this was optimised to 75°C for 30 minutes, a modification from the 
manufacturer’s instructions.  This change in the conditions for the lysis step gave the best bands in MBL2 PCR.  
 
Genomic DNA was then extracted from dried blood spots using SIGMA Extract and Amp  
kit.  Briefly, two 3mm punches were made for each dried blood ( Fig. 4.8) sample and  
incubated in 20µl Lysis solution (SIGMA) at 75°C for 30 minutes.  Subsequently 180µl of  
Neutralizing solution (SIGMA) was added and mixed by pipetting  in the plate wells and  
centrifuged for 1 min at 1000rpm.  The extracted DNA quantified using the Qubit kit 
according to manufacturer’s instructions and stored at 4°C[3].  
 
Optimization of MBL2 PCR 
The MBL initial PCR method was optimised by initially using the enzyme Taq DNA Poymerase for 
amplification.  We obtained very weak amplification bands using the Taq DNA Poylmerase enzyme and the 
standard MBL2genotyping  method used at Serum State Institute.  We then changed the amplification enzyme to 
TEMPase Hot Start DNA Polymerase (VWR, Belgium) which gave us better bands for all the MBL2 SNPS, HL, 
YX, PQ and Exon 1.  The amount of template DNA to be used for the PCR reaction was also optimised.  We 
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used 2µl, 5µl and 10µl and obtained the best clear bands by using 2µl of the template DNA, 2µl was therefore 
used throughout all the MBL2 genotyping assays [3].   
 
 
 
 
Figure 4.7  Dried blood spots from mother and baby pairs 
 
 
 
Figure 4.8.  Preparation of dried blood spots, punching 3mm spots for DNA extraction 
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Table 4.4:  The oligonucleotide  primer sequences that were used in this study for detection of MBL2 coding 
and promoter normal and variant alleles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.13.0  Pyrosequencing Method 
4.13.1  Amplification of MBL2 genes by Initial general PCR 
DNA was amplified by PCR using the following reaction mixture (per sample) 41.125 µl Milli-Q water, 
0.625µl dNTPs at 10mM each (from Pharmacia Biotech), 0.25µl of 5U/µl HotStar DNA Taq Polymerase 
Enzyme (QIAGEN), 1µl of 20 pmol of MBL2 Exon 1, H/L and Y/X labelled forward and reverse PCR primer 
Oligonucleotide 
name 
 
Primer name Specific primer sequence 
         5´-3´ 
Primer 
modification 
MBL exon 
1 codons 52, 
54 and 57     
Forward 
Reverse 
Sequencin
g 
5´AGT ATG GTG GCA GCG TCT TAC TCA G 3´ 
5´/5Bio/GGC AGT TTC CTC TGG AAG GTA AAG A 3´ 
5´ CAG GCA AAG ATG GG 3´ 
 
 
5´ biotin 
 
H/L 
Forward 
Reverse 
Sequencin
g 
5´ /5Bio/GCC AGG GCC AAC GTA GTA A 3´ 
5´ GAG TTT GCT TCC CCT TGG T 3´ 
5´ TCC CCT TGG TGT TTT 3´ 
5´biotin 
 
Y/X 
 
Forward 
Reverse 
Sequencin
g 
5´ /5Bio/TCC CCT AAG CTA ACA GCC ATA AG 3´ 
5´ TGA TGA GCA GTG GGG ATC CTA 3´ 
5´ AAG ACT ATA AAC ATG CTT TC 3´ 
5´ biotin 
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(DNA Technology), 5µl of 10x HotStar PCR buffer and 2µl sample DNA extract.  A positive (a Danish DNA 
sample of known MBL2 genotype) and a negative control (no DNA added) was included in each PCR run.  The 
oligonucleotide primer sequences used for MBL2 genotyping are as shown (Supplementary Table 1).  The 
following thermo cycling program was used: an initial denaturation step at 95°C for 15 min, followed by 38 
cycles of 95°C 30s, 53°C for 30s and 72°C for 30s, the reaction was completed by a final elongation/extension 
step at 72°C for 10min.  The PCR was expected to produce one specific amplicon of approximately 240 bp, this 
was evaluated by agarose gel electrophoresis.  This PCR product was used for the MBL2 pyrosequencing  
reaction [3]. 
4.13.2  Visualisation of PCR products by agarose gel electrophoresis 
The PCR products were separated by a 2% agarose gel (Invitrogen) electrophoresis run in an electrophoresis 
chamber (Sub-cell Biorad) at 150V, 400mA for 32 minutes including the positive and negative control samples.  
The gels were then carefully transferred to the UV Transilluminator (Syngene Synoptics Ltd, Denmark) where a 
photograph of the gel was taken.  Samples that showed the required MBL2 band were used for pyrosequencing  
[3, 250-254] 
 
4.13.3 Pyrosequencing reaction 
In preparation for the pyrosequencing reaction (Fig. 4.9), 25µl of biotinylated PCR product was mixed with 3µl 
of streptavidin-coated magnetic beads (Streptavidin Sepharose High performance, GE Healthcare Life Sciences) 
37µl of binding buffer (Qiagen) and 15 µl Milli-Q water.  This mixture was agitated for 10-20 minutes at 1000 
rpm on a plate shaker to allow the biotinylated PCR product to bind to the streptavidin sepharose beads.  
Subsequently, immobilized DNA was transferred, using as PSQ 9 magnetic sample prep tool (Biotage, 
Pyrosequencing), through a series of washing steps and finally released into a primer plate(Fig. 4.10)(Pyromark 
82 
 
Q96, Qiagen) containing 39µl annealing buffer (Qiagen), 1µl of 16 pmol/µl of each specific pyrosequencing  
primer  ie Exon1, HL, YX and PQ (DNA Technology) (Supplementary Table S1). This plate was incubated for 2 
minutes at 80°C followed by cooling in the pyrosequencing  machine (Pyromark Q96, Qiagen)  for 10 
minutes.Enzymes (DNA polymerase, ATP sulfurylase, luciferase and apyrase), luciferine and adenosine-5-
phoshosulphate (APS) (Pyromark Q96 cartridge reagents kit, Qiagen) were added to the cartridge wells 
according to instructions from the installed pyro programme(Fig. 4.9).The pyrograms produced by this 
programme are used in determination of the MBL genotype and promoter type for each sample (Fig. 4.11)[3].  
 
 
Figure 4.9.  Principle of the pyrosequencing reaction. 
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Figure 4.10.  Preparation of pyrosequencing primers 
 
 
 
Figure 4.11:   Checking quality of the pyrosequencing MBL2 genotyping pyrograms. 
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4.13.4  MBL2 genotypes and haplotype functional groups 
Participants were classified into the different MBL2 Exon 1 genotypes, normal MBL2 allele designated as A and 
point mutations in the MBL2 gene and the variants designated as B (codon 54, rs1800450  A>G), C (codon 57, 
rs1800451 A>G), and D (codon 52, rs5030737 T>C) and the different combinations of variants [6, 7].  
Participants were classified into six MBL2 haplotype functional groups which were combined into three groups 
for statistical analysis, haplotypes that give normal plasma MBL levels (YA/YA, YA/XA), intermediate levels 
(XA/XA, YA/YO) and deficient levels (XA/YO, YO/YO) [101, 252].  We did not have plasma nor serum samples 
to determine plasma MBL concentration for our study population but available literature indicates MBL2 
genotypes can be used as proxy for plasma MBL levels [40, 45, 48, 212-215, 217, 218]and to classify 
individuals into normal plasma MBL levels, intermediate levels and deficient levels [3, 40, 45, 48, 212-215, 
217, 218].   
4.14 Data Management and Analysis 
All management, data entry, data processing, data cleaning and all statistical analysis for data from the two sub-
studies MUSH and PMTCT, were done using Stata 11 statistical package (STATA Corp, Timberlake 
Consultants)[1, 2].  Normality of plasma MBL levels was checked graphically.  Non-parametric tests (Mann-
Whitney and Kruskal-Wallis) were used for comparison of median plasma MBL concentrations by age, gender, 
HIV-1 and schistosoma infection status.  Differences in proportions of MBL deficiency between males and 
females and infection status were done using Chi Square or Fisher’s exact tests and confidence intervals were 
calculated using binomial exact methods.  The frequencies of the MBL2 alleles were obtained by direct gene 
counting.  Conformation to the Hardy-Weinberg Equilibrium was determined using the Chi Square test in the 
SHEsis online programme [255, 256].  For MBL2 genotype analysis, normal homozygous MBL2 was denoted as 
A/A.  The variant genotypes A/B (A>G), A/C (G>A), A/D (C>T) were grouped together as A/O heterozygous 
MBL2 as they all give low plasma MBL levels and all homozygous and compound homozygotes were grouped 
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together as O/O.  The differences in frequency of the MBL2 genotypes, promoter region variants and haplotypes 
between infection status groups were determined using the Chi Square test or Fisher’s exact tests[1, 2].  
 
Model assumptions were checked graphically using residual and Kaplan-Meier plots. Viral load was included in 
the model as log-transformed units.  We used Mann-Whitney and Kruskall-Wallis tests to compare plasma 
MBL concentrations according to two CD4+ T-cell count groups, above or below 350 cells/µl [56], the level 
recommended by WHO then (2007) to initiate ART and viral load above or below the median viral load of this 
study population of 60 000 copies per ml.  Generalised Estimating Equations (GEE) models [257-259] were 
used to compare rates of change of the CD4+ T cell count and viral load measurements over the three-year 
follow-up period. The role of plasma MBL deficiency and MBL2 genetic variants on survival over the 3-year 
period were estimated using the Cox proportional hazard models. Regression analysis was used to test for 
interaction and confounding between MBL deficiency, MBL2 genetic variance, age and sex. We used the Wald 
Chi-square statistic to choose between full and nested models. All tests were conducted at 5% level of statistical 
significance[1, 2]. 
 
For the PMTCT MBL study,  to determine the prevalence of MBL deficiency, MBL2 genotypes were used as 
proxy for MBL levels, MBL2 A/A genotype was considered as normal and those with A/O and O/O categorised 
as deficient MBL.Participants were classified into six MBL2 haplotype functional groups which were combined 
into three groups for statistical analysis, haplotypes that give normal plasma MBL levels (YA/YA, YA/XA), 
intermediate levels (XA/XA, YA/YO) and deficient levels (XA/YO, YO/YO) and promoter region haplotypes [101, 
252]. Differences in proportions of MBL deficiency were determined using Chi Square or Fisher’s exact tests.  
The differences in distribution frequency between HIV-1 infected and uninfected children, of the MBL2 
genotypes, promoter region variants and promoter haplotypes, were determined by the Chi Square test or 
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Fisher’s exact tests.  The effect of maternal MBL deficiency on HIV status of the children was determined in a 
logistic regression model after controlling for use of ART.  The level of statistical significance used was 
p<0.05[3]. 
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Data Analysis for the specific objectives in full detail  
1. To determine the prevalence of MBL deficiency among the Zimbabwean adult population. 
Exposures to be measured 
 MBL plasma concentration in the adult cohort 
 MBL deficiency 
Confounders to be measured 
 Age, gender, education, socio-economic factors 
Outcomes to be measured 
 HIV status by standard HIV testing kits 
 Prevalence of MBL plasma deficiency  
Statistical Analysis: Participants with initial mean MBL concentration of 0µg/L will be assigned the minimum 
MBL detection limit value of 20µl/L.  Data analysis will be done initially using MBL plasma concentration as a 
continuous variable.  Normality and variance of MBL concentration will be checked using Skewness and 
Kurtosis tests, Shapiro Wilk test, box plots and stem and leaf plots. If not normally distributed, Mann-Whitney 
and Kruskal-Wallis non-parametric tests will be used for comparison of MBL concentrations (medians) by age, 
gender and HIV infection status.  The difference in MBL concentration between infection groups will be given 
as medians, p values and interquartile ranges.To determine prevalence of MBL deficiency, MBL concentration 
will be categorised into normal ( 
1000µg/L and above)and deficient (below 1000µg/L).Differences in proportions of MBL deficiency between 
HIV positive and HIV negative will be determined using Chi Square or Fishers Exact tests. Factors associated 
with MBL deficiency will be determined using logistic regression, adjustment for age and gender and results 
given as odds ratios.  Mann-Whitney and Kruskall-Wallis non-parametric tests for unpaired group comparisons, 
supplemented with logistic regression will be used to compare plasma MBL concentrations between HIV 
infection status groups, according to CD4+ T-cell count, above or below 250 cells/µl.   
 
2. To determine the relationship of MBL deficiency with HIV infection in the MUSH adult cohort in 
Zimbabwe.  
Exposures to be measured 
 MBL plasma concentration in the adult cohort 
 MBL deficiency 
Confounders to be measured 
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 Age, gender, education, socio-economic factors 
Outcomes to be measured 
 HIV status by standard HIV testing kits 
 Prevalence of MBL plasma deficiency  
Statistical Analysis: Participants with initial mean MBL concentration of 0µg/L will be assigned the minimum 
MBL detection limit value of 20µl/L.  Data analysis will be done initially using MBL plasma concentration as a 
continuous variable.  Normality and variance of MBL concentration will be checked using Skewness and 
Kurtosis tests, Shapiro Wilk test, box plots and stem and leaf plots. If not normally distributed, Mann-Whitney 
and Kruskal-Wallis non-parametric tests will be used for comparison of MBL concentrations (medians) by age, 
gender and HIV infection status.  The difference in MBL concentration between infection groups will be given 
as medians, p values and interquartile ranges.To determine prevalence of MBL deficiency, MBL concentration 
will be categorised into normal (above 1000µg/L)and deficient (below 1000µg/L).Differences in proportions of 
MBL deficiency between HIV positive and HIV negative will be determined using Chi Square or Fishers Exact 
tests.  Factors associated with MBL deficiency will be determined using logistic regression, adjustment for age 
and gender and results given as odds ratios.  Mann-Whitney and Kruskall-Wallis non-parametric tests for 
unpaired group comparisons, supplemented with logistic regression will be used to compare plasma MBL 
concentrations between HIV infection status groups, according to CD4+ T-cell count, above or below 250 
cells/µl.   
 
3. To determine the effect of MBL deficiency on disease progression and survival among the Zimbabwean 
adults. 
Exposure to be measured 
 MBL plasma concentration in the adult cohort 
 MBL genotype and promoter type in the adult cohort 
Confounders to be measured 
 Age, gender 
Outcomes to be measured 
 Mortality 
 Viral load change 
 CD4 T cell count change 
Statistical Analysis: Normality and variance of CD4 counts and viral load will be checked using Skewness and  
89 
 
 
 
 
Kurtosis tests, Shapiro Wilk test, box plots and stem and leaf plots.  If the CD4 counts and  
viral load are not normally distributed they will be log transformed to approximate normality.   
Random effects models will be used to take care of repeated CD4 and viral load  
measurements and to determine change in CD4 count and viral load at baseline, 3, 6 and 12  
months and adjust for factors associated with disease progression.  Generalised Estimating  
Equations (GEE) will also be used to determine association between MBL deficiency and  
disease progression.  
 
The effect of MBL genetic variants on survival, in HIV-1 positive participants, will be  
estimated by the Kaplan Meier plots and differences will be tested by the log-rank test. 
Survival analysis using Kaplan Meier plots and Log rank tests will done only among the 197  
HIV-1 positive participants to determine influence of MBL plasma concentration and MBL  
polymorphism in the MBL coding and promoter region, on survival. Results will be  
presented as hazard ratios and CIs after adjusting for gender and age using the Cox regression  
analysis.   
 
 
4. To determine prevalence of MBL deficiency among mother and their infants in a Zimbabwean 
population. 
Exposures to be measured 
 MBL genotype and promoter type in the PMTCT cohort 
Confounders to be measured 
 Age, Gender 
 Use of ART by the mothers and children in the PMTCT cohort 
Outcomes to be measured 
 HIV status of the children by standard HIV testing kits 
Statistical Analysis: The frequencies of the MBL alleles will be obtained by direct gene counting.For MBL 
genotype analysis, normal homozygous MBL will be denoted as A/A.  The variant genotypes AB, AC, AD 
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will be grouped together as A/O heterozygous MBL as they all give low MBL plasma levels and all 
homozygous and compound homozygotes will grouped together as O/O.The fit to the Hardy-Weinburg 
equilibrium, the differences in distribution frequency of the MBL genotypes, promoter haplotypes between 
the HIV infected and uninfected will be determined by the Chi Square test.  Odds ratios with CIs will be 
calculated using Logistic regression.   
 
 
5.To determine the relationship between MBL deficiency and HIV transmission from mother to child. 
Exposures to be measured 
 MBL genotype and promoter type in the PMTCT cohort 
Confounders to be measured 
 Age, Gender 
 Use of ART by the mothers and children in the PMTCT cohort 
Outcomes to be measured 
 HIV status of the children by standard HIV testing kits 
Statistical Analysis: The frequencies of the MBL alleles will be obtained by direct gene counting.For MBL 
genotype analysis, normal homozygous MBL will be denoted as A/A.  The variant genotypes AB, AC, AD 
will be grouped together as A/O heterozygous MBL as they all give low MBL plasma levels and all 
homozygous and compound homozygotes will grouped together as O/O.The differences in distribution 
frequency of the MBL genotypes, promoter haplotypes and the fit to the Hardy-Weinburg equilibrium will 
determined by the Chi Square test.  Odds ratios with CIs will be calculated using Logistic regression.   
 
 
4.15 Additional statistical analysis carried out post publication of the three papers 
4.15.1 Fractional polynomials to analyse disease progression 
Additional analysis was done treating MBL as a continuous variable [260-263]  to determine relationship 
between change in CD4+ T cell count and MBL levels using GEE models..  Fractional polynomials [260-263] 
were carried out to determine the response of CD4+ T cell count to plasma MBL levels using the GEE model, 
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after controlling for schistosomiasis infection at baseline.  MBL was considered as a continuous exposure 
variable.  Fractional polynomials of first and second order were used to test for non-linearity in the response of 
CD4+ T cell count to MBL. 
4.15.2 Power analysis for MUSH MBL study 
This was done to determine the power of the MUSH study based on HIV as the outcome. 
Additionally, for the relationship of MBL to disease progression, this is a cohort study and the analysis is a time 
to event analysis, with exposure being MBL sufficiency level.  So the exposed and unexposed groups were not 
of equal size.  Power analysis was done using stpower in Stata to give the power corresponding to different 
hazard ratios 
 
4.15.3  Power analysis for PMTCT study 
This was done to determine the power of the PMTCT study based on HIV as the outcome. 
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4.16. Ethics Considerations 
4.16.1 Ethics clearance for the PhD research project 
This PhD research project made use of blood samples from an adult cohort and dried blood samples from a 
PMTCT national survey of mothers and their babies.  The PhD project was granted permissionby the National 
Research Ethics Committee of the Medical Research Council of Zimbabwe (MRCZ/A/1770) and University of 
the Witwatersrand Human Research Ethics Committee (clearance number M130348).  The details of the 
clearance processes for the main MUSH study and the PMTCT were as follows: 
4.16.2 Ethics clearance and considerations for the main MUSH study 
Ethics approval to conduct the MUSH study, on which the MBL study was a sub-study, was granted by the 
Medical Research Council of Zimbabwe, Ministry of Health and Child Welfare (MRCZ/A/918) local health and 
political authorities in Shamva District Zimbabwe.   In addition, permission was given by the provincial medical 
director of Mashonaland Central Province, the district medical officer of Shamva District, and the village 
leaders. 
 
Informed written consent was sought and granted by all research participants.  Only those individuals who 
volunteered to participate after obtaining detailed information about the study including the need for HIV 
testing was provided, were recruited into the study.  All participants were asked to sign a consent form and were 
informed of their freedom to withdraw at any time even after signing.   All participants were given the study 
information leaflet to take home, read and keep, in a language of their choice (English or Shona).   The 
following ethical issues were also considered and adhered to during the main MUSH study:   
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4.16.3 Blood sampling 
The amount of blood taken for serum/plasma processing, PBMCs and HIV testing was small.  However 
participants had the right to withdraw from the study or refuse to give blood samples at any time. 
 
4.16.4 Testing the participants for HIV 
Two tests were done before confirmation of positive diagnosis.  During recruitment, the participants were 
counselled extensively in order to make personal decisions as to receive test results or not.  Post-test counselling 
was also given. 
 
4.16.5 The prevention of HIV and other STIs 
All participants were given information on prevention of HIV, those included in the study or not and anyone 
asking for any information was helped if possible.   Treatment for STIs was offered at the research satellite 
clinic but all complicated cases were referred for further management at Mt Darwin Karanda Hospital. 
 
4.16.6 Treatment for schistosomiasis 
Treatment with praziquantel was administered to all infected people after the baseline  
Survey.  Praziquantel was given to pregnant women after delivery as well as at the end of the study. 
 
4.16.7Ethics considerations for the PMTCT survey and access to dried blood samples 
The CESHAAR PMTCT study was approved by the National Research Ethics Committee of the Medical 
Research Council of Zimbabwe (MRCZ/A/1655), University of California and University of London Human 
Research Ethics Committees.  All the mothers who took part in the main PMTCT National Survey gave written 
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informed consent for specimen collection, storage and future laboratory studies.  Permission to access the 
PMTCT samples was granted by the Directorate at the CESHAAR Research Centre and their collaborators.  
Approval to carry out the MBL assays on mother and baby pairs was sought both from the Medical Research 
Council of Zimbabwe and from the Witwatersrand Human Research Ethics Committee.  Permission to ship the 
dried blood samples to Denmark was also sought from the CESHAAR Research Centre and from the Research 
Council of Zimbabwe. 
 
4.16.8 Data protection and absolute confidentiality 
Was assured in both the MUSH study and PMTCT survey.  Access to participants’ personal information was 
restricted to authorised personnel only.  All participants data was anonymized, kept confidential and access to 
information restricted to authorized personnel. 
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CHAPTER 5  RESULTS: SUMMARY OF KEY FINDINGS 
5.0 Introduction 
This chapter gives a summary of the results for this research project.  Details of the results are reported in 
papers 1,2 and 3 attached (Appendices A-C) and the fourth manuscript is under review (appendix D).  This 
chapter also describes in detail all the data analysis carried out after publication of papers 1, 2 and 3.  The 
findings reported below have been divided into three sub sections.  The first subsection, by way of introduction 
and background provides a short demographic description of the two study populations, the adult and PMTCT 
studies. The second subsection presents the five themes of this thesis based on the five research questions 
explored during this research and the five specific study objectives.   Throughout this chapter references are 
given of the specific papers in which the detailed reports are given.  The third sub-section reports the results 
from the additional statistical analysis that was carried out after publication of papers 1,2 and 3.   
 
5.1   Socio-demographic characteristics of the two study populations 
This sub section provides a brief description of the two study populations involved in this research.  Our study 
comprised of two populations, an adult MUSH population and a PMTCT population of mothers and their 9-18 
months old babies.  Detailed descriptions of the populations are given in original papers 1,2 and 3.  Briefly 
MUSH study-population comprised of adults 379 adult males and females,18 years old and above, residing in 
the area, who were willing to be bled and tested for HIV (reported in papers 1 and 2) Median age (IQR) of the 
MUSH participants was 30 (17 to 41) years old and the majority were females (80%).  Baseline demographic 
characteristics of this study population and prevalence of HIV-1, S. haematobium and S. mansoni among the 
1545 participants screened during the main MUSH study have been described elsewhere [65] and also for this 
thesis reported in pares 1 and 2.   
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From the PMTCT study, the median age (IQR) of the mothers was 30 (26 - 34) years and the children mean age 
(IQR) was 12 (11-15) months old at the time of enrolment.   All 622 mothers were HIV-1 infected, 574 babies 
were HIV negative and 48 were HIV-1 positive babies.  For the PMTCT MBL study, stored dried blood 
samples from mothers and baby pairs which were obtained from the CESHAAR Research Centre in Zimbabwe 
that had stored whole blood samples for mother –infant pairs from a national PMTCT survey carried out in 
2012 (reported in paper 3).  
 
5.2.     Synthesising the two sub-studies 
This sub section presents a synthesis of the five thesis themes derived from the five research questions and the 
five study specific objectives set out to be explored at protocol development stage, explaining the relationship 
between MBL genetic polymorphism and HIV infection in the adult and PMTCT sub-studies. The five themes 
have already been introduced in Chapter 3.  
5.3.   Study themes 
We used the MUSH study population to answer research questions 1, 2, and 3 indicated in this section as 
themes 1, 2 and 3.  And we also used the mothers and children PMTCT stored dried blood samples to answer 
our study research questions 4 and 5 indicated in this section as themes 4 and 5.   
 
5.3.1.    Determination of plasma MBL levels, prevalence of MBL deficiency, prevalence of normal and 
variant MBL2 genotypes and promoter region types in Zimbabwean adult males and females, MUSH 
study (THEME 1, PAPER 1). 
From the MUSH study a total of 379 plasma and whole blood samples were available for MBL analysis. The 
median (IQR) plasma MBL concentration was 800µg/L (192-1936µg/L) (paper 1).  Prevalence of plasma MBL 
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deficiency was 18% with high frequency of the C (codon 57G>A) mutant allele (20%).  The prevalence of 
normal and variant MBL genotypes are as reported in Table 3 (paper 1).   
 
5.3.2.   Determination of the role of Mannose Binding Lectin Deficiency in HIV-1 Infection in a Rural 
Adult Population in Zimbabwe (THEME 2, PAPER 1).  
We found no significant difference in median plasma MBL levels between HIV negative S. mansoni (912µg/L) 
and HIV positive (688µg/L), p=0.066 as reported in Table 3 (paper 1).  However plasma MBL levels at the 
assay detection limit of 20µg/L were more frequent among the HIV-1 infected (p=0.007) (as reported in paper 
1).  This adult population had some of the study participants co-infected with S. haematobium and S. mansoni, 
this variable was also analysed (Table 1, paper 1).  The prevalence of HIV-1, S. haematobium, S. mansoni and 
co-infection with both schistosoma species among the 379 participants used for the MBL sub-study was 52%, 
58%, 7% and 10%, respectively (Table 1) (Paper 1). Study participants co-infected with S. haematobium and 
had significantly higher MBL levels than the uninfected uninfected (Table 1, paper 1).  All MBL2 variants were 
not associated with HIV-1 infection (Table 4, paper 1) but promoter variants LY and LL were significantly 
associated with S. haematobium infection(Table 5, paper 1) 
 
5.3.3.   Determination of the role of Mannose Binding Lectin Deficiency in HIV-1 disease progression and 
survival in a rural adult population in Zimbabwe (THEME 3, PAPER 2). 
We assessed 197 HIV positive adults where 83% (164) were women with a median age of 31 years old (paper 
2).  Prevalence of plasma MBL deficiency (less than 100µg/L) and MBL2 deficient genetic variants (A/O and 
O/O genotypes) was 21% (42 out of 197) and 39% (74 out of 190), respectively (paper 2).  We did not observe 
a significant role to explain individual variation in mortality, change of CD4+ T cell count and viral load by 
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MBL plasma deficiency or MBL2 genetic variants from baseline to 3 years follow up period in this adult 
population as reported in Tables 3,4,5, paper 2). 
 
5.3.4.   Determination of prevalence of normal and variant MBL2 genotypes and promoter region in 
Zimbabwean mothers and their babies (THEME 4, PAPER 3).  
From the PMTCT study, the median age (IQR) of the mothers was 30(26 - 34) years and the children mean age 
(IQR) was 12 (11-15) months old at the time of enrolment.   All 622 mothers were HIV-1 infected, 574 babies 
were HIV negative and 48 were HIV-1 positive babies (Figure 1, paper 3).  MBL2 normal structural allele A and 
variants B (codon 5A>G), C (codon 57 A>G) and promoter region SNPs -550(H/L) and -221(X/Y) were 
detected Table 1, paper 3).  Prevalence of MBL deficiency was 34% among the mothers and 32% among the 
children Table 1, paper 3).   
5.3.5.   Determination of the role of Mannose Binding Lectin Deficiency in HIV-1 infection and vertical 
transmission in a PMTCT national survey in Zimbabwe (THEME 5, PAPER 3). 
We found no association between maternal MBL2 deficiency and HIV-1 transmission to their children.  We 
found no difference in the distribution of HIV-1 infected and uninfected children between the MBL2 genotypes 
of the mothers and those of the children Tables 2 and 3, paper 3).  Taken together, the present study in a large 
sample of mother-infant pairs in Zimbabwe adds to the emerging literature and the hypothesis that MBL2 
variation as predicted by haplotypes do not influence the vertical transmission risk for HIV.   
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5.4 Additional statistical analysis not included in paper 1 
5.4.1 Power analysis for the Adult MBL study 
Analysis of power for the MBL adult study based on HIV infection as an outcome, was then done after all 
laboratory work had been completed.  Pocock’s formula [109] was used to retrospectively carry out power 
analysis in sample size (n) required for the adult MBL sub-study : 𝑛 =
𝑝1(1−𝑝1)+𝑝2(1−𝑝2)(𝑍𝛼−𝑍𝛽)
2
(𝑝1−𝑝2)2
, where 𝑝1 and 
𝑝2are proportions of MBL deficiency among HIV positive and HIV negative, 𝑍𝛼 and 𝑍𝛽 are values of standard 
normal distribution at α = Significance level and 𝛽 = power.  Given that the final 𝑛 = 378 (HIV+= 197, HIV −
181), 𝑝1 = 0.43 and 𝑝2 = 0.33, the sample size had power of 61% to detect a difference in distribution of 
MBL deficiency between the two HIV status groups.  The adult MBL study therefore had 61% power to detect 
a difference in prevalence of MBL deficiency between the HIV infected and the HIV negative.   
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5.4.2 Power analysis of the adult MBL study corresponding to different hazard ratios 
Analysis of power of the adult MBL study was done corresponding to different hazard ratios. This was done 
using the 3 MBL plasma categories, initially hazard ratio of MBL 100-500ug/ml against MBL plasma normal 
levels.  The adult MBL study therefore had 9% power to detect a difference in prevalence of MBL deficiency 
between the HIV infected and the HIV negative after taking consideration of the different hazard ratios.   
 
Then using hazard ratio of MBL <100µg/ml against MBL plasma normal levels.  The adult MBL study 
therefore also had 9% power to detect a difference in prevalence of MBL deficiency between the HIV infected 
and the HIV negative after taking consideration of the different hazard ratios.    
 
5.5 Additional statistical analysis not included in paper 2 
This section provides details about the additional analysis that were carried out after publication of papers 1, 2 
and 3, now incorporated in this integrating narrative. 
5.5.1 Role of MBL deficiency in disease progression after controlling for schistosomiasis 
Additional GEE analysis was carried out to determine role of MBL deficiency in change in CD4+ T cell 
countand viral load, after controlling for schistosomiasis.  Our results showed that MBL deficiency had no role 
in change in CD4 T cell count (Table 5.1) and viral load (Table 5.2), after controlling for schistosomiasis.   
 
5.5.2 Multiple GEE regression analysis 
This analysis was carried out including all variables in the analysis. Our results showed the MBL deficiency had 
no role in change in CD4 T cell count (Table 5.3) and viral load (Table 5.4) after controlling for 
schistosomiasis. 
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5.5.3 Analysis of disease progression, treating MBL as a continuous variable using fractional 
polynomials 
Additional analysis was done treating MBL as a continuous variable [260-263]  to 
determine relationship between change in CD4+ T cell countsand MBL levels using GEE  
models.  In the models used there was no evidence of non-linearity so MBL was fitted as a  
continuous explanatory variable without transformation.   We found no relationship between  
change in CD4+ T cell count, viral load and MBL levels in our GEE models,after controlling  
for schistosomiasis infection. 
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TABLE 5.1.  The factors associated with change in CD4+ T cell counts from baseline to 3 years follow up 
period, after controlling for schistosomiasis. 
Factor N Parameter Estimate 
(cell counts) 
95% CI P value 
Plasma MBL level     
Normal plasma MBL level >100µg/L 
(reference) 
113 353 310-396 <0.001 
MBL intermediate level 100-500µg/L 43 -38 -115-38 0.325 
MBL deficient level  <100µg/L 41 -14 -98-69 0.731 
MBL exon 1 genotype     
MBL normal genotypes A/A 116 351 307-395 <0.001 
MBL deficient genotypes A/O and 
O/O combined 
74 -16 -87-53 0.644 
MBL haplotypes     
MBL normal haplotypes  
(YAYA/YAXA) 
110 347 303-391 <0.001 
1.MBL deficient genotype (XA/XA, 
YA/YO) (intermediate levels 
72 -3 -66-58 0.902 
2.MBL deficient genotype XA/YO, 
YO/YO (deficient levels) 
8 -30 -203-143 0.732 
MBL promoter region genotypes     
MBL normal promoter region H/Y 14 315 193-437 <0.001 
MBL promoter variants LY/LX 176 32 -95-159 0.621 
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Age at t0     
Below 25 years old 21 423 321-525 <0.001 
Above 25 years old 177 -90 -198-16 0.098 
Sex     
Female 16 361 324-397 <0.001 
Male 34 -108 -196--21 0.015 
 
Change in CD4+ T cell count (cells/µl) over the 3 year follow up period, after controlling for schistosomiasis.  Reference plasma MBL 
levels is normal levels above 500µg/L.  Reference MBL2 genotype is normal wild type genotype A/A and YAYA/YAXA.  Reference 
MBL2 promoter region genotype is H/Y.   Reference age was below 25 years old.  Reference sex was females.   
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TABLE  5.2  The factors associated with change in viral load from baseline to 3 years follow up period, after 
controlling for schistosomiasis. 
Factor n Parameter Estimate 
viral load 
95% CI P value 
Plasma MBL level     
Normal plasma MBL level >100µg/L 
(reference) 
113 4.58 4.41-4.75 0.000 
MBL intermediate level 100-500µg/L 43 0.19 -0.11-4.90 0.220 
MBL deficient level  <100µg/L 41 0.02 -0.31-0.35 0.890 
MBL2 exon 1 genotype     
MBL normal genotypes A/A 116 4.63 4.45-4.79 0.00 
MBL deficient genotypes A/O and O/O 
combined 
74 -0.025 -0.30-0.25 0.860 
MBL2 haplotypes     
MBL normal haplotypes  (YAYA/YAXA) 110 4.62 4.44-4.79 0.000 
MBL deficient genotype (XA/XA, 
YA/YO) (intermediate levels 
72 -0.01 -0.28-0.25 0.925 
MBL deficient genotype XA/YO, YO/YO 
(deficient levels) 
8 0.03 -0.66-0.73 0.932 
MBL2 promoter region genotypes     
MBL normal promoter region H/Y 14 4.67 4.21-5.14 0.000 
MBL promoter variants LY/LX 176 -0.068 -0.55-0.41 0.780 
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Age at t0     
Below 25 years old 21 4.49 4.10-4.88 0.000 
Above 25 years old 177 0.15 -0.26-0.57 0.464 
Sex     
Female 16 4.54 4.40-4.69 0.000 
Male 34 0.471 0.13-0.81 0.006 
 
Change in viral (load log10 scale) over the 3 year follow up period, after controlling for schistosomiasis.  Reference plasma MBL 
levels is normal levels above 500µg/L.  Reference MBL2 genotype is normal wild type genotype A/A and YAYA/YAXA.  Reference 
MBL2 promoter region genotype is H/Y.   Reference age was below 25 years old.  Reference sex was females.   
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Table 5.3.  GEE Multiple Regression analysis of the factors associated with change in CD4+ T cell counts from 
baseline to 3 years follow up, after controlling for schistosomiasis infection. 
Factor n Parameter Estimate 
(cell counts) 
95% CI P value 
Plasma MBL level     
Normal plasma MBL level >100µg/L 
(reference) 
113 441 278-604 <0.001 
MBL intermediate level 100-500µg/L 43 -37 -128-53 0.421 
MBL deficient level  <100µg/L 41 -7 -141-126 0.915 
MBL exon 1 genotype     
MBL normal genotypes A/A 116 356 312-400 <0.000 
MBL deficient genotypes A/O and 
O/O combined 
74 -24 -168-120 0.741 
MBL haplotypes     
MBL normal haplotypes  
(YAYA/YAXA) 
110 353 309-396 <0.001 
1.MBL deficient genotype (XA/XA, 
YA/YO) (intermediate levels 
72 10 -94-114 0.848 
2.MBL deficient genotype XA/YO, 
YO/YO (deficient levels) 
8 4 -204-214 0.965 
MBL promoter region genotypes     
MBL normal promoter region H/Y 14 318 196-440 <0.001 
MBL promoter variants LY/LX 176 19 -104-144 0.757 
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Age at t0     
Below 25 years old 21 429 327-531 <0.001 
Above 25 years old 177 -88 -198-20 0.112 
Sex     
Female 16 367 331-403 <0.001 
Male 34 -111 -199--23 0.013 
 
Change in CD4+ T cell count (cells/µl) over the 3 year follow up period, after controlling for schistosomiasis infection.  Reference 
plasma MBL levels is normal levels above 500µg/L.  Reference MBL2 genotype is normal wild type genotype A/A and YAYA/YAXA.  
Reference MBL2 promoter region genotype is H/Y.   Reference age was below 25 years old.  Reference sex was females.  
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Table 5.4.  GEE Multiple regression analysis of the factors associated with change in viral load from baseline to 
3 years follow up, after controlling for schistosomiasis 
Factor n Parameter Estimate 
viral load 
95% CI P value 
Plasma MBL level     
Normal plasma MBL level >100µg/L 
(reference) 
113 4.37 3.75-5.00 <0.001 
MBL intermediate level 100-500µg/L 43 0.30 -0.06-0.67 0.108 
MBL deficient level  <100µg/L 41 0.22 -0.31-0.75 0.426 
MBL2 exon 1 genotype     
MBL normal genotypes A/A 116 4.63 4.45-4.79 <0.001 
MBL deficient genotypes A/O and O/O 
combined 
74 -0.26 -0.92-0.40 0.443 
MBL2 haplotypes     
MBL normal haplotypes  (YAYA/YAXA) 110 4.62 4.44-4.79 <0.001 
MBL deficient genotype (XA/XA, 
YA/YO) (intermediate levels 
72 0.08 -0.47-0.63 0.772 
MBL deficient genotype XA/YO, YO/YO 
(deficient levels) 
8 0.06 -0.85-0.96 0.901 
MBL2 promoter region genotypes     
MBL normal promoter region H/Y 14 4.67 4.21-5.14 <0.001 
MBL promoter variants LY/LX 176 -0.04 -0.52-0.44 0.872 
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Change in viral (load log10 scale) over the 3 year follow up period.  Reference plasma MBL levels is normal levels above 500µg/L.  
Reference MBL2 genotype is normal wild type genotype A/A and YAYA/YAXA.  Reference MBL2 promoter region genotype is H/Y.   
Reference age was below 25 years old.  Reference sex was females.   
 
5.6 Additional statistical analysis not included in paper 3 
Pocock’s formula [109]was used to retrospectively carry out power analysis in sample size (n) required for the 
PMTCT MBL sub-study: 𝑛 =
𝑝1(1−𝑝1)+𝑝2(1−𝑝2)(𝑍𝛼−𝑍𝛽)
2
(𝑝1−𝑝2)2
, where 𝑝1 and 𝑝2are proportions of normal MBL and 
MBL deficiency among mothers,  𝑍𝛼 and 𝑍𝛽 are values of standard normal distribution at α = Significance level 
and 𝛽 = power. Given that the final 𝑛 = 622 (normal MBL = 411, deficient MBL = 211), 𝑝1 = 0.09 and 𝑝2 =
0.07, the sample size had power of 17% to detect a difference in distribution of MBL deficiency between the 
two HIV status groups of the children.  The PMTCT MBL study therefore had 17% power to detect a difference 
in prevalence of MBL deficiency between the HIV infected and the HIV negative children.   
  
Age at t0     
Below 25 years old 21 4.49 4.10-4.88 <0.001 
Above 25 years old 177 0.15 -0.27-0.57 0.476 
Sex     
Female 16 4.54 4.40-4.69 <0.001 
Male 34 0.50 0.15-0.84 0.004 
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CHAPTER 6:  DISCUSSION, CONCLUSIONS, PUBLIC HEALTH IMPLICATIONS OF THE STUDY 
AND RECOMMENDATIONS FOR FURTHER RESEARCH. 
6.1 Introduction 
This chapter provides in brief, a discussion on the key results obtained from this research project.  A detailed 
comparison of our results on both the adult and PMTCT MBL studies to results available in literature in relation 
to the specific objectives and study themes set out for this research, are provided in papers 1, 2 and 3 (Appendix 
A-D) .  This chapter also describes the conclusions we drew from the adult MBL study and the PMTCT MBL 
study on the role of MBL deficiency on HIV infection, disease progression and survival in adults and HIV 
vertical transmission.  In addition this chapter also discusses the public health implications of these findings for 
policy and recommendations for further research.   
 
The results from the adult MUSH study showed a high prevalence of plasma MBL deficiency, high frequency 
of MBL2 genetic variant C (G>A).  These findings are consistent with other observations that the C (G>A) 
variant allele is the predominant variant allele in Sub-Saharan Africa. We found no evidence of an association 
between MBL deficiency and HIV-1 infection, however plasma MBL levels at assay detection limit were 
associated with HIV-1 infection indicating a possible role of MBL deficiency in HIV infection.  Lower plasma 
MBL levels were protective against both S. haematobium and S. mansoni infections and higher plasma MBL 
levels associated with increased susceptibility to schistosoma infections.  All the other MBL gene and promoter 
region variants detected played no role in both HIV and schistosoma infections but presence of promoter region 
variants LY and LL increased susceptibility to both S. haematobium and S. mansoni infections.  The available 
evidence on the association of polymorphism in the MBL2 promoter region with HIV-1 infection is still 
conflicting.  In light of all this conflicting evidence it would be difficult  to recommend the use of MBL plasma 
levels, MBL2 structural variants and promoter region mutations as a biomarker  of HIV infection and for the 
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monitoring of ARV therapy together with viral load and CD4+ T cell lymphocyte counts in the population 
represented by our study participants. Our results on role of plasma MBL levels in schistosoma infections are in 
conflict with the only available report that found lower plasma MBL levels to increase susceptibility to 
schistosoma infections.  There is therefore, need to carry out a much bigger study to verify these results.  In 
addition, future immunological studies looking at the association between MBL deficiency and other diseases 
are highly recommended for the Zimbabwean population where persistent recurrent bacterial, viral, fungal and 
other parasitic infections remain prevalent affecting both adults and children (discussed in more detail in paper 
1)[1].    
 
The results from an analysis of the role of MBL deficiency in HIV disease progression and survival cannot 
support recommendations to use MBL2 polymorphism as a prognostic tool for AIDS progression using CD4+ T 
cell counts and viral load as has been recommended by others[49] (discussed in more detail in paper 2)[2]. 
 
Finally, our results showed a high prevalence of MBL2 genetic variant AC among the mothers and their 
children, in accordance with other studies of MBL2 genetic variation in African populations [6, 39].  This MBL2 
variant form is associated with MBL deficiency; however the high prevalence of MBL deficiency among the 
mothers and their children in our study was not associated with HIV-1 vertical transmission.  It is important to 
explore the genetic make-up of the Zimbabwean population in view of the high prevalence of several viral, 
parasitic and bacterial infections considering the conflicting evidence associating MBL deficiency and 
protection against some infections and increased susceptibility in others (discussed in more detail in paper 3) 
[3]. 
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6.2 Study Limitations 
1. The main limitation of our study was inclusion of few men in the main MUSH study [1, 181, 182, 198].  
There is a gold panning area in the neighbouring district, most men work away from their rural homes 
and were not available during our study recruitment phase.  This has the potential to bias our findings 
but every effort was done to enrol all eligible men into the main MUSH study.    
 
2. It was not possible to determine the effect of MBL deficiency on HIV treatment outcome because the 
ARVs were not readily available in Zimbabwe during that time. 
 
3. Another limitation in this study was that serum/plasma samples were not available from the PMTCT 
study to determine MBL concentration for the PMTCT mothers and their babies.  However, MBL2 exon 
1 region and promoter region polymorphisms can be used as proxy to classify participants into normal 
plasma/serum MBL levels, intermediate and deficient [5-7, 138, 264-267].    
 
4. The low statistical power of 60% for the adult MBL study and 9% for the PMTCT MBL study is another 
limitation of our study.  We therefore cannot generalise our findings to the general Zimbabwean 
population.  Our major recommendation is therefore the need in future to carry out a study with a larger 
adult sample size and a larger PMTCT sample size.   
 
6.3 Public Health Implications 
In our study we did not find a role of MBL deficiency in HIV infection in the adult population.  In our study we 
also did not find a role of MBL deficiency in survival and disease progression among the adults infected with 
HIV.  We did also did not find a role of MBL deficiency in HIV vertical transmission.  In conclusion we did not 
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find a role for MBL genetic variants in HIV infection nor in HIV vertical transmission from mothers to their 
children in our study population.   
 
However this still remains a critical and interesting area of research around HIV prevention strategies as other 
studies have reported a protective role of normal MBL levels and normal MBL2  genotypes in HIV infection 
[21].    
6.4 Recommendations for Future Studies 
This section gives an outline of recommendations and suggestions for future studies arising out of the findings 
of this study: 
1.     A bigger study with power above 80% to be carried out involving more adults to  
determine the role of MBL deficiency on HIV infection.  Our adult MUSH MBL study had 61% power to  
determine a difference in HIV susceptibility.  
 
2.  A bigger study with power above 80% to be carried out involving more mother baby pairs to determine 
the role of MBL deficiency on HIV vertical transmission.  The PMTCT MBL study had 9% power to 
determine a difference in HIV susceptibility between the HIV infected children and the HIV negative 
children. 
3. Future work to include genotyping of other related loci which encode proteins along the same 
complement pathway for example the MASP loci.  As dysfunctional MASP genotypes would also cause 
low levels of MBL. 
4. Future work to also look at MBL genotypes and MBL levels in TB infections since Zimbabwe has a 
high TB prevalence.  
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Abstract 
BackgroundPolymorphism in the MBL2 gene lead to MBL deficiency, which has been s
hown toincreasesusceptibilitytovariousbacterial, viralandparasiticinfections. Weassessedrol
eofMBLdeficiencyin HIV-
1andschistosoma infections in Zimbabweanadults enrolled in the Mup-
fureSchistosomiasis andHIVCohort(MUSHCohort). 
Methods 
HIV-
1,S.haematobium andS. mansoni infections weredeterminedatbaseline.PlasmaMBL conce
ntrationwas measuredby ELISAandMBL2genotypesdeterminedby PCR. Wecalculatedand
comparedthe proportionsofplasmaMBLdeficiency,MBL2 structuralvari-
ant alleles B(codon54A>G),C (codon 57A>G),andD (codon 52T>C)as wellas MBL2promo
tervariants-550(H/L),-221(X/Y)and+4(P/Q)between HIV-1andschistosomaco-in-
fectionandcontrol groupsusing ChiSquaretest. 
Results 
Weassessed379adults,80%females,medianage (IQR)30 (17–41)years. HIV-1,S. hae- 
matobiumandS. mansoniprevalence were26%,43%and18%respectivelyin theMUSH 
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baselinesurvey. Median(IQR)plasmaMBLconcentration was800μg/L(192-
1936μg/L).PrevalenceofplasmaMBLdeficiencywas18%withhigh frequency oftheC (codon5
7G>A)mutantallele(20%).Therewasno significant difference in medianplasmaMBLlevelsbet
ween HIV negative (912μg/L)and HIV positive (688μg/L),p=0.066.HoweverplasmaMBLleve
lsattheassaydetectionlimit of20μg/L weremorefrequentamongtheHIV-
1infected (p=0.007).S. haematobiumandS. mansoniinfectedparticipantshadsignif-
icantlyhigherMBLlevelsthanuninfected.AllMBL2 variantswerenotassociated withHIV-
1 infection butpromotervariantsLYandLL weresignificantlyassociated withS. haemato-
biuminfection. 
Conclusion 
Ourdataindicatehighprevalence ofMBL deficiency,no evidenceofassociationbetweenMB
L deficiency andHIV-
1infection. However,lower plasmaMBLlevelswereprotectiveagainstbothS. haematobiuma
ndS. mansoniinfectionsandMBL2promoter andvariantsLYandLL increasedsusceptibility t
o S. haematobiuminfection. 
Introduction 
HIV-1andschistosomiasisco-
infectionsareverycommoninAfricaandhavebeenreportedinseveralstudies[1–6].Sub-
SaharanAfricaistheregionhardesthitbytheHIV/AIDSpandemicwhere63%ofthe33millioninfected
peoplelive[7].HIVinfectionhasremainedamajorpub-
lichealthchallengesinceitsdiscoveryin1983[8].TheHIVpandemicisstillravagingmostpartsofSouth
ernAfricancountrieswithcurrentprevalenceinthesecountriesbetween10–
20%[7].SeveralreportsindicatethatindividualsworldwidedifferintheirsusceptibilitytoHIVinfectio
nanditiswidelyagreedthatgeneticpolymorphismsinthehostgenesimportantinim-
muneregulationcanincreaseorreducetheriskofHIVinfections[9,10].Anunderstandingoftheimmu
nologicalfactorsfuellingtheHIV-1epidemicinAfricaisveryimportantinanefforttocurbtheHIV-
1scourge. 
Schistosomiasisisoneoftheneglectedtropicaldiseases,whichtheWorldHealthOrganiza-
tionistargetingforelimination[11–13].Anestimated85%oftheworld’sestimated200mil-
lionpeoplewithschistosomiasisliveinSub-
SaharanAfrica[11,13].S.haematobium isassociatedwithurogenitalschistosomiasischaracterisedb
yseverepathologicalconditionsin-
cludinghematuriaandbladdercancerandS.mansonicausesintestinalschistosomiasischarac-
terisedbychronicorintermittentabdominalpainbleedingfromgastro-
oesophagealvaricesandbloodystool[14].Schistosomesarecomplexmulti-
cellularhelminthswithseveraldevelop-mentalstageswelldocumentedinthehumanhost[14]. 
Mannose-BindingLectin(MBL)isakeycomponentoftheinnateimmunesystemandpoly-
morphismintheMBL2geneandpromoterregionleadtoMBLdeficiency[15–17].MBLdefi-
ciencyisassociatedwithimpairedfunctionoftheinnateimmunesystemandleadstoincreasedsuscepti
bilitytoseveralinfections[18–
20].MBLactsasanopsoninbybindingtosugargroupsnaturallyfoundonthesurfaceofvariousinfectio
usbacteria,virusesandparasitesandactivatesthecomplementsystem[21,22]throughassociatingwit
hMBL-associatedserineproteasesMASP-1,MASP-2andMASP-3[23–25].Sub-
SaharanAfricahasahighburdenofviral[26–28],bacterial[27–
29]andparasiticinfections[12,13,27].Assessmentofpolymor- 
phismsintheMBL2geneandpromoterregiontodeterminefunctionalMBLdeficiencyhas 
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beencarriedoutindifferentpopulationswithfewstudiesinSub-
SaharanAfrica[17,30,31].Schistosomescarrysugarmoleculesorglycoconjugatesonthesurfaceofallt
heirdevelopmen-
talstages[32,33]andtheseglycoconjugatesinteractwithinnateimmunerecognitionmole-
culesincludingMBL[34–
36].In vitrostudieshavedemonstratedcomplimentmediatedkillingofallstagesoftheschistosomepa
rasite[35]. 
Severalstudieshavebeenconductedworldwide[37–43]includingseveralAfricanpopula-
tions[17,30,44–
48]lookingatMBL2geneticvariantsandplasma/serumMBLconcentrationandtheirassociationtoin
creasedinfectionsusceptibility.TheroleofMBLdeficiencyininfec-
tionshasbeenshowntobedifferentacrossdifferentinfections[44].ForexampleMBLdefi-
ciencyhasbeenshowntoincreaseriskofrecurrentrespiratoryinfections[49]andmalaria[50]whilstbe
ingprotectiveinTB[44],leprosy[51]andleishmaniasis[52,53].ResultsontheroleofMBLdeficiencyin
HIVinfectionsareconflicting[54,55].Inaddition,studiesconductedinSub-
SaharanAfrica,inMozambique[17,56,57],SouthAfrica[48,58]andZimbabwe[31]havebeendonein
childrenandnoneamongadults.OnestudyreportsinvestigationsonMBLdeficiencyandschistosoma
infectionsinNigeria[59]. 
InthispaperwedescribetheroleofplasmaMBLdeficiencyandMBL2polymorphisminHIV-
1,S.mansoniandS.haematobium infectionsinZimbabweanadultsenrolledintheMUSHcohort.The
infectionratesinZimbabwearecurrently15%forHIV-
1[60]and40%and20%forSchistosomahaematobium andSchistosomamansonirespectively[61].S.
haema-tobiumisthemostcommonspeciesfollowedbyS.mansoniinZimbabwe[61–64].Inthecon-
textofpublichealth,itisimportanttounderstandtheroleofMBLdeficiencyintheseinfectionsinourad
ultpopulation. 
Materials and MethodsStu y desi
gn and study population 
Thiswasasub-studyoftheMupfureSchistosomiasisandHIVCohort(MUSHCohort)estab-
lishedin2001aimedatstudyingtheimmunologicalinteractionsbetweenHIV-1andschistoso-
miasisinfections[35,36,38,44,45].Weusedplasmaandwholebloodsamplescollectedatbaselinein20
01–
2002todetermineprevalenceofMBLdeficiencyinthispopulation.DetailsoftheMUSHCohortandpr
oceduresaredescribedelsewhere[1,2,65].Briefly,recruitmentintotheMUSHstudy,samplecollectio
nandlaboratoryassaystookplacebetweenOctober2001andNovember2007.Atotalof1574adultmale
sandfemaleswerescreenedforHIVandschis-
tosomiasisinfectionsatbaseline(Fig.1)and379mettheMUSHeligibilitycriteria:adultmales/females
above18yearsold,HIVpositiveornegative,positiveforS.haematobium orS.mansoniorbothoruninfe
cted,noactiveTBinfection,non-
pregnantwomenandnotcurrentlyonschistosomiasistreatment.AfterscreeningforHIV-
1andschistosomiasisstatus,partici-pantswerecategorisedintofourgroups:HIV-
1only,schistosomiasisonly,co-
infectedwithbothdiseasesandcontrolswithnoneofthesetwoinfections. 
Thissub-
studywasapprovedbytheNationalResearchEthicsCommitteeoftheMedicalResearchCouncilofZi
mbabwe(MRCZ/A/1770)andtheUniversityofWitwatersrandHumanResearchEthicsCommittee(
M130348).PermissionwasgivenbytheProvincialMedicalDirec-
torofMashonalandCentralProvinceandtheDistrictMedicalOfficerofShamvaDistrict,thevillagehe
admenandatvillagemeetings.AllindividualsinthemainMUSHstudygavewritteninformedconsentf
orspecimencollection,storageandfuturelaboratorystudies. 
Laboratory proc dures 
HIV testing.ParticipantswerescreenedforS.haematobium,S.mansoniandHIV-1asde-
scribedearlier(1,65).Briefly,HIVpre-andpost-testcounsellingwasdoneintheparticipants’ 
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nativelanguage(Shona)byqualifiedmedicalpersonnel.ArapidHIV-
1/2testkitwasusedonadrybloodspotinthefield(Determine,AbbottLaboratories,Tokyo,Japan),follo
wedbytwodifferentrapidHIVtestsOraquick(byOrasure)andSerodia(byFujirebio)forallwhotestedi
nitiallypositive.NodiscrepanciesinresultswerefoundbetweentheinitialDetermineHIVtestandthet
wosubsequentELISAs.Strictconfidentialitywasmaintainedthroughoutthestudy.Allthosewhorequ
estedtheirHIVresultsweregivenafterpost-testcounsellingfromthenursingstaff. 
Schistosoma parasitology.Microscopicexaminationoffixed-volumeurinesamplesfil-
teredonNytrelfilters(VesterGaardFrandsen)wasusedtoidentifyandquantifyeggsofS. 
Fig 1.Participant Flow diagram. Flow chart showing the recruitment proceduresfor the adult cohort. A total of 2281 community dwelling rural adult malesa
nd females were screened forHIV and schistosomiasis, 379 males and females who met the inclusion criteria were enrolled and their baseline bloodsampl
es used for MBL plasma and MBL2 genotype analysis. 
doi:10.1371/journal.pone.0122659.g001 
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haematobiumbythesyringeurinefiltrationtechnique[66].Duetothediurnalandday-to-
dayvariationineggoutput,theurinesampleswerecollectedon3consecutivedays[67,68].Themodifie
dformol-etherconcentrationtechniquewasusedon1stoolsamplefromeachpartici-
panttodetecteggsofS.mansoniandotherhelminthorparasites[69].LevelsofCirculatingAnodicAntig
en(CAA)weremeasuredinserumsamplesusinganELISAassay,tocomplementparasitologicaldetect
ionmethods.CAAoriginatesfromtheparasitegutandisusedasamark-
erofanactiveschistosomeinfection[70]. 
Determinationof plasmaMBLconcentration.Baselineplasmasamplesstoredat-
20°CwereusedformeasurementofplasmaMBLconcentrationsusingthedoubleenzymeimmuno-
assay(EIA)(AntibodyShop,Denmark)asdescribedpreviously[30,71].Microtitreplates(Maxisorp,
NUNC,Denmark)werecoatedwithamouseanti-humanMBLmonoclonalanti-body,clone131–
1,IgG1,Kappa(AntibodyShop,Denmark).Plasmasampleswerediluted1/25and1/400inTris/HCLb
uffer(BieandBernsten)containingEDTA(BieandBernsten)and0,05%Tween20(Sigma)[71].Apool
ofEDTAplasmawithaknownconcentrationofMBLwasusedasthestandard.Biotinylatedclone131–
1anti-
MBL(AntibodyShop,Denmark)wasusedasthedetectionantibody.Horseradishperoxidaselabelleds
treptavidin(Amersham,UK)wasadded.ThesubstrateusesO-
phenylenediamine(OPD)(DakoCytomation)hydrochlorideincitrate-
phosphate(BieandBernsten)bufferpH5.0,thecolourreactionwasstoppedbyaddi-
tionofsulphuricacid(Sigma).ParallelcontrolplateswerecoatedwithequivalentamountsofmouseIg
G1andprocessedasabove.Parallelplatesaredoneinordertorevealbindingofrheu-
matoidfactors,antimouseimmunoglobulinsandnon-
specificbindingofMBLinterferinginthesystem.Opticaldensity(OD)wasreadonanELISAreader(M
R5000/7000,DynatechLab-
oratories,Denmark)at490nmwithreferencefilter630nm.FinalMBLvaluesaregivenasμgMBLperlitr
e.TodetermineprevalenceofMBLdeficiency,plasmaMBLconcentrationwascategorisedintonormal
(above500μg/L),intermediate(100μg/L-500μg/L)anddeficient(below100μg/L)[30,72–74]. 
MBLgenotyping.Genomicdeoxyribonucleicacid(DNA)wasusedforMBL2genotyping.TheDN
AwasextractedfromfrozenbaselinePeripheralBloodMononuclearCells(PBMCs)usingthestandar
dsaltingoutprocedure[75].TheMBL2genotypesandpromoterregional-lelesweredetectedbyallele-
specificoligonucleotidePCR(ASO-
PCR)wherespecificsequenceswereusedforeachallele[42].Briefly,thePCRmastermixwasmadebym
ixingthefollowing:400μlsterilewater(H/SApoteket,Rigshospital,Copenhagen),150μlof1.5mMMg
Cl2(Invitro-
gen,Denmark),150μlat0.07mMfinalconcentrationofeachdeoxynucleotidetriphosphate(dNTPs)(
AmershamBiosciences,UKLimited),500μlPCRBuffercontaining50mMKCL, 
10mMTris-
HCl(pH8.3),0.001%(w/v)gelatinp.H.8.3(Invitrogen,Denmark),250μlglycerolat5%finalconcentra
tion,50μlcresolredatfinalconcentration100μg/μl.Cresolred(Invitro-
gen,Denmark)wasaddedasacolourmarker.ThePCRMastermixcouldbekeptat4°Cfor 
2weeks. 
Thenatotalof12primersolutions(DNATechnology)werepreparedforeachsample 
(S1Table).Thesetof12primersforMBL2variantsandpromoterregionmutationswerepre-
paredbymixing5´senseand3´senseprimerswithwateraccordingtothemanufacturer’sin-
structions.Finalconcentrationofeachprimerwas0.25uMforeachspecificprimer.Primersfor5and3
senseexon4oftheMBL2gene(DNATechnology,Denmark)wereincludedineachPCRreactionasani
nternalpositivecontrol.PCRprimerswerepre-aliquotedin5μlvol-
umesintothePCRplatesandtheplatescouldbekeptat4°Cfor1week. 
MBLPCRandsamplereactionmixtureswerethenpreparedas10μlvolumescontaining30nggeno
micDNAand0.25μmMofthespecificprimer,54μlofPCRmastermix,3,5μlsampleDNA(iftheDNAco
ncentrationwas0,3μg/μl),31μlsterilewater,and0.25UnitsofPlatinumTaq DNApolymerase(Invitro
gen,Denmark)ineach90μlinitialreactionmixturevolume. 
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PCRreactionmixturewasmixedandaddedtothe12wells,clearlymarkedforeachsample,whichcontai
ned5μlofdifferentsetsofprimersforthegenotypingandpromotertyping.Onlyeightsamplescouldber
unoneachPCRplate.Plateswereputinaplatemicrocentrifugeat3000rpmfor1minutetospindownthe
wellcontents.Platesweretightlysealedwithfoilpaper. 
DNAwasthenamplifiedbyPCRinaprogrammedthermocycler(GeneAmpPCRSystems9600,Per
kinElmer).AllPCRswereinitiatedbya2-mindenaturationstepat94°Candcom-pletedbya5-
minextensionstepat72°C.ThetemperaturecyclesforthePCRwereasfollows:10cyclesof10sat94°Can
d60sat65°C,andafurther20cyclesof10sat94°C,50sat61°C,30sat72°Cand2minutesat25°C.Gelelectr
ophoresiswasdoneonthePCRproductsonthesamedayorkeptat4°Cforamaximum1week.ThePCRp
roductswereseparatedbya2%aga-
rosegel(Invitrogen)electrophoresisruninanelectrophoresischamber(Sub-
cellBiorad)at150V,400mAfor32minutes.ThegelswerethencarefullytransferredtotheUVTransillu
mi-
nator(SyngeneSynopticsLtd,Denmark)whereaphotographofthegelwastakenandusedtodetermine
theMBL2 genotypeofeachsample.MBL2genotypesA/O,O/OandXAYO/YOYOwereclassifiedasM
BLdeficientproducersandthenormalMBL2denotedA/A.MBL2singlenucleotidepolymorphisms(S
NPs)intheformofstructuralvariantsnamedB (codon54,rs1800450A>G),C (codon57,rs1800451A
>G)andD (codon52,rs5030737T>C),aswellastheregulatorypromoterregionvariantsH/L (-
550,rs11003125G>C),X/Y(-
221,rs7096206C>G)andPQ (+4,rs7095891T>C)[76,77]weredetermined[42].Allthesinglenucleo
tidepolymorphisms(SNPs)andtheirreferencesequencenumbersarefoundontheonlinedatabasehtt
p://www.ncbi.nlm.nih.gov/snp/. 
Statistical analysis 
AllstatisticalanalysisweredoneusingStata11statisticalpackage(STATACorp,TimberlakeConsulta
nts).NormalityofplasmaMBLlevelswascheckedgraphically.Non-parametrictests(Mann-
WhitneyandKruskal-Wallis)wereusedforcomparisonofmedianplasmaMBLcon-
centrationsbyage,gender,HIV-
1andschistosomainfectionstatus.DifferencesinproportionsofMBLdeficiencybetweenmalesandfe
malesandinfectionstatusweredoneusingChiSquareorFisher’sexacttestsandconfidenceintervalswe
recalculatedusingbinomialexactmethods.ThefrequenciesoftheMBL2alleleswereobtainedbydirect
genecounting.ConformationtotheHardy-
WeinbergEquilibriumwasdeterminedusingtheChiSquaretestintheSHEsison-
lineprogramme[78,79].ForMBL2genotypeanalysis,normalhomozygousMBL2wasde-
notedasA/A.ThevariantgenotypesA/B(A>G),A/C (G>A),A/D(C>T)weregroupedtogetherasA/
O heterozygousMBL2 astheyallgivelowplasmaMBLlevelsandallhomozygousandcompoundhom
ozygotesweregroupedtogetherasO/O.ThedifferencesinfrequencyoftheMBL2genotypes,promoter
regionvariantsandhaplotypesbetweeninfectionstatusgroupsweredeterminedusingtheChiSquaret
estorFisher’sexacttests. 
Results 
Atotalof379plasmaandwholebloodsampleswereavailableforMBLanalysis.Medianage(IQR)ofthe
participantswas30(17to41)yearsoldandthemajoritywerefemales(80%).Baselinedemographiccha
racteristicsofthisstudypopulationandprevalenceofHIV-1,S.hae-
matobiumandS.mansoniamongthe1545participantsscreenedduringthemainMUSHstudyhavebe
endescribedelsewhere[65]. 
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Prevalence of HIV-1, S. haematobium and S. mansoni in theMBL sub-
study 
TheprevalenceofHIV-1,S.haematobium,S.mansoniandco-
infectionwithbothschistosmaspeciesamongthe379participantsusedfortheMBLsub-
studywas52%,58%,7%and10%,re-spectively(Table1). 
Plasma MBL levels 
ResultsforplasmaMBLconcentrationareavailablefor378individuals;onesamplerepeatedlygavein
consistentplasmalevelresultsandwasdroppedfromthisanalysis.Themedian(IQR)plasmaMBLcon
centrationinalltheinvestigatedindividualswas800μg/L(192–
1936μg/L).TherewasnodifferenceinthemedianplasmaMBLconcentrationbetweenmalesandfema
les(p=0.553)andbytoage(p=0.204)(Table1). 
Table 1.Comparisonof median plasma MBL concentrations between groups. 
Variable n MedianMBLlevelsμg/L IQRμg/L p-value 
Sex 
824
800 
159–
1968200–
1936 
0.561 
Males
 76F
emales 302 
Agegroups 920
776 
209–
2608166–
1864 
0.202 
<25 yearsold
 82
>25 yearsold 297 
HIVstatus 688
912 
147–
1904272–
1968 
0.065 
Positive                                                                 
197Negative                                                              
181 
Schistosomiasisinfectionstatus 6569
1210
1668
8 
139–
1152213–
2320258–
2192297–
2432 
0.036 
Noinfection
 89S
.haematobium only
 205
S.mansoni only
 24
Coinfectedwithboth species 37 
Schistosomiasisand HIVstatus 
824
944
656
707 
151–
2160251–
249665–
1176163–
1152 
0.037 
S.haematobium+/ HIV+
 102
S.haematobium+/ HIV-
 103
S.haematobium-/ HIV+
 44S
.haematobium-/ HIV- 45 
S.haematobiuminfectiononly 
912
656 
213–
2320139–
1152 
0.006 
S.haematobiumpositive
 205
S.haematobium negative 89 
Circulatinganodicantigen Above40pg/ml(CAA positive) 293 848 161–2232 
Below 40pg/ml(CAA negative) 63 784 346–1152 0.308 
Eggsper10mlurine,S.Haematobiuminfection 
0 (noinfection) 108
 705<10(lightinfection) 123
 89610-
<50(mediuminfection) 55 1408 
>50(heavy infection) 9 295 
145–
1264230–
2112182–
2528 
87–2816 0.109 
The concentration of MBL in plasma was measuredin μg/L.Differences inmedianplasma MBL concentration inthedifferentinfection statuscategorieswere 
analysed by usingnon-parametrictestsMann-Whitney fortwo categoriesand Kruskal-Wallis forthreeormorecategories. 
doi:10.1371/journal.pone.0122659.t001 
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Association between HIV-
1, schistosoma infections and plasma MBLconcentration 
TherewasnodifferenceinthemedianplasmaMBLconcentrationbetweenHIVinfectedanduninfecte
dindividuals(p=0.065).However,therewere37participantswithplasmaMBLlev-
elsattheassaydetectionlimitof20μg/L.ThislevelofplasmaMBLwasfoundmorefrequentlyamongHI
V-1infected14%(27of196,95%CI8.4–18.2),comparedwithHIV-
1uninfected6%(10of181,95%CI2.7–
9.9)(χ2=7.24,p=0.007),indicatingapossibleroleofMBLdeficiencyinHIV-1infection. 
Therewasasignificantdifference(p=0.037)inmedianplasmaMBLlevelsbetweenthefourschistos
omainfectionstatusgroups,namely,noinfection,S.haematobiumonly,S.man-sonionlyandthoseco-
infectedwithbothspecies.ThosewithS.mansoniinfectiononlyhadthehighestmedianplasmaMBLlev
elof1016μg/LfollowedbythosewithS.haematobiumonlymedianMBLlevel912μg/L,p=0.037(Table1
).Therewerealsosignificantdifferencesinme-dianplasmaMBLlevelsbetweenthefourHIV-
1andS.haematobiumco-
infectiongroups,withthosepositiveforS.haematobiumandnegativeforHIVhavingthehighestmedia
nplas-maMBLlevel(944μg/L,p=0.037,Table1).FurthercomparisonwasdonebetweentheS.hae-
matobiuminfectedanduninfectedindividualsafterexcludingthosewithS.mansoniorco-
infectedwithbothspecies.TherewasasignificantdifferenceinplasmaMBLlevels,thoseS.haematobiu
minfectedhavinghighermedianMBLlevelsthantheuninfected,p=0.006 
(Table1)indicatingprotectiverolelowplasmaMBLlevels.TherewasnodifferenceinplasmaMBLleve
lswhencomparisonwasdonebetweenCAAlevelsgroupsaboveorbelow40pg/ml(p=0.381)andfour
eggcountgroupsamongthosewithS.haematobiuminfectiononly 
(p=0.114,Table1). 
Association between HIV-
1, schistosoma infections and plasma MBLdeficiency 
PlasmaMBLconcentrationwascategorisedintonormal(above500μg/L),intermediate(100μg/L-
500μg/L)anddeficient(below100μg/L)(Table2)(72,73).TheprevalenceofplasmaMBLdeficiencyina
llparticipantsanalysedwas18%(67of378,95%CI:14–22%),20%(77of378,95%CI:16–
24%)hadintermediateplasmaMBLlevelsand62%(234of378,95%CI:56–
66%)hadnormalplasmaMBLlevelsabove500μg/L.Therewasnodifferenceinproportionofmaleswit
hMBLdeficiency20%(15of76,95%CI:11–
30%)andfemaleswithMBLdeficiency17%(52of302,95%CI:13–22%). 
WefoundnodifferenceindistributionfrequencyofparticipantsaccordingtoHIV 
(p=0.070)andamongS.haematobium infectedanduninfectedparticipantsafterexcludingS.manson
i andco-
infections(p=0.446)betweenthethreeplasmaMBLlevelscategories,normal,reducedanddeficient(T
able2).Therewasalsonodifferencewhenasimilaranalysiswasdoneamongtheschistosomainfections
tatusgroups(p=0.351)andamongHIVandS.haemato-biumco-infectiongroups(p=0.546). 
MBL2 polymorphism 
MBL2genotypingwassuccessfullydoneon366samplesoutof379andthesewereusedinthisanalysis,t
heothersamplescouldnotbeamplified.AlltheknownMBL2codingalleles,wild-
typeA/A,B (codon54,rs1800450A>G),C (codon57,rs1800451A>G)andD (codon52,rs5030737
T>C),werefoundinthisstudypopulation.IntheMBL2codingregion,233/366(64%)wereclassifieda
sA/Agenotype,3(0.8%)wereA/B,117(32%)wereA/C,1(0.3%)A/Dand12(3%)C/C (Table3).There
wereneitherB/B,C/D,D/D norB/Dvariants.Thefrequency 
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ofMBL2geneticvariantswas36%and64%hadthenormalhomozygousA/Agenotype.Thenormalho
mozygousMBL2,A/Agenotypewasfoundatfrequenciesof64%(233of366,95%CI:58.5–
68.5%),heterozygousMBL2A/Ovariantsat33%(121of366,95%CI:28.3–
38.1)andhomozygousO/Ovariantsat3.3%(12of366,95%CI:1.7–
5.7%)(Table3).AlltheMBL2SNPsdetectedamongtheHIVnegativeinthisstudywereinHardy-
WeiburgEquillibrium(structur-alallelesp=0.400,-550H/Lp=0.820,-
221Y/Xp=0.550and+4P/Qp=0.170(S2Table). 
Frequency of MBL2 genotypes and haplotypes 
MBL2wild-typegenotypeA/A hadthehighestfrequencyof64%(233of366,95%CI:77.1–
83%)andgenotypeA/Dthelowestfrequencyof0.1%(1of366,95%CI0.003–
0.76,Table3).AllthecurrentlyknownMBL2 promoterregionalleles,-550H,-550L,-221Y,-
221X,+4P and+-
4Q,weredetected.PromoterregionalleleLhadthehighestfrequency95%(694of732,95%CI:92.9–
96.3%)comparedto5%(38of732,95%CI:3.69–
7.1%)fortheH allele(Table3).TheLL MBL2promoterregiongenotype(89%)hadthehighestfrequen
cyandHH(0.3%)thelow-
estfrequency.Elevendifferenthaplotypesweredetectedintheseindividualsincludingthreerarehaplo
typesnamelyLXQA,LXQC andLXPC.HaplotypeLYPAhadthehighestfrequency(35%),followedby
LYQAandLYPB,LYPC andHYPDthelowest(0.1%)(Table3).MBL2ge-
notypesA/A showedthehighestlevelsofplasmaMBLconcentrationsandO/Ogenotypeshadthelowes
t(S3Table). Association between HIV-
1, schistosoma infections and MBL2genotypes and promoterr
egion genotypes AnalysiswasdonetodetermineifMBL2geneticandpromoterregionvariantswereassociatedwithHI
V-1infection.Thedistributionofthethreegenotypes(A/A,A/OandO/O)didnotdif-
ferbetweentheHIV-
1infectedanduninfected(p=0.429,Table4).TheMBL2haplotypeswerefurthercombinedandsubdiv
idedintothreegroupsnamelygenotypesthatgivenormal 
Table 2.Distribution of participants between three plasma MBL levels, participants stratified according HIV, S. haematobium and S. mansoni in-
fection and co-infection status. 
HIVstatus n NormalMBLlevels ReducedMBLlevels DeficientMBLlevels P value 
43(22%) 113 
(57%)121 
(67%) 
41 
(21%)36 
(20%) 
24(13%) 0.070 
HIV positive                                         
197HIV negative181 
S.haematobiuminfection 
36(17%) 131 
(64%)51(5
7%) 
38(19%)
17(19%) 21(24%) 0.446 
S.haematobium positive
 205
S.haematobium negative 89 
Schistosoma co-infection Noinfection (controls)
 89S
.haematobium only
 205
S.mansoni only 24 
Co-infected withboth species 37 
51(57%)1
31(64%)1
5(63%) 
23(62%) 
17 
(195)38(
19%)6(2
5%) 
11(30%) 
21(24%)
36(18%0
3(13%) 
3(8%) 0.351 
HIV andS.haematobiumco-infection 
HIV+/S. 
haematobium+HIV+/S. 
haematobium-HIV-/S. 
haematobium+ 
HIV-/S. haematobium- 
102
 64(63%)
44
 23(52%)
103 67(65%) 
45 28(62%) 
17(17%)
8(18%)2
1(20%) 
9(20%) 
21(21%)
13(30%)
15(15%) 
8(18%) 0.546 
Prevalenceof MBL deficiency,plasmaMBL concentration was categorisedinto normal (above 500μg/L), intermediate(100μg/L- 500μg/L) and 
deficient(below100μg/L), analysedby the Chi Square or Fisher’s exacttests,n = 378. 
doi:10.1371/journal.pone.0122659.t002 
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Table 3.Gene, promoter alleles and haplotype frequencies obtained for MBL2 polymorphism amongt
he enrolled Zimbabwean participants. 
N Frequency% 
Exon1allele 
80
0.4
20
0.1 
59
51
88
24
75
3 
64
0.8
32
0.2
3 
0.31
0.18
9.66
6.13
0.03
.220
.226
.553
.3 
A normal
 587
B(A>G)
 3C(
G>A)
 141
D(C>T)
 1Pr
omoteralleles 
-550H 38-
550L
 694
-221X
 134
-221Y
 598
+4P
 343
+4Q
 389
MBL2Exon 1genotype 
AA wild-type
 233
AB(A>G)
 3A
C(G>A)
 117
AD(C>T)
 1C
C(C>T)
 12P
romoterregiongenotypes 
-550HH 1-
550HL 37 
-550LL
 328
-221YY
 242
-221XY
 112
-221XX
 12+
4PP
 74+
4QQ
 97+
4PQ
 195
MBL2 Haplotypes 
1.MBL2*LYPA
 260
2.MBL2*LYQA
 183
3.MBL2*LYQC
35.5
25.0
14.6
7.96
.15.
64.2
0.30
.30.
1 
0.1 
MBL2gene and allele frequencies obtainedby direct genecounting,frequencies expressedas 
percentages. 
doi:10.1371/journal.pone.0122659.t003 
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plasmaMBLlevels(YA/YA,YA/XA),intermediatelevels(XA/XA,YA/YO)anddeficientlevels(XA/Y
O,YO/YO)(20,77).Therewasnodifferenceindistributionfrequencywhencomparisonwasdoneamo
ngtheHIV-
1strataandthethreeMBL2genotypegroupsYAYA/YAXA,XAXA/YAYOandXAYO/YOYO(p=0.34
7,Table4).NoneoftheseMBL2genotypesandpromotervariantswereassociatedwithHIV-
1infection(Table4). 
WefoundnoassociationbetweenMBL2genotypesandPQpromotergenotypesandschis-
tosomainfections(Table5).However,therewasasignificantassociationbetweenS.haemato-
biumandS.mansoniinfectionsandLL(p=0.051)andLY_LX(p=0.026)promotergenotypes.Therefor
epromoterregiongenotypesLL,LYandLXwhichencodeforlowplasmaMBLlevelsweresignificantly
associatedwithS.haematobiumandS.mansoniinfections. 
AnalysisamongS.haematobiuminfectedanduninfectedafterexcludingthosewithS.man-
soniandco-infectionwithbothspeciesshowedasignificantdifferenceindistributionfrequen-
cyoftheLY promoterregionvariant,participantswithLY promotergenotypebeingmoresusceptiblet
oS.haematobium infection(p=0.048,Table6). 
AnalysisamongHIV-1andS.haematobiumco-infections,afterexcludingS.mansoniinfec-
tionsandschistosomaco-infectionsshowednodifferenceindistributionfrequencyofMBLge-
notypesandpromotergenotypesbetweenthefourco-
infectionstatusgroups(Table7).MBL2genotypesandpromoterregiongenotypeswerenotassociated
withHIV-1andS.haemato-biumco-infections. 
Table 4.Distribution of participants between MBL2 genotypes and promoter region haplotypes, participants stratified according to HIV-
1 infectionstatus. 
MBL2genotypes/haplotypes n HIVnegative HIVpositive P value 
116(50%)
66(55%) 
8 (67%)
 0.429
110(49%) 
72(55%) 
233
 117(50%)
121 55 
(45%)12 4 
(33%)223
 113(51%)
131
 59(45%)1
2 4(33%) 
8(67%) 0.347 
0(0%)15
(41%) 
175(53%)
 0.141
12(39%) 
172(53%) 6(67%)
 0.229
122(50%) 
60(54%) 8(67%)
 0.521
15(39%) 
175(53%)
 0.105
37(50%) 
42(43%) 
A/A
A/O
O/O 
YAYA/YAXAXAXA/YA
YOXAYO/YOYOProm
otergenotypes-
550HH 
-
550HL-
550LL-
550HY-
550LY-
221LX-
221YY-
221XY-
221XX-
550HY 
-
221LY*LX+
4C/C(PP)+
4TT(QQ) 
+4C/TPQ 
1
 1 100%)3
7
 22(59%)3
28
 153(47%)
31
 19(61%)3
26
 154(47%)
9
 3(33%)24
2
 120(50%)
112
 52(46%)1
2 4(33%)38
 23(61%)3
28
 153(47%)
74
 37(50%)9
7 55(57%) 
195 98(50%) 
9 49 0.545 
Thisanalysis was done usingthe ChiSquareand Fisher’s exacttests,n =366 
doi:10.1371/journal.pone.0122659.t004 
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Discussion 
ThisstudyshowedthatplasmaMBLdeficiency,allMBLgeneticandpromoterregionvariantsdetected
werenotassociatedwithHIV-
1infectioninthispopulation,howeverparticipantswithplasmaMBLlevelsattheassaydetectionlimit
weresignificantlymorefrequentamongtheHIV-
1infected.HigherplasmaMBLlevels,LY andLL promotergenotypeswereassociatedwithincreaseds
usceptibilitytobothS.haematobium andS.mansoniinfections.Toourknowl-
edge,thisisthefirststudythathasinvestigatedtheroleofMBLdeficiencyinHIV-1andschis-tosomaco-
infectionsandsecondstudythatassessedtheroleofMBLdeficiencyinschistosomainfections[59].Our
resultsalsoconfirmpreviouslyreportedassociationofMBLpolymor-phismwithMBLlevels[15–17]. 
Inviewofavailableliterature,wehypothesizedthatplasmaMBLdeficiencyduetosinglelocussubsti
tutionsinMBL2resultinginvaryinglevelsofcirculatingMBLwouldhaveaneffectonsusceptibilitytoH
IV-
1andschistosomainfectionsinthisstudypopulation.Theresultsofourstudyshowednodifferenceinp
lasmaMBLconcentrationbetweentheHIVpositiveandHIVnegativeindividuals,consistentwithoth
erreports[80–82].Incontrast,somehavere-
portedprotectiveeffectofnormalplasmaMBLlevelsandincreasedsusceptibilityduetolowMBLlevels
[30,37,83,84],butsomereportedadeleteriouseffectofnormalplasmaMBLlevelswherehighMBLlevel
swereassociatedwithacquiringHIVinfection[39]. 
Inaddition,weinvestigatedtheroleofplasmaMBLdeficiencyinadultssinglyinfectedorco-
infectedwithHIV-
1,S.haematobiumandS.mansonianduninfectedcontrols.Ourresultsshowedasignificantdifferenc
einplasmaMBLlevelswiththoseS.mansoniandS.haemato-
biumpositivehavingsignificantlyhigherMBLlevelsthantheuninfectedparticipants.When 
Table 5.Distribution of participants between MBL2 genotypes and promoter region haplotypes according to schistosoma infection status. 
MBL2Genotype/Haplotype N Noinfection(controls) S.haematobium only S.mansonionly Coinfectedwithbothspecies P value 
22(10%)
13(11%) 
1(9%)
 0.893
22(11%) 
13(10%) 
51(24%)
33(28%)
4(36%)4
9(23%)3
5(28%)4
(36%) 
128(59%)
62(53%)6
(55%)123
(59%)67(
54%)6(55
%) 
15(7%)
9(8%)0
(0%)14
(7%)10
(8%)0(
0%) (9%) 0.903 
0(0%)
1(3%) 
35(11%)
 0.051
1(4%) 
34(11%) 1(1 %)
 0.072
27(12%) 
8(8%) 1 10%)
 0.351
1(3%) 
35(11%)
 0.026
7(10%) 
13(15%) 
A/A
 216
A/O
 117
O/O
 11Y
AYA/YAXA
 208
XAXA/YAYO
 125
XAYO/YOYO.
 11P
romoterregiongenotypes 
-550HH 1-
550HL 34 
-550LL
 309
-550HY 28-
221LY
 307
-221LX 9 
-221YY
 228
-221XY
 106
-221XX 10-
550HY 35-
221LY*LX
 309
+4PP
 69+
4QQ 88 
+4PQ 187 
0(0%)15(
44%)73(
24%)14(
50%)72(
24%)2(2
2%)65(2
9%)21(2
0%)2(20
%)15(43
%)73(24
%)16 
(23%)17(
19%) 
55(29%) 
1(100%)1
8(53%)17
7(57%)13
(46%)178
(58%)5(5
6%)122(5
4%)68(64
%)6(60%)
19(54%)1
77(57%)4
3(62%)50
(57%) 
103(55%) 
0(0%)0
(0%)24
(8%)0(
0%)23(
7%)1(1
1%)14(
6%)9(8
%)1(10
%)0(0
%)24(8
%)3(4
%)8(9
%) 
13(7%) 16(9 0.381 
Thisanalysis was done usingthe Fisher’s exacttests,n = 344 
doi:10.1371/journal.pone.0122659.t005 
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analysiswasdoneamongtheS.haematobium infectedanduninfected,afterexcludingthosein-
fectedwithS.mansoniandthoseco-infectedwithbothschistosomaspecies,theS.haemato-
biuminfectedparticipantshadsignificantlyhigherplasmaMBLlevels.Theclinicalrelevanceofourfin
dingsisthathigherplasmaMBLlevelsledtoincreasedsusceptibilitytoschistosomainfectionsandlowe
rlevelswereprotective.Ourresultsareincontrasttotheonlysimilarreportavailable[59]whichfoundlo
werMBLlevelsintheinfectedparticipantsandhigherMBLlevelswereprotectiveagainstS.haematobiu
m infectioninaNigerianpopulation[59].TheNigerianstudyhadasamplesizeof346almostsimilartoo
urstudywith379participants.Thereasonsforthesecontrastingfindingsonroleofplasmalevelsinschis
tosomiasisarenotclearbutmaybeduetopopulationdifferences.Therehavebeenreportsonthepossibl
eadvantageofevolu-
tionoftheMBL2variantsandthehighprevalenceofMBL2variantsresultinginreducedplas-
maMBLconcentrationsontheAfricancontinent[44,85].Wecanonlypostulatethatselectionpressure
favouringMBL2variantsandreducedplasmalevelsthatoccurredinAfricanpopulationsoffersprotect
ionagainstthenumerousintracellularinfectionspresentinthispop-
ulationatlarge.ThusinourstudypopulationwefoundahighprevalenceofplasmaMBLdefi-
ciencyat18%andthereducedplasmaMBLlevelswerefoundtobeprotectiveagainstschistosomainfect
ions. 
OurfindingsofhighplasmaMBLdeficiencyareconsistentwithfindingsfromotherAfricanpopulat
ions[16,17,30].PopulationsurveyshaveshownthattheconcentrationofMBLinplas-
ma/serumrangesfrom<20μg/Lto10000μg/L[42]andplasma/serumMBLconcentrationlessthan10
0μg/Lisconsidereddeficient[72,73].TheplasmaMBLlevelmedianof800μg/Landthewiderangeof20
–7600μg/LforourstudypopulationareconsistentwithstudiesinAfrican 
Table 6.Distribution of participants between MBL2 genotypes and promoter region haplotypes according to schistosoma infection status. 
MBL2genotype/haplotype n S.haematobiumnegative S.haematobiumpositive P value 
128(72%)
62(65%) 
6(60%)
 0.466
123(72%) 
67(66%) 
51(28%)
33(35%)
4(40%)4
9(28%)3
5(34%)4
(40%) (60%) 0.505 
1(100%)
18(55%) 
177(71%)
 0.132
13(48%) 
178(71%) 5(71%)
 0.048
122(65%) 
68(76%) (75%)
 0.161
19(56%) 
177(71%)
 0.078
43(73%) 
50(75%) 
A/A
 179
A/O
 95
O/O
 10Y
AYA/YAXA
 172
XAXA/YAYO
 102
XAYO/YOYO
 10P
romotergenotypes 
-550HH 1-
550HL 33 
-550LL
 250
-550HY 27-
221LY
 250
-221LX 7 
-221YY
 187
-221XY 89-
221XX 8 
-550HY 34-
221LY*LX
 250
+4PP
 59+
4QQ 67 
+4PQ 158 
0(0%)15
(45%)73
(29%)14
(52%)72
(29%)2(
29%)65(
35%)21(
24%)2(2
5%)15(4
4%)73(2
9%)16(2
7%)17(2
5%) 
55(35%) 103(65%) 0.289 
Thisanalysis was done usingthe ChiSquareorFisher’s exacttests, n = 284 
doi:10.1371/journal.pone.0122659.t006 
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populations[17,30].PlasmaMBLconcentrationdidnotdifferbetweenmalesandfemalesnorbyageas
reportedbyothers[30]. 
WhenanalysiswasdonecomparingtheproportionsofthosewithplasmaMBLconcentra-
tionattheassaydetectionlimit,astrongassociationwithbeingHIVpositivewasdetected,sup-
portingourhypothesisofMBLconsumptionandreductionduringHIVinfection,consistentwithothe
rfindings[82].ThepossibleexplanationfortheassociationbetweenthissevereMBLdeficiencyandbei
ngHIVpositiveinourstudycouldbethatthelowMBLlevelsmayindicatethatthereisconsumptionofth
eMBLproteinmoleculewhenitengagesinopsonicclearanceoftheHIVvirus,leadingtoMBLconsump
tion[82]andnotaccumulationasproposedbyothers[39,86].AvailableevidenceshowsthatMBLassist
sinHIVclearancethroughactivationofthecomplimentsystemandMBLboundtoHIVcanbeclearedfr
omthecirculationbytheCIqre-
ceptor,amoleculethathasbeenshowntohavehighaffinityforMBL[87,88]andMBLbindstoandneutr
alisesHIVinvitro[89].However,otherrecentstudieshaveconflictinglyshownthatMBLlevelsremain
relativelystableduringthecourseofHIVinfectionanddoesnotsup-
portthetheoryofMBLconsumptionduringHIVinfection[82].WealsonodifferencesinMBL2levelsb
etweenCDCHIVcategories,CD4
+
Tcellcountandviralloadinourstudy,simi-
lartofindingsbyothers[39],incontrasttootherfindings[39]. 
PlasmaMBLconcentrationwascategorisedintonormal(above500μg/L),intermediate(100μg/L-
500μg/L)anddeficient(below100μg/L)[72,73].Ourresultsshowednoassociationbetweenthiscateg
orisationofplasmaMBLlevel,HIV-1andschistosomainfections.Ourre-
sultsareincontrasttoareportthatshowedincreasedsusceptibilitytoHIVinfectioninpeople 
Table 7.Distribution of participants between MBL2 promoter region haplotypes according to HIV and S. haematobium co-infection status. 
MMBL2ggenotype/h
aplotype 
N HIV-
/S.haematobiu
m- 
HIV+/S.haematobium
+ 
HIV-
/S.haematobium+ 
HIV+/S.
 Phae
matobium- value 
24(13%)
17(18%) 
330(%)
 0.802
23(13%) 
18(18%) 
179    
27(15%)95
 16(17%)
10
 1(10%)1
72    
26(15%)102    
17(17%)10
 1(10%) 
64(36%)
30(32%)
3(30%)6
1(36%)3
3(32%)3
(30%) 
64(36%)
32(34%)
3(30%)6
2(36%)3
4(33%)3
(30%) 3(30%) 0.830 
0(0%)17
(21%) 
37(15%)
 0.384
6(22%) 
37(15%) 1(14%)
 0.295
32(17%) 
11(12%) (13%)
 0.729
7(21%) 
37(15%)
 0.227
9(15%) 
10(15%) 
A/A
A/O
O/O 
YAYA/YAXAXAXA/YA
YOXAYO/YOYO.Pro
motergenotypes-
550HH 
-
550HL-
550LL-
550HY-
221LY-
221LX-
221YY-
221XY-
221XX-
550HY 
-
221LY*LX+
4PP+4QQ 
+4PQ 
 0(0%)33
8 24 2
50    
36(14%)27
 8(30%)2
50    35(14%)7
 1(14%)1
87    
32(17%)89
 11(12%)
8
 1(13%)3
4
 8(24%)2
50    
36(14%)59
 7(12%)6
7 7(10%) 
158    30(19%) 
0(0%)7(
21%)90(
36%)5(1
9%)89(3
6%)3(43
%)59(32
%)34(38
%)4(50
%)7(21
%)90(36
%)20(34
%)26(39
%) 
51(32%) 
1(100%)
11(33%)
87(35%)
8(30%)8
9(36%)2
(29%)64
(34%)33
(37%)2(
25%)12(
35%)87(
35%)23(
39%)24(
36%) 
52(33%) 25(16%) 0.685 
Thisanalysis was done usingthe ChiSquareorFisher’s exacttests, n = 284 
doi:10.1371/journal.pone.0122659.t007 
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withMBLdeficiency[30].WecouldnotfindanysimilarstudiescomparingtheseMBLcatego-
rieswithschistosomainfections. 
AssessmentofMBL2polymorphismshowedahighprevalenceMBL2deficientgenotypesA/Oand
O/Oat18%,duetohighfrequencyoftheC(G>A)variantallele(20%)andhighfre-
quenciesofvariantpromoterallelesXandL.AllthecurrentlyknownMBL2alleles,wild-
typeA,B (A>G),C(A>G),andD (C>T)andpromoterregionalleles-550H,-221Y,-550L,-
221X,+4Pand +4Q,werefoundinthispopulation.PresenceofahighfrequencyofthevariantCMBL2al
leleinourpopulationisconsistentwithfindingsfromotherstudiesonAfricanswithfrequenciesashigh
as24%inMozambicans[17],27%inGambianadults[45]and15–
38%inseveralEastandWestAfricancountries[44,45].TheMBLgenotypesA/A,A/OandO/O inourst
udycorrelatedwithhigh,intermediateanddeficientplasmaMBLlevelsconfirmingre-
sultsonotherAfricanpopulations[17,30].Promoterregionvariantshavebeenreportedtosig-
nificantlyaffectMBLplasma/serumconcentration[16],alsoconfirmedbyourresults.TheHY,LY and
LX promotersareassociatedwithhigh,mediumandlowMBLexpressionrespectively[17].Inourstud
y,theL allele(94%)hadthehighestfrequencyandH allele(5%)hadthelowestfrequency,consistentwit
hotherreportsonAfricanpopulations[16]. 
WefoundnoassociationbetweenpresenceofMBL2structuralvariantsandpromotervari-
antswithHIVinfection,inaccordancewithotherfindings[38,90],incontrasttoreportsofsignificantas
sociations[37,83,84,91].SimilarresultstooursofnoassociationbetweenMBL2polymorphismandHI
Vinfection,reportedinaColombianpopulation,wereexplainedasbeingduetoexistenceofredundant
constitutiveacquiredimmunedefencesystemsthatcancomplementortakeuptheinnatedefencefunc
tionsprovidedbyMBL,whicharelikelyfa-
vouredunderconditionsofhighpathogenexposure[38].Itisindeedtruethatpolyparasitismiscommo
ninmostruralpopulationsinZimbabwe[61]. 
TherewerenodifferencesindistributionofMBL2promoterregionallelesandvariantsbe-
tweentheHIVpositiveandHIVinfectedparticipantsandnoroleofMBLpromoterregionvariantsinin
creasingsusceptibilitytoHIVinfection,inaccordwithotherreports[92,93].Incontrastpromoterregi
onvariantsLX/LXhavebeenreportedtohavehigherfrequencyamongHIV-
infectedadultsthancontrols[94].TheH/Y,L/Yand/LX promotersareassociatedwithhigh,mediuma
ndlowMBL2expressionrespectively[16].AllthecurrentlyknownMBL2pro-
moterregionvariantsH,L,Y,X,P andQ weredetectedinourstudy,theL allele(47%)hadthehighestfre
quencyandH allele(3%)hadthelowestfrequency,inaccordwithareportonAfri-
canpopulations[16].TheH alleleisfoundpredominantlyinwhitepopulationswhoalsohaveverylow
LandX alleles[16].OurresultsofnoassociationbetweenpresenceofMBL2promot-
erregionvariantsandHIVinfectionareinaccordwithotherreportsinadults[93]butincon-
trastandchildrenwithpromotertypeLwereprotectedfromHIVrapidprogression[95]. 
ThereasonforthedifferencesinplasmaMBLlevels,MBL2genotypesandHIVassociationoutcom
esisnotclear[54,55,96]butthismaybebecausestudieshavebeencarriedoutindif-
ferentpopulations,homosexualgroups[37]andsomeinheterosexuals[30,38,91]andalsothemethod
semployedinthesestudiesaredifferentwithsomemeasuringplasmaMBLlevelsonly[30,39,81,82,97,
98],othersassessingstructuralallelesonly[38,91,99],somelookedatboth[37,80,83,84,90]othersina
dditionlookedatMBL2promoterregionalleles[92,100].OurstudyinvestigatedallthreeMBLparame
ters,plasmaMBLlevels,polymorphismintheMBL2exon1geneandpromoterregionvariants.Theref
oretheconflictingreportsonassocia-
tionofHIVinfectionwithMBLlevelsandgeneticpolymorphismmaybeduetodifferencesinHIVtrans
missionroute,samplesize,ethnicity,environmentalconditionsandstudydesignaspostulatedbyothe
rs[38]. 
MBL2geneticvariantsA/OandO/Oandtheotherpromotervariantswerenotassociatedwithschi
stosomaco-infectionsinourstudysimilartofindingsinaNigerianpopulation[59]. 
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HoweverourfindingsshowedthatthepromotergenotypesL/Yand/LLwhichcodeforlowplasmalev
els,bothshowedsignificantassociationwithS.haematobiuminfection,similartofindingsintheNige
rian.IncontrasttoourfindingsofnoassociationthepromotergenotypesH/L andP/Pwerereportedt
obeprotectiveandP/Qcarriersshowedincreasedsusceptibility[59]. 
ParticipantswerefurtherstratifiedintosixMBL2haplotypegroupswhichwerecombinedintothre
egroupsforanalysisnamely,haplotypesthatgivenormalplasmaMBLlevels(YA/YA,YA/XA),interme
diatelevels(XA/XA,YA/YO)anddeficientlevels(XA/YO,YO/YO)[20,77].NoneofthethreeMBL2hap
lotypegroupswereassociatedwithHIV-1norschistosomainfec-
tionsincontrasttoareportofincreasedsusceptibilitywheretheXA/XApromotervarianthadadetrime
ntaleffectinHIVverticaltransmission[100].Ourresultsshowednoassociationbe-tweenHIV-
1andschistosomainfectionsandthesevenMBL2haplotypesdetectedinthisstudy,incontrasttofindin
gsofsignificantassociationbetweenMBL2_HYPA andS.haemato-
biuminfection,thosewithMBL2_HYPA haplotypewerereportedtobeatalowerriskforS.haematobiu
minfection,presenceofMBL2_HYPAwasprotective[59]. 
MBLdeficiencyhasbeenreportedinseveralstudiestobestronglyassociatedwithincreasedsuscepti
bilitytoseveralotherinfectionslikerespiratoryinfectionsandrecurrentinfectionsinadultsandchildre
n,infectionsthatarehighlyprevalentinZimbabwe.Availableliteraturethereforeshowsevidenceoflo
wMBLlevelstobethereforeprotectiveinsomediseasesbutin-
creasessusceptibilityinsomeinfections.Thisvaryingevidenceshowsthattheclinicalsignifi-
canceoftheMBL2variantsmaypossiblydependonthepopulationinvestigatedandthetypeofdisease.
WefoundplasmaMBLdeficiencyandMBL2geneandpromoterregionvariantstoplaynoroleinHIV-
1infection,buthighplasmaMBLlevelsandtheheterozygouspromotergenotypeLY andhomozygous
LLincreasedsusceptibilitytoschistosomainfections. 
ThemainlimitationofourstudywasinclusionoffewmeninthemainMUSHstudy.Thereisagoldpa
nningareaintheneighbouringdistrict,mostmenworkawayfromtheirruralhomesandwerenotavaila
bleduringourstudyrecruitmentphase.Thishasthepotentialtobiasourfindingsbuteveryeffortwasdo
netoenrolalleligiblemenintothemainMUSHstudyandMBLsub-study. 
Inconclusion,thisstudyshowedahighprevalenceofplasmaMBLdeficiency,highfrequen-
cyofMBL2geneticvariantC (G>A).ThesefindingsareconsistentwithotherobservationsthattheC (
G>A)variantalleleisthepredominantvariantalleleinSub-
SaharanAfrica.WefoundnoevidenceofanassociationbetweenMBLdeficiencyandHIV-
1infection,howeverplasmaMBLlevelsatassaydetectionlimitwereassociatedwithHIV-
1infectionindicatingapossibleroleofMBLdeficiencyinHIVinfection.LowerplasmaMBLlevelswere
protectiveagainstbothS.haematobiumandS.mansoni infectionsandhigherplasmaMBLlevelsassoci
at-edwithincreasedsusceptibilitytoschistosomainfections.AlltheotherMBLgeneandpromot-
erregionvariantsdetectedplayednoroleinbothHIVandschistosomainfectionsbutpresenceofprom
oterregionvariantsLY andLLincreasedsusceptibilitytobothS.haematobium andS.mansoniinfectio
ns.TheavailableevidenceontheassociationofpolymorphismintheMBL2promoterregionwithHIV-
1infectionisstillconflicting.Inlightofallthisconflictingevidenceitwouldbedifficulttorecommendth
euseofMBLplasmalevels,MBL2structuralvariantsandpromoterregionmutationsasabiomarkerof
HIVinfectionandforthemonitoringofARVtherapytogetherwithviralloadandCD4
+
Tcelllymphocy
tecountsinthepopulationrepre-
sentedbyourstudyparticipants.OurresultsonroleofplasmaMBLlevelsinschistosomain-
fectionsareinconflictwiththeonlyavailablereportthatfoundlowerplasmaMBLlevelstoincreasesusc
eptibilitytoschistosomainfections.Thereistherefore,needtocarryoutamuchbiggerstudytoverifythe
seresults.Inaddition,futureimmunologicalstudieslookingattheas-
sociationbetweenMBLdeficiencyandotherdiseasesarehighlyrecommendedforthe 
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Zimbabweanpopulationwherepersistentrecurrentbacterial,viral,fungalandotherparasiticinfecti
onsremainprevalentaffectingbothadultsandchildren. 
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Table S1.  The 12 oligonucleotide primer sequences and the Exon 1 internal control primers, that 
were used in this study for detection of MBL2 coding and promoter normal and variant alleles. 
 
 primer 
 
Specific sequence 
 
Product 
Size (bp) 
1 A54   
none B     
5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-CCTTTTCTCCCTTGGTGC-5´ 
 
 
278 
2 B 5´-GGGCTGGCAAGACAACTATTA-3´ 
3´-GCAAAGATGGGCGTGATGA-5´ 
 
278 
3 A57 
None C 
5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-CCTGGTTCCCCCTTTTCTC-5´ 
 
290 
4 C 5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-ACCTGGTTCCCCCTTTTCTT-5´ 
 
290 
5 A52 
none D 
5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-TCCCTTGGTGCCATCACG-5´ 
 
268 
6 D 5´-AGTCGACCCAGATTGTAGGACAGAG-3´ 
3´-CTCCCTTGGTGCCATCACA-5´ 
 
268 
7 Promoter 
X 
5´-CTCAGGGAAGGTTAATCTCAG-3´ 
3´-CATTTGTTCTCACTGCCACC-5´ 
 
440 
8 Promoter 
Y 
5´-CTCAGGGAAGGTTAATCTCAG-3´ 
3´-CATTTGTTCTCACTGCCACG-5´ 
 
443 
156 
 
9 Promoter 
H 
5´-GGCTTAGACCTATGGGGCTA-3´ 
3´-GCTTCCCCTTGGTGTTTTAC-5´ 
 
316 
10 Promoter 
L 
5´-GGCTTAGACCTATGGGGCTA-3´ 
3´-GCTTCCCCTTGGTGTTTTAG-5´ 
 
316 
11 P 5´-AGGATCCAGGCAGTTTCCTCTGGAAGG-3´ 
3´-TAGGACAGAGGGCATGCTC-5´ 
 
335 
12 Q 5´-AGGATCCAGGCAGTTTCCTCTGGAAGG-3´ 
3´-TAGGACAGAGGGCATGCTT-5´ 
 
331 
 Exon 1 
internal 
control 
5´-GAGTTTCACCCACTTTTTCACA-3´ 
3´-GCCTGAGTGATATGACCCTCC-5´ 
 
431 
___________________________________________________________________________ 
These primer sequences and specifications were for identification of the MBL2 and promoter region types, according to 
manufacturer’s instructions (DNA Technology, Denmark). 
 
 
 
  
157 
 
Table S3.Detailed summary of the MBL2 genotypes, haplotypes and corresponding plasma MBL 
concentrations (n=366) 
___________________________________________________________________________ 
Structural 
genotype 
Promoter Complete 
genotype 
(n) MBLconcentration 
median µg/L 
MBL 
concentration 
IQR (µg/L) 
AA HY/HY HYPA/HYPA 4 2464 1336-3368 
 LYLY LYPA/LYPA 16 1149 672-2280 
  LYQA/LYQA 47 2048 1344-2960 
  LYPA/LYQA 59 1856 992-3024 
 LX/LX LXPA/LXPA 12 856 568-1760 
 HY/LY HYPA/LYPA 3 656 136-2080 
  HYPA/LYQA 13 1520 1088-1888 
  HYPA/LXPA 5 1680 720-2400 
 LY/LX LYPA/LXPA 27 1040 688-2000 
  LYPA/LXQA 42 1016 752-1904 
  LYQA/LXQA 1 - 286 
A/O HY HYPD/LYPA 1 - 1024 
  HYPA/LYQC 10 244 20-352 
  HYPA/LXQC 1 - 192 
 LY LYPA//LYPB 1 - 512 
  LYPA/LYQB 1 - 225 
  LYPA/LYQC 48 150 24-416 
  LYQA/LYQB 1 - 202 
158 
 
  LYQA/LYQC 26 188 105-528 
 LX LYPA/LXPC 2 162 62-263 
  LYPA/LXQC 27 27 20-83 
  LYQA/LXQC 3 128 20-1920 
O/O  LYQC/LYQC 12 20 20-20 
Haplotypes      
HYPA HY  36 1024 310-1992 
HYPD HY  1 - 1024 
LYQA LY  85 1056 346-2320 
LYPA LY  217 816 163-1936 
LXPA LX  12 856 568-1760 
LYPB LY  2 368 225-512 
______________________________________________________________________________________________________________ 
Gene and allele frequencies were obtained by direct gene counting.  The three main MBL2 genotype groups AA, AO and OO were further subdivided 
according to the MBL2 gene and haplotype combinations detected.  Twenty-four different complete MBL2 genotypes were detected as shown above.  
As expected, the HYPA/HYPA genotype which codes for the homozygous  normal A/A MBL2 genotype, had the highest median plasma MBL 
concentration(median MBL 2464µg/L, IQR 1336-3368µg/L ) and LYQC/LYQC had the lowest levels, (MB220µg/L).  HYPA haplotype showed the 
highest median plasma MBL concentration(median MBL 2464µg/L, IQR 1336-3368µg/L ) and LYQC haplotype  had the lowest levels (MBL 
20µg/L).  We found varying median MBL concentrations due to the effect of HY, LY and LX promoters.   
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Table S2.MBL2 genotypes and promoter SNPs and HWE 
________________________________________________________________________ 
MBL2 variant Reference 
SNP ID 
number 
(rs#) 
Alleles Alternative 
nomenclature 
Location HWE 
controls P 
-550 11003125 G/C H/L promoter 0.830 
-221 7096206 C/G X/Y promoter 0.550 
+4 7095891 A/G P/Q Exon 1 0.170 
Exon 1 
B(codon 54) 
C(codon 57) 
D(codon 52) 
 
1800450 
1800451 
5030737 
 
A/G 
G/A 
C/T 
 
A/B 
A/C 
A/D 
 
Exon 1 
 
0.400 
__________________________________________________________________________- 
The HWE for the above MBL2 SNPs was determined among the HIV negative participants.   
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Table S3.Detailed summary of the MBL2 genotypes, haplotypes and corresponding plasma MBL 
concentrations (n=366) 
___________________________________________________________________________ 
Structural 
genotype 
Promoter Complete 
genotype 
(n) MBLconcentration 
median µg/L 
MBL 
concentration 
IQR (µg/L) 
AA HY/HY HYPA/HYPA 4 2464 1336-3368 
 LYLY LYPA/LYPA 16 1149 672-2280 
  LYQA/LYQA 47 2048 1344-2960 
  LYPA/LYQA 59 1856 992-3024 
 LX/LX LXPA/LXPA 12 856 568-1760 
 HY/LY HYPA/LYPA 3 656 136-2080 
  HYPA/LYQA 13 1520 1088-1888 
  HYPA/LXPA 5 1680 720-2400 
 LY/LX LYPA/LXPA 27 1040 688-2000 
  LYPA/LXQA 42 1016 752-1904 
  LYQA/LXQA 1 - 286 
A/O HY HYPD/LYPA 1 - 1024 
  HYPA/LYQC 10 244 20-352 
  HYPA/LXQC 1 - 192 
 LY LYPA//LYPB 1 - 512 
  LYPA/LYQB 1 - 225 
  LYPA/LYQC 48 150 24-416 
  LYQA/LYQB 1 - 202 
  LYQA/LYQC 26 188 105-528 
 LX LYPA/LXPC 2 162 62-263 
  LYPA/LXQC 27 27 20-83 
  LYQA/LXQC 3 128 20-1920 
O/O  LYQC/LYQC 12 20 20-20 
Haplotypes      
HYPA HY  36 1024 310-1992 
HYPD HY  1 - 1024 
LYQA LY  85 1056 346-2320 
LYPA LY  217 816 163-1936 
LXPA LX  12 856 568-1760 
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LYPB LY  2 368 225-512 
______________________________________________________________________________________________________________ 
Gene and allele frequencies were obtained by direct gene counting.  The three main MBL2 genotype groups AA, AO and OO were further subdivided 
according to the MBL2 gene and haplotype combinations detected.  Twenty-four different complete MBL2 genotypes were detected as shown above.  
As expected, the HYPA/HYPA genotype which codes for the homozygous  normal A/A MBL2 genotype, had the highest median plasma MBL 
concentration(median MBL 2464µg/L, IQR 1336-3368µg/L ) and LYQC/LYQC had the lowest levels, (MB220µg/L).  HYPA haplotype showed the 
highest median plasma MBL concentration(median MBL 2464µg/L, IQR 1336-3368µg/L ) and LYQC haplotype  had the lowest levels (MBL 
20µg/L).  We found varying median MBL concentrations due to the effect of HY, LY and LX promoters.   
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Abstract 
Background 
Use of dried blood spots in detection of infections and molecular testing has increased over 
the years because of ease of collection and storage especially for developing countries where 
storage of blood samples is a challenge.  But there are still lessons to be learnt in use of dried 
blood spots for laboratory assays and areas for improvement.  We share our experiences 
using stored dried blood spot samples for MBL2 genotyping to determine prevalence of MBL 
deficiency in mother–baby pairs.  Mannose Binding  Lectin (MBL) is a normal plasma 
protein produced in the liver and is a key component of the innate immune system, MBL 
deficiency leads to increased susceptibility to infections like HIV.   
 
Objectives: To share our experiences optimising use of stored dried blood spot samples for 
determination of MBL deficiency using MBL2 genotyping pyrosequencingtechnique.   
 
Methods: We assessed MBL2 polymorphism in Zimbabwean mothers and their children 
enrolled in a national PMTCT survey carried out in 2012.   The dried blood spots were 
collected on Perkin Elmer 226 filter papers and had been stored for 1 year 8 months at room 
temperature before MBL2 genotyping was done.  We used two methods to optimise DNA 
extraction, initially Sigma Generation kit and later used Gene Extract and Amp kit to extract 
DNA from dried blood spots of 632 mothers-infant pairs.  MBL2 genotyping of the 632 
mother-baby pair samples was done using the pyrosequencing technique. 
 
Results: We optimizedDNA extraction from 632 mother-baby pair dried blood spots.  We 
could not amplify by PCR the DNA extracted using theSigma Generation kit so we changed 
to Gene Extract and Amp kit.  We initially used Taq DNA Polymerase enzyme and changed 
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to TEMPaseHot Start DNA Polymerase enzyme which gave clearer bands during PCR 
amplification.  DNA extraction using the Gene Extract and Amp kit and amplification using 
the TEMPaseHot Start DNA Polymerase enzyme gave the best and optimal results. 
 
Conclusion 
DNA extraction from dried blood spots was optimal and gave the best PCR bands using the 
Gene Extract and Amp kit and amplification using the TEMPaseHot Start DNA Polymerase 
enzyme.   
 
Key words:  Mannose Binding Lectin (MBL), MBL2 genetic polymorphism, Perkin Elmer 
226 filter paper, Gene Extract and Amp kit, pyrosequencing. 
 
Short Title: Optimization of MBL2 genotyping by pyrosequencing using dried blood 
spots 
 
Introduction 
Use of dried blood spots in detection of infections has increased over the years because of 
ease of collection and storage (1) especially for developing countries where storage of blood 
samples is a challenge (2).   Available literature shows an increase in use of dried blood spots 
for detection of infections, genetic testing 3, 4 and for MBL2 genotyping (5, 6), but there are 
still lessons to be learnt and areas for improvement (2).  There are several types of filter paper 
brands available made of cellulose and the filter papers vary in their thickness and pore size.  
Only two brands, Whatman 903 also called Guthrie cards and 226 Perkin Elmer filter papers 
are approved for use by WHO and the US Food and Drug Administration for collection and 
storage of human whole blood (7, 8).   There are reports of use of Whatman 903 or Guthrie 
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cards (1, 3, 5, 7, 9-14) and others have used 226 Perkin Elmer filter paper (7) for collection 
and storage of dried blood spots for analysis of infections.    Mannose Binding Lectin (MBL) 
is a normal plasma protein produced in the liver and is a key component of the innate 
immune system.  In the absence of plasma samples, MBL2 genotyping can be used as proxy 
to determine MBL deficiency.  Currently available literature shows that MBL2 genotyping 
can be done on stored dried blood spots collected on Guthrie cards (3, 5, 6, 12, 14, 15).  We 
share our experiences using stored dried blood samples collected on 226 Perkin Elmer filter 
paper for determination of MBL deficiency using MBL2 genotyping techniques, using the 
pyrosequencing method on mother-baby dried blood spot samples collected in Zimbabwe. 
 
Materials and Methods 
Study design 
This was a laboratory based study where we optimized DNA extraction and MBL2 
genotyping (16).  The dried blood spot samples used for this sub-study were collected during 
a national survey on prevention of mother to child transmission (PMTCT) carried out in 2012 
by the Centre for Sexual Health And HIV/AIDS Research (CESHAAR), Harare Zimbabwe, 
entitled Evaluation of  Zimbabwe’s Accelerated prevention of Mother-to-Child Transmission 
of HIV Program (17-19).  This paper reports our experiences and processes in more detail as 
we optimised the DNA extraction methods and PCR amplification on 632 dried blood spots 
of mother-baby pairs collected and stored during the survey.    
 
Study population 
The PMTCT survey carried out by the CESHAAR Research team in September 2012 
targeted women aged 16 years and above who had children between 9 and 18 months old. 
Details including blood sample collection, screening procedures, the setting, the study 
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population have been described in detail elsewhere(17-19).    Briefly, recruitment into the 
CESHAAR study, sample collection and HIV laboratory assays took place between 
September 2012 and September 2013.     
 
Ethics Statement 
The CESHAAR PMTCT study was approved by the National Research Ethics Committee of 
the Medical Research Council of Zimbabwe (MRCZ/A/1655), University of California and 
University of London Human Research Ethics Committees.  The MBL2 sub-study was also 
approved by the National Research Ethics Committee of the Medical Research Council of 
Zimbabwe (MRCZ/A/1770) and University of the Witwatersrand Human Research Ethics 
Committee (M130348) (16).  All the mothers who took part in the main PMTCT National 
Survey gave written informed consent for specimen collection, storage and future laboratory 
studies.  Permission to ship the dried blood spot samples to Denmark was granted by the 
Research Council of Zimbabwe, certificate No. 02338 of 2016. 
 
Collection of dried blood spots 
Venous blood was collected on filter papers (Perkin Elmer 226, Health Sciences, USA)  
after punching the heal of the child or finger of the mother. Blood was collected on  
five designated spots on the filter papers.  The filter papers were air dried overnight and then 
packed the next day in zip lock bags with desiccant granules to prevent humid formation and 
keep the spots dry. The zip lock bags were kept at room temperature until analysis of the 
spots. 
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DNA extraction  
For routine MBL2 genotyping at Serum State Institute DNA extracted from whole blood 
samples is normally used.  To optimise DNA extraction from the PMTCT dried blood spots 
for our study, two different methods were therefore selected to be used, the Sigma Generation 
kit and SIGMA Extract and Amp kit, compared amplification of the DNA extracts by PCR, 
as fully described below: 
 
1.Sigma Generation kit 
Initially DNA was extracted using the Sigma Generation kit. Two 3mm punches [5] were 
made for each dried blood sample and put in a 200µl96 well PCR plate 
(DNA/NDase/RNase/PCR inhibitor free, SARSTEDT, UK).  One hundred and forty (140µl) 
of assay buffer were added and the plates vortexed for 45 minutes to clean the dried blood 
spots.  Supernatant was discarded and another 140µlassay buffer added, vortexed for 45 
minutes and supernatant discarded.   Ninety (90µl) Generation DNA Solution 1 added and 
allowed to stand for 1 minuteand supernatant discarded , this step repeated once more.  
Ninety (90µl) Generation DNA Solution 2 added and allowed to stand for 1 minuteand 
supernatant discarded.  Sixty (60µl) of filtered milli-Q water was added and extract vortexed 
at -20°C and transferred to a PCR machine set for 1 cycle at  99°C for 25 minutes to stabilize 
the DNA.  The extracted DNA dissolved in the water was stored in a freezer at -20°C until 
ready for use in PCR.    
 
2. SIGMA Extract and Amp kit 
Genomic DNA was extracted from dried blood spots using SIGMA Extract and Amp  
kit.  Two 3mm punches were made for each dried blood sample and put in a 96 well PCR  
plate (DNA/NDase/RNase/PCR inhibitor free, SARSTEDT, UK). Plates werecovered with  
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8 well PCR plate cover strips (SARSTEDT, UK).  Twenty (20µl) Lysis solution (SIGMA)  
was added per well using sterile pipette tips (DNA/NDase/RNase/PCR inhibitor free, 
SARSTEDT, UK).  Plates were incubated at 75°C for 30 minutes and cooledat 10 °C in a  
programmed PCR thermocycler (Applied Biosystems, 2720 thermal cycler version 2.09).  
180µl of Neutralizing solution (SIGMA) stored at room temperature, mixed by pippeting  in 
the plate wells and spun down in a plate centrifuge for 1 min at 1000rpm and the extracted 
DNA was stored at 4°C. DNA was quantified using the Qubit kitaccording to manufacturers  
instructions.  Amplification of MBL2 genes by Initial general PCR, Visualisation of PCR 
products by agarose gel electrophoresis, Pyrosequencing and Sanger Direct Genetic 
Screening were carried out according to manufacturer’s instructions 
 
Optimisation of DNA extraction 
Initially DNA extraction was done using Sigma Generation kit.  We could not amplify by 
PCR the DNA from this method.  Then extraction was done using the second kit SIGMA 
Extract and Amp kit and DNA extracts from this method could be amplified by PCR.  The 
initial protocol for the lysis step during DNA extraction was 55°C for 15 minutes this was 
optimised to 75°C for 30 minutes.  This change in the conditions for the lysis step gave the 
best bands in MBL2 PCR.  
 
Optimization of MBL2PCR 
The MBL initial PCR method was optimised by initially using the enzyme Taq DNA 
Poymerase for amplification.  We obtained very weak amplification bands using the Taq 
DNA Poylmerase enzyme and the standard MBL2genotyping  method used at Serum State 
Institute.  We then changed the amplification enzyme to TEMPase Hot Start DNA 
Polymerase (VWR, Belgium) which gave us better bands for all the MBL2 SNPS, HL, YX, 
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PQ and Exon 1.  The amount of template DNA to be used for the PCR reaction was also 
optimised.  We used 2µl, 5µl and 10µl and obtained the best clear bands by using 2µl of the 
template DNA, 2µl was therefore used throughout all the MBL2 genotyping assays (16).   
 
Statistical analysis 
All statistical analysis were done using Stata 11 statistical package (STATA Corp, 
Timberlake Consultants).  For MBL2 genotype analysis, normal homozygousMBL2 was 
denoted as A/A.  The heterozygous variant MBL2genotypes were grouped together as 
A/Oheterozygous MBL2 as they all give low MBL2 plasma levels and all homozygous and 
compound homozygotes were grouped together as O/O.  The frequencies of the MBL2 alleles 
were obtained by direct gene counting.  To determine prevalence of MBL deficiency, 
MBL2genotypes were used as proxy for MBL levels, MBL2A/A genotype was considered as 
normal and those with A/O and O/O categorised as deficient MBL, as reported earlier (16). 
 
 
 
RESULTS 
Baseline characteristics 
Mothers aged above 16 years old and their babies aged between 9 and 18 months old were 
enrolled into the national PMTCT survey.  Six hundred and thirty two (632) dried blood spot 
samples from mother-baby pairs were selected for DNA extraction and MBL2 genotyping 
(16).   
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Optimization of DNA extraction 
Initially DNA extraction was done using Sigma Generation kit.  We could not amplify the 
DNA extracts obtained from this method by PCR.  Then extraction was done using the 
second kit SIGMA Extract and Amp kit and DNA extracts from this method could be 
amplified by PCR. 
 
Optimization of MBL2 PCR 
The MBL2 initial PCR method was optimised by initially using the Taq DNA Polymerase 
enzyme for amplification of MBL2 SNPS.  The PCR products produced very weak bands 
after gel electrophoresis.   The PCR enzyme was then changed toTEMPase Hot Start DNA 
Polymerase and the PCR products produced clear bandsafter gel electrophoresis . 
 
MBL2 genotyping by pyrosequencing technique 
MBL2 genotyping was initially done on all the available 632 mother-baby pair DNA extracts 
using  pyrosequencing.  Ten mother-baby pairs were dropped from this analysis because of 
the incomplete data.  The frequencies of all the MBL2 SNPS for the mothers and their 
children using the pyrosequencing method were reported earlier (16).   
 
Discussion 
We share here our experiences optimising DNA extraction from dried blood spots collected 
on Perkin Elmer 226 filter papers and MBL2 genotyping results using the pyrosequencing 
technique.  We optimized DNA extraction by initially using the Sigma Generation kit but the 
DNA could not be amplified.  Then we used the SIGMA Extract and Amp kit and the extracts 
from this method could be amplified by PCR. We then optimized initial MBL2 PCR by using 
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Taq DNA Polymerase enzyme.  The amplification process was then improved by using 
TEMPase Hot Start DNA Polymerase enzyme. 
 
We obtained the best PCR amplification bands after substituting the Taq DNA Polymerase 
PCR enzyme with TEMPase Hot Start DNA polymerase enzyme.  TEMPase Hot Start DNA 
polymerase enzyme is a modified form of Taq DNA Polymerase PCR enzyme which is 
activated by heat treatment.  A chemical moiety is attached to the enzyme at the active site, 
which renders the enzyme inactive at room temperature.  Thus, during setup and the first 
ramp of thermal cycling, the enzyme is not active and misprimed primers are not extended.  
This results in higher specificity and greater yields when compared to standard DNA 
polymerases.  Once the reaction reaches optimal activating temperature, the chemical moiety 
is cleaved during a 15 minute heat activation step, releasing the active TEMPase Hot Start 
DNA Polymerase into the reaction.  
 
Available literature has shown MBL2 genotyping can be done on stored dried blood spots 
collected on Guthrie cards (3, 5, 6, 12, 14, 15).  The reasons for the poor quality DNA from 
our samples might have been the long storage time before analysis.  The dried blood spots we 
used for MBL2 genotyping were collected on Perkin Elmer 226 filter papers and had been 
stored for 1 year 8 months at room temperature before MBL2 genotyping was done.  The 
other possibility could be the type of filter paper that was used for collection and storage of 
the dried blood spots.  The Perkin Elmer 226 Filter paper was used for collection of the dried 
blood spots.  Important also to note is that these PMTCT dried blood spots were not initially 
intended for MBL2 genotyping but for HIV testing of the mothers and their babies for a 
different programme, the national PMTCT programme (17-19).  Available literature shows 
that studies that carried out MBL2 genotyping using dried blood spots collected on Guthrie 
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cards which were stored at room temperature before analysis  and these reported no 
challenges with DNA extraction and amplification (3, 5, 12, 14).  
 
In conclusion,DNA extraction from dried blood spots was optimal using the Gene Extract and 
Amp kit and PCR amplification was optimal using TEMPase Hot Start DNA polymerase 
enzyme.  We therefore recommend use of the Gene Extract and Amp kit for DNA extraction 
from dried blood spots and use of the enzyme TEMPase Hot Start DNA polymerase enzyme 
for genotyping by pyrosequencing using dried blood spots collected on Perkin Elmer 226 
filter papers. 
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